

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1			Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV	21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV	26	MARPAT enhanced with FSORT command
NEWS	4	NOV	26	CHEMSAFE now available on STN Easy
NEWS	5	NOV	26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC	01	ChemPort single article sales feature unavailable
NEWS	7	DEC	12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC	17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN	06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN	07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB	02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB	02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB	06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB	10	COMPENDEX reloaded and enhanced
NEWS	15	FEB	11	WTEXTILES reloaded and enhanced
NEWS	16	FEB	19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS	17	FEB	19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB	23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB	23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB	23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB	23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB	25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	EXPRESS	JUNE	27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS	HOURS			STN Operating Hours Plus Help Desk Availability
NEWS	LOGIN			Welcome Banner and News Items
NEWS	IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:35:13 ON 25 FEB 2009

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 15:35:28 ON 25 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 FEB 2009 HIGHEST RN 1111415-98-5

DICTIONARY FILE UPDATES: 24 FEB 2009 HIGHEST RN 1111415-98-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10589407.str



chain nodes :

```

7 8 9
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15
chain bonds :
7-8 7-10 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
7-8 7-10 8-9 10-11 10-15 11-12 12-13 13-14 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 10 :

```

G1:N,CH

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:Atom


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:36:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3642 TO ITERATE

```

54.9% PROCESSED      2000 ITERATIONS                        50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**

```

PROJECTED ITERATIONS: 69221 TO 76459

PROJECTED ANSWERS: 3189 TO 4895

L2 50 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 15:36:18 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 73245 TO ITERATE


100.0% PROCESSED 73245 ITERATIONS  
SEARCH TIME: 00.00.04

3685 ANSWERS

L3 3685 SEA SSS FUL L1

=> d scan


L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzoic acid, 4-[[[3-(methylamino)-2-pyrazinyl]carbonyl]amino]-, ethyl ester  
MF C15 H16 N4 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):25


L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[3-(1H-imidazol-1-ylmethyl)phenyl]-  
MF C15 H13 N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[5-[(ethylphenylamino)sulfonyl]-2-(2,2,2-trifluoroethoxy)phenyl]-5-methyl-  
MF C22 H21 F3 N4 O4 S






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[5-[(diethylamino)sulfonyl]-2-(propylamino)phenyl]-  
 MF C18 H25 N5 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[2-(2-propen-1-ylthio)phenyl]-  
 MF C14 H13 N3 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 5-methyl-N-[2-(3-methylphenoxy)phenyl]-  
 MF C19 H17 N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[3-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl]phenyl]-5-methoxy-  
 MF C17 H19 N5 O2 S  
 CI COM


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[4-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl]-2-pyridinyl]-5-methyl-  
 MF C16 H18 N6 O S  
 CI COM

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[3-(2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl)-4,5-difluorophenyl]-5-(2-methoxyethoxy)-  
MF C19 H21 F2 N5 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[3-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl]phenyl]-5-(2-pentyn-1-yloxy)-  
MF C21 H23 N5 O2 S


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[3-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl]phenyl]-5-(2-hydroxyethyl)-  
MF C18 H21 N5 O2 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C24 H28 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzoic acid, 3-[(2-pyrazinylcarbonyl)amino]-5-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]methyl]-, methyl ester  
 MF C21 H17 F3 N4 O5 S




L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[2-methoxy-5-[[2-methoxyphenyl]amino]sulfonyl]phenyl]-5-methyl-  
 MF C20 H20 N4 O5 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[4-[2-(cyclopropylamino)-2-oxoethyl]phenyl]-  
 MF C16 H16 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-N-[2-(1-piperazinyl)phenyl]-  
 MF C22 H24 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-methyl-2-(1-piperazinyl)phenyl]-  
 MF C16 H20 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-(aminocarbonyl)-2-(1-piperidinyl)phenyl]-, 2,2,2-trifluoroacetate (1:?)  
 MF C17 H20 N6 O2 . x C2 H F3 O2


CM 1



CM 2




L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 5-methyl-N-[4-[(1-methyl-1H-imidazol-2-yl)carbonyl]phenyl]-  
 MF C17 H15 N5 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(methylthio)phenyl]-  
MF C12 H12 N4 O S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-(4-hydroxyphenyl)-5-methyl-  
MF C12 H11 N3 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[2-(cyclopentylamino)-2-oxo-1-(2-thienyl)ethyl]-N-(3-hydroxyphenyl)-  
MF C22 H22 N4 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[2-(diethylamino)-5-  
[(diethylamino)sulfonyl]phenyl]-  
MF C19 H27 N5 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(2-hydroxyphenyl)-  
 MF C11 H10 N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-(4-ethoxyphenyl)-N-[2-[(4-fluorophenyl)amino]-1-(2-methylphenyl)-2-oxoethyl]-  
 MF C28 H25 F N4 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3685 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[2-[(4-fluorophenyl)amino]-1-(3-methoxyphenyl)-2-oxoethyl]-N-phenyl-  
 MF C26 H21 F N4 O3







\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\STNEXP\Queries\10589407narrower.str



```

chain nodes :
7 8 9 19
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15
chain bonds :
7-8 7-10 7-19 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
7-8 7-10 7-19 8-9 10-11 10-15 11-12 12-13 13-14 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 10 :

```

G1:N,CH

G2:H,CH3

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:Atom 19:CLASS


```

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR



G1 N,CH

G2 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l4 sss sam

SAMPLE SEARCH INITIATED 15:40:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3642 TO ITERATE

54.9% PROCESSED 2000 ITERATIONS 50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 69221 TO 76459  
PROJECTED ANSWERS: 2930 TO 4572

L5 50 SEA SSS SAM L4

=> s l4 sss full

FULL SEARCH INITIATED 15:40:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 73245 TO ITERATE

100.0% PROCESSED 73245 ITERATIONS 3230 ANSWERS  
SEARCH TIME: 00.00.03

L6 3230 SEA SSS FUL L4

=> fil cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

375.12

375.34

FILE 'CAPLUS' ENTERED AT 15:40:44 ON 25 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Feb 2009 VOL 150 ISS 9  
FILE LAST UPDATED: 24 Feb 2009 (20090224/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:35:13 ON 25 FEB 2009)

FILE 'REGISTRY' ENTERED AT 15:35:28 ON 25 FEB 2009

L1	STRUCTURE UPLOADED
L2	50 S L1 SSS SAM
L3	3685 S L1 SSS FULL
L4	STRUCTURE UPLOADED
L5	50 S L4 SSS SAM
L6	3230 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:40:44 ON 25 FEB 2009

=> s l6 and (pry<2005)  
378 L6  
4600131 PRY<2005  
L7 187 L6 AND (PRY<2005)

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.74	378.08

FILE 'REGISTRY' ENTERED AT 15:41:20 ON 25 FEB 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 FEB 2009 HIGHEST RN 1111415-98-5  
DICTIONARY FILE UPDATES: 24 FEB 2009 HIGHEST RN 1111415-98-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.96	379.04

FILE 'REGISTRY' ENTERED AT 15:42:35 ON 25 FEB 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 FEB 2009 HIGHEST RN 1111415-98-5  
DICTIONARY FILE UPDATES: 24 FEB 2009 HIGHEST RN 1111415-98-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10589407narrower2.str



chain nodes :

```

7 8 9 19
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15
chain bonds :
7-8 7-10 7-19 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
7-8 7-10 7-19 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

```

G1:N,CH

G2:H,CH3

Match level :

```



1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:Atom 19:CLASS

```

L8 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\STNEXP\Queries\10589407narrowest.str



```

chain nodes :
7 8 9 18
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15
chain bonds :
2-8 7-8 7-10 7-18 8-9

```

```

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
7-8 7-10 7-18 8-9
exact bonds :
2-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

```

G1:N,CH

G2:H,CH3

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS


```

L9 STRUCTURE UPLOADED

=> d 19

L9 HAS NO ANSWERS

L9 STR



G1 N,CH

G2 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s 19 sss sam

SAMPLE SEARCH INITIATED 15:44:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 29 TO ITERATE

100.0% PROCESSED 29 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 257 TO 903

PROJECTED ANSWERS: 22 TO 418

L10 11 SEA SSS SAM L9

=> s 19 sss full

FULL SEARCH INITIATED 15:44:59 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 594 TO ITERATE

100.0% PROCESSED 594 ITERATIONS  
SEARCH TIME: 00.00.01


178 ANSWERS

L11 178 SEA SSS FUL L9

=> d scan

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[4-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-1,3-  
thiazin-4-yl]-2-pyridinyl]-5-(2-butyn-1-yloxy)-  
MF C19 H20 N6 O2 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20


L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[6-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-1,3-  
thiazin-4-yl]-2-pyridinyl]-5-methoxy-  
MF C16 H18 N6 O2 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-(3-hydroxy-2-pyridinyl)-  
 MF C10 H8 N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-methyl-2-pyridinyl)-  
 MF C11 H11 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Thiophenecarboxylic acid, 3-[[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-5-[6-[(2-pyrazinylcarbonyl)amino]-3-pyridinyl]]-, methyl ester  
 MF C27 H31 N5 O4 S


Relative stereochemistry.






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Carbamic acid, [3-[[[(5-fluoro-2-pyridinyl)amino]carbonyl]-5-methylpyrazinyl]-3-pyridinyl-, 1,1-dimethylethyl ester (9CI)  
 MF C21 H21 F N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-(5-nitro-2-pyridinyl)-  
 MF C10 H7 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C20 H18 Br N5 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[4-[2-(4-fluoro-3-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]-2-pyridinyl]-  
 MF C23 H16 F N7 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2,3-Pyrazinedicarboxamide, N2-[2-(2-aminoethoxy)-4-(3-oxo-4-morpholinyl)phenyl]-N3-(5-chloro-2-pyridinyl)-  
MF C23 H22 Cl N7 O5  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[tetrahydro-3-(2-hydroxyethyl)-2-oxo-1(2H)-pyrimidinyl]phenyl]-  
MF C23 H22 Cl N7 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-[(3S)-  
 3-hydroxy-2-oxo-1-piperidinyl]phenyl]-  
 MF C22 H18 Cl F N6 O4

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2,3-Pyrazinedicarboxamide, N2-[4-[cyano[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]amino]phenyl]-N3-(5-cyano-2-pyridinyl)-  
 MF C27 H30 N8 O3 Si




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[cyano[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]-  
 MF C26 H30 Cl N7 O3 Si




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2,3-Pyrazinedicarboxamide, N2-(5-cyano-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-  
 MF C21 H16 N8 O3  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, hydrobromide (1:?)  
 MF C20 H16 Cl N7 O3 . x Br H



● x HBr

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-(5-bromo-6-methyl-2-pyridinyl)-  
 MF C11 H9 Br N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Butanoic acid, 2-[[[2-[6-[[[6-[2-(4-acetyl-2-ethyl-5-hydroxyphenyl)ethyl]-2-pyrazinyl]carbonyl]amino]-1-oxido-2-pyridinyl]acetyl]amino]-  
 MF C28 H31 N5 O7



L11 178 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-2-pyridinyl-5-(trifluoromethyl)-  
MF C11 H8 F3 N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

187.80

566.84

FILE 'CAPLUS' ENTERED AT 15:45:31 ON 25 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Feb 2009 VOL 150 ISS 9

FILE LAST UPDATED: 24 Feb 2009 (20090224/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:35:13 ON 25 FEB 2009)

FILE 'REGISTRY' ENTERED AT 15:35:28 ON 25 FEB 2009

L1 STRUCTURE UPLOADED

L2 50 S L1 SSS SAM



L3 3685 S L1 SSS FULL  
L4 STRUCTURE UPLOADED  
L5 50 S L4 SSS SAM  
L6 3230 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:40:44 ON 25 FEB 2009  
L7 187 S L6 AND (PRY<2005)

FILE 'REGISTRY' ENTERED AT 15:41:20 ON 25 FEB 2009

FILE 'REGISTRY' ENTERED AT 15:42:35 ON 25 FEB 2009  
L8 STRUCTURE UPLOADED  
L9 STRUCTURE UPLOADED  
L10 11 S L9 SSS SAM  
L11 178 S L9 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:45:31 ON 25 FEB 2009

=> s l11

L12 50 L11

=> s l12 and (pry<2005)

4600131 PRY<2005

L13 20 L12 AND (PRY<2005)



=> d 1-20 ibib abs hitstr

L13 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2006:655569 CAPLUS  
DOCUMENT NUMBER: 145:124579  
TITLE: Preparation of condensed imidazole compounds as p38  
MAP kinase inhibitors  
INVENTOR(S): Uchikawa, Osamu; Miwatashi, Seiji  
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan  
SOURCE: PCT Int. Appl., 308 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006070943	A1	20060706	WO 2005-JP24279	20051228 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2594325	A1	20060706	CA 2005-2594325	20051228 <--
EP 1832588	A1	20070912	EP 2005-824476	20051228 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20080167314	A1	20080710	US 2007-794300	20070627 <--
PRIORITY APPLN. INFO.:			JP 2004-381947	A 20041228 <--

OTHER SOURCE(S):  
GI

MARPAT 145:124579



AB Title compds. I [X1-X3 = (un)substituted CH or nitrogen atom with the proviso that any one thereof is a nitrogen atom; X4 = (un)substituted CH; R1 = (un)substituted Ph, (un)substituted heterocycle; R2 = (un)substituted pyridin-4-yl, (un)substituted N-oxidopyridin-4-yl, (un)substituted pyrimidin-4-yl] and salts thereof were prepared. For example, bromination of 2-(2-fluoropyridin-4-yl)-1-(3-methylphenyl)ethanone followed by reaction with 3-amino-6-chloropyridazine afforded compound II. In p38 MAP kinase inhibition assays, the IC<sub>50</sub> value of compound II was 0.11  $\mu$ M. Compds. I are claimed useful for the treatment of inflammation, autoimmune diseases, etc.


IT 896739-42-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of condensed imidazole compds. as p38 MAP kinase inhibitors for treatment of inflammation and autoimmune diseases)

RN 896739-42-7 CAPLUS

CN 2-Pyrazinecarboxamide, N-[4-[2-(4-fluoro-3-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:558961 CAPLUS

DOCUMENT NUMBER: 145:62922

TITLE: Preparation of pyrazinedicarboxamides and related compounds for the treatment of thromboembolic diseases

INVENTOR(S): Roehrig, Susanne; Jeske, Mario; Akbaba, Metin; Rosentreter, Ulrich; Boyer, Stephen; Fischer, Karin; Pohlmann, Jens; Tuch, Arounarith; Perzborn, Elisabeth; Gerdes, Christoph; Schlemmer, Karl-Heinz; Burkhardt, Nils; Allerheiligen, Swen; Nell, Peter; Arndt, Sabine; Lobell, Mario

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006061116	A1	20060615	WO 2005-EP12681	20051128 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004059219	A1	20060614	DE 2004-102004059219	20041209
CA 2594102	A1	20060615	CA 2005-2594102	20051128 <--
EP 1824844	A1	20070829	EP 2005-815232	20051128 <--
EP 1824844	B1	20081105		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008522992	T	20080703	JP 2007-544770	20051128 <--
AT 413396	T	20081115	AT 2005-815232	20051128 <--
US 20060287315	A1	20061221	US 2005-299342	20051208 <--
PRIORITY APPLN. INFO.:				
			DE 2004-102004059219A	20041209 <--
			WO 2005-EP12681	W 20051128

OTHER SOURCE(S): CASREACT 145:62922; MARPAT 145:62922  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [A = substituted pyrrolidinonyl, imidazolidinonyl, 2-oxazolidinonyl, etc.; R1, R2 = H, F, CL, etc.; R3 = H, alkyl, OH, etc.; Z = Ph, pyridyl, pyrimidinyl, etc.] and their pharmaceutically acceptable salts and their formulations were prepared For example, 1,1'-Carbonyldiimidazole mediated cyclization of aminoalc. II afforded pyrazinedicarboxamide III in 19% yield. In blood-coagulation factor Xa inhibition assays, 8-examples of compds. I exhibited IC50 values ranging from 0.16-16 nM.


IT 890822-23-8P 890822-63-6P 890822-79-4P  
890822-87-4P 890822-95-4P 890823-19-5P  
890823-27-5P 890824-07-4P 890824-36-9P  
890824-43-8P 890824-50-7P 890824-58-5P  
890824-73-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazinedicarboxamides and related compds. for the treatment of thromboembolic diseases)


RN 890822-23-8 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (CA INDEX NAME)




RN 890822-63-6 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-oxo-3-oxazolidinyl)phenyl]- (CA INDEX NAME)



RN 890822-79-4 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-(3-hydroxy-2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 890822-87-4 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-[(3S)-3-hydroxy-2-oxo-1-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 890822-95-4 CAPLUS


CN 2,3-Pyrazinededicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-[(3R)-3-hydroxy-2-oxo-1-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 890823-19-5 CAPLUS


CN 2,3-Pyrazinededicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 890823-27-5 CAPLUS


CN 2,3-Pyrazinededicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-(3-oxo-

4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 890824-07-4 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(tetrahydro-3-methyl-2-oxo-1(2H)-pyrimidinyl)phenyl]- (CA INDEX NAME)



RN 890824-36-9 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(tetrahydro-3-methyl-2-oxo-1(2H)-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 890824-43-8 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[tetrahydro-2-oxo-3-[2-(1-pyrrolidinyl)ethyl]-1(2H)-pyrimidinyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 890824-50-7 CAPLUS



CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-[3-(hydroxymethyl)-2-oxo-1(2H)-pyridinyl]phenyl]- (CA INDEX NAME)




RN 890824-58-5 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[3-[(cyclopropylamino)methyl]-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 890824-57-4


CMF C26 H21 Cl F N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 890824-73-4 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-[2-(2-aminoethoxy)-4-(3-oxo-4-morpholinyl)phenyl]-N3-(5-chloro-2-pyridinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 890824-72-3


CMF C23 H22 Cl N7 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 43200-83-5P 890052-06-9P 890826-99-0P


890827-06-2P 1096601-39-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazinedicarboxamides and related compds. for the treatment of thromboembolic diseases)


RN 43200-83-5 CAPLUS

CN 2-Pyrazinecarboxylic acid, 3-[[[5-chloro-2-pyridinyl)amino]carbonyl]- (CA INDEX NAME)




RN 890052-06-9 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (CA INDEX NAME)




RN 890826-99-0 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-(3-formyl-2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 890827-06-2 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]-4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 1096601-39-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:542131 CAPLUS

DOCUMENT NUMBER: 145:46051

TITLE: Preparation of 2-imino-3-phenyloxazolidines and related compounds for the treatment of thromboembolic diseases

INVENTOR(S): Roehrig, Susanne; Pohlmann, Jens; Arndt, Sabine; Jeske, Mario; Akbaba, Metin; Perzborn, Elisabeth; Gerdes, Christoph; Schlemmer, Karl-Heinz; Tuch, Arounarith; Lobell, Mario; Nell, Peter; Burkhardt, Nils

PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006058630	A1	20060608	WO 2005-EP12465	20051122 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004058062	A1	20060608	DE 2004-102004058062	20041202
CA 2589740	A1	20060608	CA 2005-2589740	20051122 <--
EP 1819701	A1	20070822	EP 2005-815274	20051122 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008521844	T	20080626	JP 2007-543733	20051122 <--
US 20080214533	A1	20080904	US 2007-792108	20071213 <--
PRIORITY APPLN. INFO.:			DE 2004-102004058062A	20041202 <--
			WO 2005-EP12465	W 20051122
OTHER SOURCE(S):		MARPAT 145:46051		
GI				



I



II



III

AB Title compds. I [Y = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R<sub>1</sub> = H, alkyl, CN, etc.; R<sub>2</sub>, R<sub>3</sub> = H, halo, CN, etc.; A = phenylene, 5 or 6-membered heteroaryl ring with provisos; Z = Ph, pyridyl, pyrimidinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, methanesulfonic acid mediated cyclization of cyanoamine II afforded the methanesulfonic acid salt of claimed phenyloxazolidine III in 81% yield. In blood-coagulation factor Xa inhibition assays, 4-examples of compds. I

exhibited IC50 values ranging 0.3-4.4 nM.


IT 890051-67-9P 890051-68-0P 890051-71-5P  
890051-72-6P 890051-73-7P 890051-74-8P  
890051-75-9P 890051-76-0P 890051-77-1P  
890051-78-2P 890051-95-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of 2-imino-3-phenyloxazolidines and related compds. for the  
treatment of thromboembolic diseases)


RN 890051-67-9 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-  
oxazolidinyl)phenyl]- (CA INDEX NAME)



RN 890051-68-0 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(dihydro-2-  
imino-2H-1,3-oxazin-3(4H)-yl)phenyl]- (CA INDEX NAME)



RN 890051-71-5 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-  
oxazolidinyl)phenyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CRN 890051-67-9  
 CMF C20 H16 Cl N7 O3




CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 890051-72-6 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, hydrobromide (1:?) (CA INDEX NAME)



●x HBr

RN 890051-73-7 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 890051-74-8 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(dihydro-2-imino-2H-1,3-oxazin-3(4H)-yl)phenyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 890051-68-0  
 CMF C21 H18 Cl N7 O3






CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 890051-75-9 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-[4-(2-imino-3-oxazolidinyl)phenyl]-N3-(5-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 890051-76-0 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-[4-(2-imino-3-oxazolidinyl)phenyl]-N3-(5-methyl-2-pyridinyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 890051-75-9  
CMF C21 H19 N7 O3




CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 890051-77-1 CAPLUS  
CN 2,3-Pyrazinedicarboxamide, N2-(5-cyano-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]- (CA INDEX NAME)



RN 890051-78-2 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-cyano-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 890051-77-1  
 CMF C21 H16 N8 O3




CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 890051-95-3 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[(2Z)-2-(hydroxyimino)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.




IT 43200-83-5P 313973-42-1P 890051-99-7P  
 890052-06-9P 890052-07-0P 890052-08-1P  
 890052-09-2P 890052-10-5P 890052-11-6P  
 890052-12-7P 890052-34-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 2-imino-3-phenyloxazolidines and related compds. for the  
 treatment of thromboembolic diseases)  
 RN 43200-83-5 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 3-[[[5-chloro-2-pyridinyl]amino]carbonyl]- (CA  
 INDEX NAME)



RN 313973-42-1 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 3-[[[5-methyl-2-pyridinyl]amino]carbonyl]- (CA  
 INDEX NAME)




RN 890051-99-7 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 3-[[[5-cyano-2-pyridinyl]amino]carbonyl]- (CA  
 INDEX NAME)




RN 890052-06-9 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (CA INDEX NAME)




RN 890052-07-0 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[cyano[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (CA INDEX NAME)




RN 890052-08-1 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]propyl]amino]phenyl]- (CA INDEX NAME)




RN 890052-09-2 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[cyano[3-[(1,1-dimethylethyl)dimethylsilyl]oxy]propyl]amino]phenyl]- (CA INDEX NAME)




RN 890052-10-5 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-[4-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]-N3-(5-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 890052-11-6 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-[4-[cyano[2-[[[1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]-N3-(5-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 890052-12-7 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-[4-[cyano[2-[[[1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]-N3-(5-cyano-2-pyridinyl)- (CA INDEX NAME)



RN 890052-34-3 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-cyano-2-pyridinyl)-N3-[4-[[2-[[1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1288059 CAPLUS

DOCUMENT NUMBER: 144:36255

TITLE: Preparation of heteroaryl amides for therapeutic use as cannabinoid receptor modulators

INVENTOR(S): Amin, Kosrat; Broddefalk, Johan; Desfosses, Helene; Evertsson, Emma; Liu, Ziping; Milburn, Claire; Nilsson, Karolina; Tremblay, Maxime; Walpole, Christopher; Wei, Zhong-Yong; Yang, Hua

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 257 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115986	A1	20051208	WO 2005-SE753	20050520 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005247834	A1	20051208	AU 2005-247834	20050520 <--
CA 2565065	A1	20051208	CA 2005-2565065	20050520 <--
EP 1756060	A1	20070228	EP 2005-745177	20050520 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 101001840	A	20070718	CN 2005-80024696	20050520 <--
BR 2005011531	A	20080102	BR 2005-11531	20050520 <--
JP 2008500336	T	20080110	JP 2007-514980	20050520 <--
IN 2006DN06643	A	20070831	IN 2006-DN6643	20061109 <--
US 20070225292	A1	20070927	US 2006-569315	20061117 <--
MX 2006013538	A	20070126	MX 2006-13538	20061122 <--
NO 2006005878	A	20070221	NO 2006-5878	20061218 <--
PRIORITY APPLN. INFO.:			SE 2004-1345	A 20040525 <--
			WO 2005-SE753	W 20050520
OTHER SOURCE(S):			CASREACT 144:36255; MARPAT 144:36255	
GI				




AB Heteroaryl amides, such as I [A1, A2, A3, A4 = N, CR1; R = (CH2)nR4; R1 = H, CN, NH2, NHCOMe, OH, halogen, alkylamino, alkoxy, etc.; R2 = aryl, heterocyclyl; R3 = H, alkyl; R4 = cycloalkyl, aryl, heterocyclyl, heterocyclylamino, etc.; m = 0-2; n = 0-5], were prepared for use in pharmaceutical compns. as cannabinoid types CB1 and CB2 receptor modulators which are useful in therapy, in particular in the management of pain. These amides are also claimed for use in the treatment of functional gastrointestinal disorders, irritable bowel syndrome, anxiety, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, and cardiovascular disorders. Thus, N-(cyclobutylmethyl)-3-[(1-naphthalenylcarbonyl)amino]-2-pyridinecarboxamide II (R2 = 1-naphthalenyl) was prepared starting from cyclobutylmethylamine, 1-naphthalenecarbonyl chloride, and 3-amino-2-pyridinecarboxylic acid. Some of the prepared amides were assayed for CB1 and CB2 receptor binding activity.

IT 280115-50-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of heteroaryl amides for therapeutic use as

cannabinoid receptor modulators)  
 RN 280115-50-6 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-(5-chloro-2-pyridinyl)-3-[[4-(1,1-dimethylethyl)benzoyl]amino]- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:962046 CAPLUS  
 DOCUMENT NUMBER: 143:266952  
 TITLE: Preparation of bipyridyl amides as modulators of metabotropic glutamate receptor-5  
 INVENTOR(S): Bonnefous, Celine; Kamenecka, Theodore M.; Vernier, Jean-Michel  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 79 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079802	A1	20050901	WO 2005-US3952	20050209 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005215379	A1	20050901	AU 2005-215379	20050209 <--
CA 2555402	A1	20050901	CA 2005-2555402	20050209 <--
EP 1715867	A1	20061102	EP 2005-713111	20050209 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1933838	A	20070321	CN 2005-80004732	20050209 <--
JP 2007524682	T	20070830	JP 2006-553189	20050209 <--
IN 2006DN04346	A	20070713	IN 2006-DN4346	20060727 <--

US 20070149547 A1 20070628 US 2006-589407 20060811 <--  
 PRIORITY APPLN. INFO.: US 2004-544627P P 20040212 <--  
 WO 2005-US3952 W 20050209  
 OTHER SOURCE(S): CASREACT 143:266952; MARPAT 143:266952  
 GI




AB The title compds. I [X = N, C; Y = N, C, C(halo); R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, aryl, etc.; R3 = aryl, halo, alkyl, etc.; R2 and R3 may be joined together with the atoms to which they are attached to form a (un)saturated 4-7 membered ring containing 0-2 heteroatoms selected from


O, S and N; R4 = aryl, heteroaryl, halo, etc.] which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases, were prepared. Thus, amidation of pyridin-2-amine with 3-amino-5,6-diphenylpyrazine-2-carboxylic acid afforded the amide II. The exemplified compds. I have mGluR5 inhibitory activity as shown by inhibition at 10  $\mu$ M or less in the calcium flux assay or 100  $\mu$ M or less or less in the PI assay. The invention is also directed to pharmaceutical compns. comprising compds. I.

IT 848187-30-4P 863909-18-6P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of bipyridyl amides as modulators of metabotropic glutamate receptor-5)

RN 848187-30-4 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-bromo-N-2-pyridinyl- (CA INDEX NAME)



RN 863909-18-6 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-N-[6-[2-(trimethylsilyl)ethynyl]-2-pyridinyl]- (CA INDEX NAME)




IT 37804-11-8P 848187-22-4P 848187-24-6P  
 848187-26-8P 848187-27-9P 848187-28-0P  
 848187-29-1P 848187-31-5P 848187-32-6P  
 848187-34-8P 848187-35-9P 863908-32-1P  
 863908-34-3P 863908-36-5P 863908-42-3P  
 863908-44-5P 863908-46-7P 863908-64-9P  
 863908-66-1P 863908-69-4P 863908-71-8P  
 863908-73-0P 863908-77-4P 863908-79-6P  
 863908-81-0P 863908-83-2P 863908-87-6P  
 863908-92-3P 863908-94-5P 863908-98-9P  
 863909-02-8P 863909-04-0P 863909-07-3P  
 863909-09-5P 863909-11-9P 863909-16-4P  
 863909-22-2P 863909-38-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bipyridyl amides as modulators of metabotropic glutamate receptor-5)


RN 37804-11-8 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-5-(dimethylamino)-N-2-pyridinyl- (CA INDEX NAME)




RN 848187-22-4 CAPLUS

CN 2-Pyrazinecarboxamide, 6-chloro-5-(dimethylamino)-N-2-pyridinyl- (CA INDEX NAME)




RN 848187-24-6 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-5-(1-piperidinyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 848187-26-8 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-N-2-pyridinyl- (CA INDEX NAME)




RN 848187-27-9 CAPLUS  
 CN 2-Pyrazinecarboxamide, 6-chloro-N-2-pyridinyl- (CA INDEX NAME)




RN 848187-28-0 CAPLUS  
 CN 2-Pyrazinecarboxamide, 6-methyl-N-2-pyridinyl- (CA INDEX NAME)




RN 848187-29-1 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-2-pyridinyl- (CA INDEX NAME)




RN 848187-31-5 CAPLUS  
CN 2-Pyrazinecarboxamide, 3-amino-6-methyl-N-2-pyridinyl- (CA INDEX NAME)




RN 848187-32-6 CAPLUS  
CN 2-Pyrazinecarboxamide, 6-chloro-3-(methylamino)-N-2-pyridinyl- (CA INDEX NAME)



RN 848187-34-8 CAPLUS  
CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-N-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 848187-35-9 CAPLUS  
CN 2-Pyrazinecarboxamide, 3-amino-6-methyl-N-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 863908-32-1 CAPLUS  
CN 2-Pyrazinecarboxamide, 3-amino-5,6-diphenyl-N-2-pyridinyl- (CA INDEX NAME)

NAME)




RN 863908-34-3 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-5-[(2-furanylmethyl)amino]-N-2-pyridinyl- (CA INDEX NAME)




RN 863908-36-5 CAPLUS

CN 2-Pyrazinecarboxamide, 6-chloro-3-(dimethylamino)-5-[(2-furanylmethyl)amino]-N-2-pyridinyl- (CA INDEX NAME)




RN 863908-42-3 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-phenyl-N-2-pyridinyl- (CA INDEX NAME)




RN 863908-44-5 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-5-(methylthio)-N-2-pyridinyl- (CA INDEX NAME)




RN 863908-46-7 CAPLUS  
 CN 2-Pyrazinecarboxamide, 6-bromo-3-(methylthio)-N-2-pyridinyl- (CA INDEX NAME)



RN 863908-64-9 CAPLUS  
 CN 2-Pyridinecarboxylic acid, 6-[[[(3-amino-6-chloro-2-pyrazinyl)carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 863908-66-1 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-N-(3-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 863908-69-4 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-(2-cyanophenyl)-N-2-pyridinyl- (CA INDEX NAME)







RN 863908-71-8 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-2-pyridinyl-6-(3-pyridinyl)- (CA INDEX NAME)




RN 863908-73-0 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-methoxy-N-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 863908-77-4 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-N-(6-phenyl-2-pyridinyl)- (CA INDEX NAME)




RN 863908-79-6 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-N-(6-cyano-2-pyridinyl)- (CA  
 INDEX NAME)




RN 863908-81-0 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-N-[6-(1H-imidazol-1-yl)-2-  
 pyridinyl]- (CA INDEX NAME)




RN 863908-83-2 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-[2,4'-bipyridin]-6-yl-6-chloro- (CA  
 INDEX NAME)




RN 863908-87-6 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-5-methoxy-N-2-pyridinyl- (CA  
 INDEX NAME)




RN 863908-92-3 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-2-pyridinyl-5-(trifluoromethyl)- (CA INDEX NAME)




RN 863908-94-5 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-2-pyridinyl-6-(trifluoromethyl)- (CA INDEX NAME)




RN 863908-98-9 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-5-chloro-6-phenyl-N-2-pyridinyl- (CA INDEX NAME)




RN 863909-02-8 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-5-(ethylamino)-N-2-pyridinyl- (CA INDEX NAME)




RN 863909-04-0 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-ethyl-N-2-pyridinyl- (CA INDEX NAME)




RN 863909-07-3 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-5-[(1-methylethyl)amino]-N-2-pyridinyl- (CA INDEX NAME)




RN 863909-09-5 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-butyl-N-2-pyridinyl- (CA INDEX NAME)




RN 863909-11-9 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-5,6-dimethyl-N-2-pyridinyl- (CA INDEX NAME)




RN 863909-16-4 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-5,6-dimethyl-N-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 863909-22-2 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-N-(6-ethynyl-2-pyridinyl)- (CA INDEX NAME)




RN 863909-38-0 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-cyano-N-2-pyridinyl- (CA INDEX NAME)




IT 863909-60-8 863909-63-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of bipyridyl amides as modulators of metabotropic glutamate receptor-5)  
 RN 863909-60-8 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-bromo-N-(6-methyl-2-pyridinyl)- (CA INDEX NAME)

INDEX NAME)



RN 863909-63-1 CAPLUS  
CN 2-Pyrazinecarboxamide, 3-amino-N-(6-bromo-2-pyridinyl)-6-chloro- (CA  
INDEX NAME)





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:216820 CAPLUS  
DOCUMENT NUMBER: 142:297926  
TITLE: Preparation of substituted 8-heteroaryl xanthines for  
use in pharmaceutical compositions as selective  
antagonists of A2B adenosine receptors  
INVENTOR(S): Wang, Guoquan; Rieger, Jayson M.; Thompson, Robert D.  
PATENT ASSIGNEE(S): Adenosine Therapeutics, LLC, USA  
SOURCE: PCT Int. Appl., 91 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021548	A2	20050310	WO 2004-US27133	20040820 <--
WO 2005021548	A3	20050630		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,			

SN, TD, TG

AU 2004268964	A1	20050310	AU 2004-268964	20040820	<--
CA 2536553	A1	20050310	CA 2004-2536553	20040820	<--
US 20050065341	A1	20050324	US 2004-923592	20040820	<--
US 7342006	B2	20080311			
EP 1658291	A2	20060524	EP 2004-781752	20040820	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004013922	A	20061024	BR 2004-13922	20040820	<--
CN 1894250	A	20070110	CN 2004-80031455	20040820	<--
JP 2007503443	T	20070222	JP 2006-524755	20040820	<--
MX 2006002223	A	20061211	MX 2006-2223	20060224	<--
KR 2006132549	A	20061221	KR 2006-703776	20060224	<--
IN 2006CN01014	A	20070629	IN 2006-CN1014	20060324	<--
US 20080200456	A1	20080821	US 2007-956876	20071214	<--
PRIORITY APPLN. INFO.:			US 2003-497875P	P	20030825 <--
			US 2004-923592	A1	20040820 <--
			WO 2004-US27133	W	20040820 <--
OTHER SOURCE(S):			CASREACT 142:297926; MARPAT 142:297926		
GI					



AB Xanthines, such as I [R = H, alkyl, haloalkyl, alkenyl, alkynyl, etc.; R1, R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl, heteroalkyl, etc.; X = 5-10 membered heteroaryl containing at least one nitrogen atom and optionally other heteroatoms; Z = alkoxy, alkylthio, amino, heterocyclyl, etc.; Z1 = alkyl, alkenyl, alkynyl, etc.; n = 0-8], were prepared for therapeutic use in the treatment of pathol. conditions or symptoms, wherein the activity of adenosine A2B receptors is implicated and antagonism of their action is desired. These xanthine derivs. are claimed for use in the treatment of asthma, allergies, allergic disease, autoimmune disease, diarrheal disease, insulin resistance, diabetes, cancer, ischemia/reperfusion injuries, diabetic retinopathy or hyperbaric oxygen-induced retinopathy. Thus, xanthine derivative II (R3 = NHCH2Me) was prepared via cyclocondensation of 6-chloronicotinoyl chloride with 5,6-diamino-1,3-dipropyluracil to form chloride II (R3 = Cl) and a subsequent amination reaction of the chloride with MeCH2NH2. The prepared xanthines were screened for A2B adenosine receptor antagonist activity.


IT 847611-96-5P 847611-98-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of substituted 8-heteroaryl xanthines for use in pharmaceutical compns. as selective antagonists of A2B adenosine receptors)

RN 847611-96-5 CAPLUS

CN 2-Pyrazinecarboxamide, N-[5-(1,3-diethyl-2,3,6,9-tetrahydro-2,6-dioxo-1H-purin-8-yl)-2-pyridinyl]-N-methyl- (CA INDEX NAME)



RN 847611-98-7 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-methyl-N-[5-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-2-pyridinyl]- (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:515503 CAPLUS  
 DOCUMENT NUMBER: 141:71452  
 TITLE: Preparation of pyridine derivatives as JNK inhibitors  
 INVENTOR(S): Kallin, Elisabeth; Plobeck, Niklas; Swahn, Britt-Marie  
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.  
 SOURCE: PCT Int. Appl., 98 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052880	A1	20040624	WO 2003-SE1911	20031208 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003302919	A1	20040630	AU 2003-302919	20031208 <--
PRIORITY APPLN. INFO.:			SE 2002-3654	A 20021209 <--
			WO 2003-SE1911	W 20031208 <--
OTHER SOURCE(S):		MARPAT 141:71452		
GI				





AB The title compds. [I; R1 = aryl or heteroaryl, each of which is optionally substituted with one or more of R3, OR3, OCOR3, COOR3, COR3, CONR3R4, NHCOR3, NR3R4, NHSO2R3, SO2R3, SO2NR3R4, SR3, CN, halo, NO2; R2 = R5, R6, COR5, COR6, CONHR5, CONHR6, CON(R6)2, COOR5, COOR6, SO2R5, SO2R6; R3, R4 = H, alkyl, cycloalkyl, etc.; R5 = (un)substituted (hetero)aryl; R6 = H, alkyl, cycloalkyl, etc.], were prepared and formulated. E.g., a 4-step synthesis of N,N'-bis[4-(trifluoromethyl)phenyl]-4,4'-bipyridine-2,2'-diamine, starting from 2-chloropyridine, was given. Typical Ki values for the compds. I are in the range of about 0.001 to about 10,000 nM in assay for inhibition of JNK3.


IT 712268-69-4P 712269-06-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4,4-bipyridine-2,2'-diamine derivs. as JNK inhibitors)


RN 712268-69-4 CAPLUS

CN 2-Pyrazinecarboxamide, N-[2'-(phenylamino)[4,4'-bipyridin]-2-yl]- (CA INDEX NAME)



RN 712269-06-2 CAPLUS

CN 2-Pyrazinecarboxamide, 5-methyl-N-[2'-(phenylamino)[4,4'-bipyridin]-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 2000:457058 CAPLUS

DOCUMENT NUMBER: 133:73942

TITLE: Preparation of heteroroaromatic amides as factor Xa inhibitors

INVENTOR(S): Beight, Douglas Wade; Craft, Trelia Joyce;  
 Franciskovich, Jeffrey Bernard; Goodson, Theodore, Jr.;  
 Hall, Steven Edward; Herron, David Kent; Joseph, Sajan  
 Pariyadan; Klimkowski, Valentine Joseph; Masters, John  
 Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez,  
 Marta Maria; Sawyer, Jason Scott; Shuman, Robert  
 Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise;  
 Tinsley, Jennifer Marie; Weir, Leonard Crayton; Wikel,  
 James Howard; Wiley, Michael Robert; Yee, Ying Kwong  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Kyle, Jeffrey Alan  
 SOURCE: PCT Int. Appl., 93 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039117	A1	20000706	WO 1999-US29887	19991215 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2358095	A1	20000706	CA 1999-2358095	19991215 <--
EP 1140905	A1	20011010	EP 1999-967352	19991215 <--
EP 1140905	B1	20030514		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 240316	T	20030515	AT 1999-967352	19991215 <--
ES 2196917	T3	20031216	ES 1999-967352	19991215 <--
US 6689780	B1	20040210	US 2001-857749	20010608 <--
PRIORITY APPLN. INFO.:			US 1998-113452P	P 19981223 <--
			EP 1999-967352	A 19991215 <--
			WO 1999-US29887	W 19991215 <--
OTHER SOURCE(S):			MARPAT 133:73942	
GI				



AB R2Z2ZCONHZ1R1 [I; R1 = Cl, F, Me; R2 = N-(un)substituted azacycloalkyl,  
 4-(un)substituted -1-piperazinyl, 4-aminocyclohexyl,  
 4-amino-1-piperidinyl, etc.; Z = (un)substituted-2,3- or

-3,2-pyridinediyl, -5,4- or -4,5-pyrimidinediyl, -2,3-pyrazinediyl, etc.; Z1 = 2,5-pyridinediyl (R1 may addnl. = MeO or MeS), 2,5-pyrimidinediyl, 3,6-pyridazinediyl, 2,6-benzothiazolediyl; Z2 = NHCOX, NHCO2X, NHCONHX, NHCH2; X = bond or CH2] were prepared as factor Xa inhibitors (no data).

Thus, 2-chloronicotinic acid was aminated by


1-(4-pyridinyl)piperidine-4-methylamine (preparation given) and the product amidated by 2-amino-5-chloropyridine to give title compound II.

IT 280115-50-6P 280115-72-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of heteroroarom. amides as factor Xa inhibitors)


RN 280115-50-6 CAPLUS

CN 2-Pyrazinecarboxamide, N-(5-chloro-2-pyridinyl)-3-[[4-(1,1-dimethylethyl)benzoyl]amino]- (CA INDEX NAME)



RN 280115-72-2 CAPLUS

CN 2-Pyrazinecarboxamide, N-(5-chloro-2-pyridinyl)-3-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]- (CA INDEX NAME)




IT 280115-75-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heteroroarom. amides as factor Xa inhibitors)

RN 280115-75-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(5-chloro-2-pyridinyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:260225 CAPLUS

DOCUMENT NUMBER: 132:294010

TITLE: Preparation of diaminopropionic acid derivatives as intracellular adhesion molecule-1 (ICAM-1) binding inhibitors

INVENTOR(S): Fotouhi, Nader; Gillespie, Paul; Guthrie, Robert William; Pietranico-Cole, Sherrie Lynn; Yun, Weiya

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 259 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021920	A1	20000420	WO 1999-EP7620	19991012 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6331640	B1	20011218	US 1999-407534	19990929 <--
CA 2344058	A1	20000420	CA 1999-2344058	19991012 <--
BR 9914602	A	20010703	BR 1999-14602	19991012 <--
EP 1121342	A1	20010808	EP 1999-953772	19991012 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101038	T2	20010921	TR 2001-1038	19991012 <--
JP 2002527416	T	20020827	JP 2000-575829	19991012 <--
JP 3720709	B2	20051130		
AU 766468	B2	20031016	AU 2000-10349	19991012 <--
CN 1274670	C	20060913	CN 1999-812099	19991012 <--
MX 2001003284	A	20011011	MX 2001-3284	20010329 <--
ZA 2001002608	A	20020930	ZA 2001-2608	20010329 <--
US 20020052512	A1	20020502	US 2001-879700	20010612 <--
US 20040006236	A1	20040108	US 2003-349289	20030122 <--
US 6803384	B2	20041012		
US 20050080119	A1	20050414	US 2004-945650	20040921 <--
US 7217728	B2	20070515		
US 20070155671	A1	20070705	US 2007-703925	20070208 <--
US 7491741	B2	20090217		
PRIORITY APPLN. INFO.:			US 1998-104120P	P 19981013 <--
			US 1999-407534	A3 19990929 <--
			WO 1999-EP7620	W 19991012 <--

US 2001-879700

B3 20010612 <--

US 2003-349289

A3 20030122 <--


US 2004-945650

A3 20040921 <--

OTHER SOURCE(S):

MARPAT 132:294010

GI



AB Diaminopropionic acid derivs. I [R1 = substituted 1-naphthyl, 4-indolyl, 4-benzimidazolyl, 4-benzodiazolyl, 4-benzotriazolyl, or phenyl; R2 = CHR3NHCO (R3 = H, carboxy, alkyl), CH2CH2CO, 1,2-cyclopropanediylcarbonyl, OCH2CO, CH:CHCHR3, CH2CH2CH(OH), CONHCHR3, or CH2NH-5,1-tetrazolediyl; U, V, W = H, halo, alkyl provided that U and V are not both hydrogen; X = CO, phenylalkylene, sulfonyl; Y = alkylene which may be substituted by amino or cycloalkyl, alkenylene, alkylenethio; Z = H, alkylthio, CO2H, CONH2, 1-adamantyl, diphenylmethyl, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-2-pyrazinyl, hydroxy, phenylmethoxy, 2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]phenyl, [(2,6-dichlorophenyl)methoxy], Ph, (un)substituted cycloalkyl or aryl or fused ring system which may contain 0-3 heteroatoms; m, n = 0, 1] or their pharmaceutically acceptable salts or esters were prepared and are useful for treating rheumatoid arthritis, psoriasis, multiple sclerosis, Crohn's disease, ulcerative colitis, atherosclerosis, restenosis, pancreatitis, transplant rejection, delayed graft function and diseases of ischemia reperfusion injury, including acute myocardial infarction and stroke. Thus, N-[2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]benzoyl]-3-(3-methoxybenzoylamino)-L-alanine was prepared by the solid-phase method and showed IC50 = 1.2 nM in the LFA-1 (lymphocyte function-associated antigen-1)/ICAM-1 protein-protein assay.

IT 264274-09-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of diaminopropionic acid derivs. as intracellular adhesion mol.-1 (ICAM-1) binding inhibitors)

RN 264274-09-1 CAPLUS


CN L-Alanine, N-[2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]benzoyl]-3-[[[3-[(5-chloro-2-pyridinyl)amino]carbonyl]pyrazinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



IT 43200-83-5  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of diaminopropionic acid derivs. as intracellular adhesion  
mol.-1 (ICAM-1) binding inhibitors)  
RN 43200-83-5 CAPLUS  
CN 2-Pyrazinecarboxylic acid, 3-[[5-chloro-2-pyridinyl)amino]carbonyl]- (CA  
INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:479386 CAPLUS

DOCUMENT NUMBER: 127:121881

ORIGINAL REFERENCE NO.: 127:23517a, 23520a

TITLE: Preparation of  
[(carbamoylheterocyclyl)methyl]phosphonic acid diester  
derivatives as drugs

INVENTOR(S): Miyata, Kazuyoshi; Sakai, Yasuhiro; Shoji, Yasuo;  
Tsuda, Yoshihiko; Inoue, Yasuhide; Sato, Keigo; Miki,  
Shinya

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724360	A1	19970710	WO 1996-JP3775	19961224 <--
W: AU, CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2241679	A1	19970710	CA 1996-2241679	19961224 <--
CA 2241679	C	20020212		
AU 9711734	A	19970728	AU 1997-11734	19961224 <--
AU 702980	B2	19990311		
EP 882730	A1	19981209	EP 1996-942639	19961224 <--
EP 882730	B1	20021002		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1206419	A	19990127	CN 1996-199436	19961224 <--
CN 1070863	C	20010912		
AT 225357	T	20021015	AT 1996-942639	19961224 <--
ES 2181928	T3	20030301	ES 1996-942639	19961224 <--
JP 3500468	B2	20040223	JP 1997-524176	19961224 <--
TW 438806	B	20010607	TW 1996-85116065	19961226 <--
US 5985858	A	19991116	US 1998-91946	19980626 <--
PRIORITY APPLN. INFO.:			JP 1995-340909	A 19951227 <--
			WO 1996-JP3775	W 19961224 <--
OTHER SOURCE(S):			MARPAT 127:121881	
GI				



I

AB Phosphonic acid diester derivs. represented by general formula  
 $R_1R_2NCO-A-CH_2P(=O)(OR_3)OR_4$  [R1 = cycloalkyl, (un)substituted Ph, lower haloalkyl, 1,3,4-thiadiazol-2-yl, thiazolyl, (halo)pyridyl, benzothiazol-2-yl having 1 or 2 lower alkyl group on the Ph ring, 4,5-dihydrothieno[3,2-e]benzothiazol-2-yl; R2 = H, phenyl-lower alkyl; R3, R4 = lower alkyl; A = a heterocycle selected from among pyrazine, thiophene and phenyl-substituted thiazole rings] which are useful as remedies for hyperlipidemia and diabetes, antitumor agents, and preventives or remedies for cataract, are prepared Thus, 5-bromomethyl-2-thiophenecarboxylic acid was heated with tri-Et phosphite at 160° under stirring for 1 h and the reaction mixture was dissolved in 200 mL EtOH, treated dropwise with 4 N aqueous NaOH under ice-cooling, and stirred at room temperature for 12 h to give 5-[(diethoxyphosphoryl)methyl]-2-thiophenecarboxylic acid. The latter compound was stirred with SOCl2 at room temperature for 4 h to give 5-[(diethoxyphosphoryl)methyl]-2-thiophenecarbonyl chloride which was condensed with 4-methoxyaniline in the presence of pyridine in CH2Cl2 at room temperature for 12 h to give the title compound (I; X = MeO, X1 = H). I

(X =

Cl, X1 = COMe) at 100 mg/kg p.o. lowered the serum triglyceride level by 71% in rats administered i.v. with Triton WR1339.


IT 192723-78-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of [(carbamoylheterocyclyl)methyl]phosphonic acid diester  
 derivs. as drugs)

RN 192723-78-7 CAPLUS

CN Phosphonic acid, [[5-[(2-pyridinylamino)carbonyl]pyrazinyl]methyl]-,  
 diethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:476652 CAPLUS

DOCUMENT NUMBER: 125:142578

ORIGINAL REFERENCE NO.: 125:26685a,26688a

TITLE: Pyridopyrimidones, quinolines and fused N-heterocycles  
 as bradykinin antagonists.

INVENTOR(S): Oku, Teruo; Kayakiri, Hiroshi; Satoh, Shigeki; Abe,  
 Yoshito; Sawada, Yuki; Inoue, Takayuki; Tanaka,  
 Hirokazu

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 263 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9613485	A1	19960509	WO 1995-JP2192	19951025 <--
W: AU, CA, CN, HU, JP, KR, MX, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2203659	A1	19960509	CA 1995-2203659	19951025 <--
AU 9537536	A	19960523	AU 1995-37536	19951025 <--
AU 705883	B2	19990603		
EP 807105	A1	19971119	EP 1995-935563	19951025 <--
EP 807105	B1	20040616		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
CN 1168667	A	19971224	CN 1995-196602	19951025 <--
JP 10507764	T	19980728	JP 1996-514166	19951025 <--
JP 3697486	B2	20050921		
AT 269310	T	20040715	AT 1995-935563	19951025 <--
ES 2218554	T3	20041116	ES 1995-935563	19951025 <--
US 5994368	A	19991130	US 1997-809416	19970425 <--
PRIORITY APPLN. INFO.:			GB 1994-21684	A 19941027 <--
			GB 1995-12339	A 19950616 <--
			WO 1995-JP2192	W 19951025 <--

OTHER SOURCE(S): MARPAT 125:142578

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*



AB The invention relates to title compds. I [Z = group Q1 or Q2; X1 = N or CR1; X2 = N or CR9; X3 = N or CR2; R1 = alkyl; R2 = H, (un)substituted alkyl, alkoxy, halo, aryl, amino, etc.; R3 = H, alkyl, alkoxy, halo; R4 = alkyl, alkoxy, halo; R5 = OH, nitro, (un)substituted alkoxy, substituted piperazinyl, NR6R7; R6 = H, alkyl; R7 = H, alkoxy, carbonyl, (un)substituted aroyl, carbamoyl, -(AA)COQR8, -(AA)R10; R8 = (un)substituted arylthio, aryloxy, arylamino, heterocyclylthio, heterocyclylamino, etc.; R9 = H, alkyl; R10 = H, acylbiphenyl; A = alkylene; (AA) = amino acid; Y = O, NR11; R11 = H, N-protective group], and pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compns., and therapeutic use in the prevention and/or the treatment of bradykinin-mediated diseases. Such diseases include allergy, inflammation, autoimmune disease, shock, and pain. For instance, amidation of 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoline with (E)-3-[6-(ethoxycarbonyl)-3-pyridyl]acrylic acid [preps. given] using EDC and HOBt in DMF gave title compound II. The similarly prepared title compound III.HCl gave 100% inhibition of [3H]-bradykinin binding to rat ileum receptors in vitro at 10<sup>-6</sup> M.


IT 179621-24-0P 179621-25-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyridopyrimidones, quinolines, and fused N-heterocycles as bradykinin antagonists)

RN 179621-24-0 CAPLUS

CN Pyrazinecarboxamide, N-[5-[3-[[2-[[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl]amino]-3-oxo-1-propenyl]-2-pyridinyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


PAGE 1-A



—Me

RN 179621-25-1 CAPLUS  
 CN Pyrazinecarboxamide, N-[5-[3-[[2-[[2,4-dichloro-3-[[ (2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl]amino]-3-oxo-1-propenyl]-2-pyridinyl]-, trihydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● 3 HCl

— Me

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:163886 CAPLUS

DOCUMENT NUMBER: 124:202306

ORIGINAL REFERENCE NO.: 124:37409a, 37412a

TITLE: Preparation of  
N-pyridylheterocycl(alkane)carboxamides as  
antiinflammatories

INVENTOR(S): Robert, Jean-Michel; Rideau, Odile; Robert-Piessard,  
Sylvie; Courant, Jacqueline; Le Baut, Guillaume;  
Caignard, Daniel-Henri; Renard, Pierre; Adam, Gerard

PATENT ASSIGNEE(S): Adir et Compagnie, Fr.

SOURCE: Eur. Pat. Appl., 35 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 684241	A1	19951129	EP 1995-401194	19950523 <--
EP 684241	B1	19970827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2720396	A1	19951201	FR 1994-6412	19940527
FR 2720396	B1	19960628		
AT 157362	T	19970915	AT 1995-401194	19950523 <--
ES 2107284	T3	19971116	ES 1995-401194	19950523 <--
FI 9502550	A	19951128	FI 1995-2550	19950524 <--
CA 2150162	A1	19951128	CA 1995-2150162	19950525 <--
CA 2150162	C	20020514		
AU 9520288	A	19951207	AU 1995-20288	19950525 <--
AU 683151	B2	19971030		
US 5712294	A	19980127	US 1995-450346	19950525 <--
NO 9502075	A	19951128	NO 1995-2075	19950526 <--
NO 308359	B1	20000904		
ZA 9504314	A	19960124	ZA 1995-4314	19950526 <--
CN 1121074	A	19960424	CN 1995-105512	19950526 <--
CN 1053904	C	20000628		
JP 07330764	A	19951219	JP 1995-130573	19950529 <--
JP 3048511	B2	20000605		
US 5843947	A	19981201	US 1997-827344	19970326 <--
PRIORITY APPLN. INFO.:			FR 1994-6412	A 19940527 <--
			US 1995-450346	A3 19950525 <--

OTHER SOURCE(S):  
GI

MARPAT 124:202306




AB Title compds. [I; R1,R2 = (di)(alkyl)amino, alkyl, OH, alkoxy, halo; R3,R4 = H, groups cited for R1; R5 = NRC(:X)ZR6; R = H, alkyl; R6 = heterocyclyl, heteroaryl; 1 of Z1,Z2 = NOm and the other = CH; m = 0 or 1] were prepared. Thus, thiophene-2-acetic acid was amidated by 2-amino-4,6-dimethylpyridine to give title compound II which gave 70% inhibition of carrageenin-induced rat paw inflammation at 10mg/kg orally.

IT 160363-91-7P 174454-08-1P 174454-09-2P  
174454-10-5P 174454-19-4P 174454-26-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-pyridylheterocyclyl(alkane)carboxamides as antiinflammatories)


RN 160363-91-7 CAPLUS

CN 2-Pyrazinecarboxamide, N-(4,6-dimethyl-2-pyridinyl)-5-methyl- (CA INDEX NAME)




RN 174454-08-1 CAPLUS

CN 2-Pyrazinecarboxamide, N-(4,6-dimethyl-2-pyridinyl)- (CA INDEX NAME)




RN 174454-09-2 CAPLUS


CN 2-Pyrazinecarboxamide, N-(5-bromo-4,6-dimethyl-2-pyridinyl)- (CA INDEX NAME)




RN 174454-10-5 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-(3,5-dibromo-4,6-dimethyl-2-pyridinyl)- (CA INDEX NAME)



RN 174454-19-4 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-(4,6-dimethyl-1-oxido-2-pyridinyl)- (CA INDEX NAME)




RN 174454-26-3 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-(4,6-dimethyl-5-nitro-2-pyridinyl)- (CA INDEX NAME)



L13 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1993:169102 CAPLUS  
 DOCUMENT NUMBER: 118:169102  
 ORIGINAL REFERENCE NO.: 118:29009a, 29012a  
 TITLE: Preparation of phoxymethyl(carbamoyl)arenes as leukotriene B4 antagonists  
 INVENTOR(S): Nagata, Hideo; Kawakami, Hajime  
 PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 147 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 516069	A1	19921202	EP 1992-108916	19920527 <--
EP 516069	B1	19960424		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE				
CA 2069667	A1	19921201	CA 1992-2069667	19920527 <--
AU 9217193	A	19930311	AU 1992-17193	19920527 <--
AU 643140	B2	19931104		
AT 137223	T	19960515	AT 1992-108916	19920527 <--
JP 05239004	A	19930917	JP 1992-164065	19920528 <--
US 5225422	A	19930706	US 1992-891256	19920601 <--
PRIORITY APPLN. INFO.:			JP 1991-157725	A 19910531 <--
OTHER SOURCE(S):	MARPAT 118:169102			
GI				




AB Title compds. I (A = alkylene; B, X = (substituted) phenylene, heteroarylene; Y = bond, O; Z = bond, alkylene; R1 = alkyl; R2 = OH, C1-C5 alkoxy; R3, R4 = H, alkyl, alkenyl or alkynyl; R5 = H, C1-C5 alkyl or hydroxyalkyl; R6 = (modified) carboxy; NR5R6 = heteroarom.) were prepared as allergy inhibitors and antiinflammatories (no data). Thus, 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxylic acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, 2-aminothiazole-4-carboxamide, and triethylamine were stirred in CH<sub>2</sub>Cl<sub>2</sub>/DMF at room temperature for 44 h to give 2-[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxamid]thiazol-4-ylcarboxamide.

IT 146460-86-8P 146460-87-9P 146461-18-9P 146461-19-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as antiallergic and antiinflammatory agent)


RN 146460-86-8 CAPLUS

CN 2-Pyridineacetic acid, 6-[[[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]-2-pyrazinyl]carbonyl]amino]- (CA INDEX NAME)




RN 146460-87-9 CAPLUS

CN 2-Pyridineacetic acid, 6-[[[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]-2-pyrazinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 146461-18-9 CAPLUS

CN 2-Pyridineacetic acid, 6-[[[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]-2-pyrazinyl]carbonyl]amino]-, 1-oxide (CA INDEX NAME)



RN 146461-19-0 CAPLUS

CN 2-Pyridineacetic acid, 6-[[[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]-2-pyrazinyl]carbonyl]amino]-, ethyl ester, 1-oxide (CA INDEX NAME)



L13 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:147571 CAPLUS

DOCUMENT NUMBER: 118:147571

ORIGINAL REFERENCE NO.: 118:25387a, 25390a

TITLE: Preparation of  
N-(2-pyridinesulfonyl)-N'-(2-pyrimidinyl)urea  
derivatives as herbicides

INVENTOR(S): Sakashita, Nobuyuki; Nakajima, Toshio; Murai, Shigeo;  
Yoshida, Tsunezo; Nakamura, Yuji; Sawaki, Masahiko;  
Motosawa, Shoichi

PATENT ASSIGNEE(S): Ishihara Sangyo Kaisha, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04253974	A	19920909	JP 1991-100628	19910205 <--

PRIORITY APPLN. INFO.:




JP 1991-100628

19910205 &lt;--

OTHER SOURCE(S):

MARPAT 118:147571

GI




AB The title compds. (I; R1 = cycloalkyl, alkoxyalkyl, (un)substituted Ph, pyridyl, thienyl, furyl, pyrazolyl, or piperazinyl; R2 = (halo)alkyl, cycloalkyl, Ph, PhCH2; R3 = H, halo, (halo)alkyl; X, Y = halo, alkyl, (halo) alkoxy; A = CH, N) are prepared by reaction of 2-pyridinesulfonamide derivs. (II; Z1 = NH2, isocyanato, NHCOR4; R4 = alkyl, aryl; R1 - R3 = same as above) with pyrimidine derivs. (III; Z2 = NH2, when Z1 = isocyanato or NHCOR4; Z2 = isocyanato or NHCOR4, when Z1 = NH2). Thus, cyanation of 2,6-dibromopyridine with CuCN in refluxing DMF and hydrolysis of the resulting 2-bromo-6-cyanopyridine with aqueous NaOH followed by acidification gave 6-bromopicolinic acid. Chlorination of the latter compound with POCl3 under reflux, condensation of the product with N-tert-butyl-6-methylaminopyridine-2-ylsulfonamide in CH2Cl2 containing Et3N, and deprotection of the resulting 6-bromo-N-(6-tert-butylaminosulfonylpyridin-2-yl)-N-methylpicolinamide to 6-bromo-N-(6-aminosulfonylpyridin-2-yl)-N-methylpicolinamide followed by carbamoylation with Ph 2,4- dimethoxypyrimidin-2-yl carbamate gave I (R1 = 6-bromo-2-pyridyl, R2 = Me, R3 = H, X = Y = OMe, A = CH) (IV). IV at 0.31 g/are postemergence completely controlled Ipomoea and Amaranthus retroflexus. A total of 82 I were prepared and were also effective for controlling Sida spinosa and Echinochloa crus-galli.

IT 146371-95-1P 146371-96-2P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)


RN 146371-95-1 CAPLUS

CN 2-Pyrazinecarboxamide, N-[6-[[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-2-pyridinyl]- (CA INDEX NAME)






RN 146371-96-2 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-[6-[[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-2-pyridinyl]-N-methyl- (CA INDEX NAME)




IT 146372-53-4P 146372-54-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as intermediate for (pyridinesulfonyl)pyrimidinylurea herbicide)

RN 146372-53-4 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-[6-(aminosulfonyl)-2-pyridinyl]- (CA INDEX NAME)



RN 146372-54-5 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-[6-(aminosulfonyl)-2-pyridinyl]-N-methyl- (CA INDEX NAME)




L13 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1981:156973 CAPLUS  
 DOCUMENT NUMBER: 94:156973  
 ORIGINAL REFERENCE NO.: 94:25669a,25672a  
 TITLE: Heterocyclic compounds for pharmaceutical compositions  
 INVENTOR(S): Cotrel, Claude; Crisan, Cornel; Jeanmart, Claude; Messer, Mayer N.  
 PATENT ASSIGNEE(S): Rhone-Poulenc Industries S. A., Fr.  
 SOURCE: U.S., 16 pp. Cont.-in-part of U.S. Ser. No. 628,926, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	----	-----	-----	-----
US 4220646	A	19800902	US 1977-790801	19770425 <--
FR 2313060	A1	19761231	FR 1974-36963	19741107
FR 2322600	A1	19770401	FR 1975-27160	19750904
FR 2322600	B1	19790914		
FR 2322601	A1	19770401	FR 1975-27161	19750904
FR 2322601	B1	19790914		
FR 2322602	A1	19770401	FR 1975-27162	19750904
FR 2322602	B1	19790914		
JP 51070776	A	19760618	JP 1975-132198	19751105 <--
ZA 7506954	A	19761027	ZA 1975-6954	19751105 <--
AU 7586331	A	19770512	AU 1975-86331	19751105 <--
AU 503200	B2	19790830		
BE 835325	A1	19760506	BE 1975-161652	19751106 <--
PL 100434	B1	19781031	PL 1975-184578	19751107 <--
JP 52033685	A	19770314	JP 1976-1850	19760110 <--
JP 61041919	B	19860918		
AT 7704019	A	19771015	AT 1977-4019	19770607 <--
AT 7704020	A	19771015	AT 1977-4020	19770607 <--
CS 231958	B2	19850116	CS 1977-5983	19770914 <--
CS 231959	B2	19850116	CS 1977-5984	19770914 <--
JP 55040671	A	19800322	JP 1979-105633	19790821 <--
JP 59019551	B	19840507		
JP 55051087	A	19800414	JP 1979-105632	19790821 <--
JP 60003397	B	19850128		
PRIORITY APPLN. INFO.:			FR 1974-36963	A 19741107 <--
			FR 1975-27160	A 19750904 <--
			FR 1975-27161	A 19750904 <--
			FR 1975-27162	A 19750904 <--
			US 1975-628926	A2 19751105 <--
			FR 1974-56963	A 19741107 <--
			AT 1975-8486	A 19751107 <--
			CS 1975-7510	A3 19751107 <--

OTHER SOURCE(S): MARPAT 94:156973  
GI



I




II

AB The heterocyclic compds. (.apprx.40) I (R1R2 together with the pyrroline ring form an isoindoline, a 2,3,6,7-tetrahydro-5H-1,4-oxathiino[2,3-c]pyrrole, or a 2,3,6,7-tetrahydro-5H-1,4-dithiino[2,3-c]pyrrole; R3 = H, C1-4 alkyl, C2-4 alkenyl, CF3; R4 = chloro-1,8-naphthyridin-2-yl), useful (no data) as tranquilizers, anticonvulsants, muscle relaxants, and hypnotics, were prepared Thus, acetylation of II (R = H) by AcCl gave II (R = Ac). Several pharmaceutical formulations were reported.

IT 43200-83-5  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with thionyl chloride)

RN 43200-83-5 CAPLUS

CN 2-Pyrazinecarboxylic acid, 3-[[ (5-chloro-2-pyridinyl) amino] carbonyl]- (CA INDEX NAME)



L13 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1976:446758 CAPLUS

DOCUMENT NUMBER: 85:46758

ORIGINAL REFERENCE NO.: 85:7607a,7610a

TITLE: Heterocyclic compounds and compositions containing them

INVENTOR(S): Cotrel, Claude; Crisan, Cornel; Jeanmart, Claude; Messer, Mayer N.

PATENT ASSIGNEE(S): Rhone-Poulenc S. A., Fr.

SOURCE: Ger. Offen., 54 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
DE 2550111	A1	19760513	DE 1975-2550111	19751107 <--
DE 2550111	C2	19830915		
FR 2313060	A1	19761231	FR 1974-36963	19741107
FR 2322600	A1	19770401	FR 1975-27160	19750904
FR 2322600	B1	19790914		
FR 2322601	A1	19770401	FR 1975-27161	19750904
FR 2322601	B1	19790914		
FR 2322602	A1	19770401	FR 1975-27162	19750904
FR 2322602	B1	19790914		
NL 7512732	A	19760511	NL 1975-12732	19751030 <--
NL 177405	B	19850416		
NL 177405	C	19850916		
CA 1057755	A1	19790703	CA 1975-238909	19751103 <--
JP 51070776	A	19760618	JP 1975-132198	19751105 <--
DD 122684	A5	19761020	DD 1975-189261	19751105 <--
ZA 7506954	A	19761027	ZA 1975-6954	19751105 <--
AU 7586331	A	19770512	AU 1975-86331	19751105 <--
AU 503200	B2	19790830		
HU 173108	B	19790228	HU 1975-RO868	19751105 <--
IL 48423	A	19790312	IL 1975-48423	19751105 <--
BE 835325	A1	19760506	BE 1975-161652	19751106 <--
DK 7504992	A	19760508	DK 1975-4992	19751106 <--
DK 141098	B	19800114		
DK 141098	C	19800707		
NO 7503713	A	19760510	NO 1975-3713	19751106 <--
NO 143576	B	19801201		
NO 143576	C	19810311		
SE 7512477	A	19760510	SE 1975-12477	19751106 <--
SE 407063	B	19790312		
SE 407063	C	19790621		
GB 1468497	A	19770330	GB 1975-46103	19751106 <--
CH 609057	A5	19790215	CH 1975-14378	19751106 <--
SU 673173	A3	19790705	SU 1975-2186208	19751106 <--
FI 7503127	A	19760508	FI 1975-3127	19751107 <--

FI 60707	B	19811130		
FI 60707	C	19820310		
AT 7508486	A	19770915	AT 1975-8486	19751107 <--
PL 100434	B1	19781031	PL 1975-184578	19751107 <--
PL 101248	B1	19781230	PL 1975-199797	19751107 <--
CS 231957	B2	19850116	CS 1975-7510	19751107 <--
JP 52033685	A	19770314	JP 1976-1850	19760110 <--
JP 61041919	B	19860918		
AT 7704019	A	19771015	AT 1977-4019	19770607 <--
AT 7704020	A	19771015	AT 1977-4020	19770607 <--
CS 231958	B2	19850116	CS 1977-5983	19770914 <--
CS 231959	B2	19850116	CS 1977-5984	19770914 <--
JP 54098790	A	19790803	JP 1978-125257	19781013 <--
JP 55008508	B	19800304		
JP 55040671	A	19800322	JP 1979-105633	19790821 <--
JP 59019551	B	19840507		
JP 55051087	A	19800414	JP 1979-105632	19790821 <--
JP 60003397	B	19850128		

PRIORITY APPLN. INFO.:

FR 1974-36963	A	19741107 <--
FR 1975-27160	A	19750904 <--
FR 1975-27161	A	19750904 <--
FR 1975-27162	A	19750904 <--
FR 1974-56963	A	19741107 <--
AT 1975-8486	A	19751107 <--
CS 1975-7510	A3	19751107 <--


OTHER SOURCE(S): CASREACT 85:46758  
GI



AB Tranquilizing (no data) piperazinocarbonyloxypyrrolones I [RR1 = (CH)<sub>4</sub>, N:CHCH:N, CH:CHCCl:CH, OCH<sub>2</sub>CH<sub>2</sub>S, SCH<sub>2</sub>CH<sub>2</sub>S; R<sub>2</sub> = H, Me, Et, Pr, CHMe<sub>2</sub>, CH:CH<sub>2</sub>, cyclopropyl, cyclohexyl, CH<sub>2</sub>Cl, CF<sub>3</sub>, 3-pyridyl, CH:CHMe, CMe:CH<sub>2</sub>, C.tplbond.CH, CH:CMe<sub>2</sub>, OEt, OMe<sub>2</sub>] and some related compds. (39 compds.) were prepared Thus, 2-amino-1,8-naphthyridin-7-ol was treated with phthalic anhydride, the phthalimide chlorinated, reduced, the indolone II (R<sub>3</sub> = H) treated with ClCO<sub>2</sub>Ph, II (R<sub>3</sub> = CO<sub>2</sub>Ph) treated with piperazine, and II (R<sub>3</sub> = piperazinocarbonyloxy) treated with CH<sub>2</sub>:CHCOCl to give I (RR1 = (CH)<sub>4</sub>, R<sub>2</sub> = CH:CH<sub>2</sub>].

IT 43200-83-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and cyclization of)

RN 43200-83-5 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 3-[[ (5-chloro-2-pyridinyl)amino]carbonyl]- (CA  
 INDEX NAME)



L13 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1973:492284 CAPLUS  
 DOCUMENT NUMBER: 79:92284  
 ORIGINAL REFERENCE NO.: 79:14995a,14998a  
 TITLE: Anticonvulsive and tranquilizing pyrrolopyrazines  
 INVENTOR(S): Cotrel, Claude; Jeanmart, Claude; Messer, Mayer N.  
 PATENT ASSIGNEE(S): Rhone-Poulenc S. A.  
 SOURCE: Ger. Offen., 18 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 2300491	A1	19730719	DE 1973-2300491	19730105 <--
DE 2300491	B2	19770908		
FR 2166314	A1	19730817	FR 1972-505	19720107
FR 2205318	A2	19740531	FR 1972-39731	19721109
DD 102698	A5	19731220	DD 1972-167951	19721228 <--
PL 82478	B1	19751031	PL 1972-159840	19721228 <--
PL 91759	B1	19770331	PL 1972-174539	19721228 <--
PL 91760	B1	19770331	PL 1972-174540	19721228 <--
NL 7217852	A	19730710	NL 1972-17852	19721229 <--
US 3862149	A	19750121	US 1972-319876	19721229 <--
ZA 7300072	A	19730926	ZA 1973-72	19730104 <--
HU 164821	B	19740411	HU 1973-RO691	19730104 <--
AU 7350754	A	19740704	AU 1973-50754	19730104 <--
BE 793730	A1	19730705	BE 1973-126194	19730105 <--
JP 48076892	A	19731016	JP 1973-69	19730105 <--
JP 52003952	B	19770131		
GB 1358680	A	19740703	GB 1973-796	19730105 <--
CH 560702	A5	19750415	CH 1974-11606	19730105 <--
CH 560703	A5	19750415	CH 1974-11607	19730105 <--
AT 323181	B	19750625	AT 1973-100	19730105 <--
CH 564558	A5	19750731	CH 1973-113	19730105 <--
CA 991183	A1	19760615	CA 1973-160620	19730105 <--
SU 548212	A3	19770225	SU 1973-1873290	19730105 <--
NO 136843	B	19770808	NO 1973-62	19730105 <--
CS 180649	B1	19770831	CS 1976-4995	19730105 <--
CS 180650	B2	19770831	CS 1976-4996	19730105 <--
SE 398503	B	19771227	SE 1973-159	19730105 <--
SE 398503	C	19780406		
CS 180610	B2	19780131	CS 1973-122	19730105 <--
FI 54124	B	19780630	FI 1973-27	19730105 <--
FI 54124	C	19781010		
DK 139359	B	19790205	DK 1973-69	19730105 <--

DK 139359	C	19790709		
SU 507240	A3	19760315	SU 1974-1993903	19740206 <--
SU 504484	A3	19760225	SU 1974-1995434	19740213 <--
JP 52048687	A	19770418	JP 1976-106831	19760908 <--
JP 52031358	B	19770813		
JP 52048688	A	19770418	JP 1976-106832	19760908 <--
PRIORITY APPLN. INFO.:			FR 1972-505	A 19720107 <--
			FR 1972-39731	A 19721109 <--


GI For diagram(s), see printed CA Issue.

AB Five pyrrolopyrazines (I; R = 3-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 5-chloro-2-pyridyl, 6-methyl-3-pyridazinyl, or 7-chloro-2-quinolyl; n = 0 or 1), useful as tranquilizers and anticonvulsants, were prepared by reaction of II with YCl or successively with ClCO<sub>2</sub>Ph and 1-methylpiperazine, optionally followed by oxidation II were prepared by reaction of RNH<sub>2</sub> with 2,3-pyrazinedicarboxylic anhydride, followed by ring closure, and KBH<sub>4</sub> reduction of the resulting 5,7-dioxopyrrolopyrazine derivs.

IT 43200-83-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 43200-83-5 CAPLUS

CN 2-Pyrazinecarboxylic acid, 3-[[5-chloro-2-pyridinyl)amino]carbonyl]- (CA INDEX NAME)



L13 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1972:434570 CAPLUS

DOCUMENT NUMBER: 77:34570

ORIGINAL REFERENCE NO.: 77:5763a, 5766a

TITLE: Pyrazinamide derivatives as diuretics and natriuretics

INVENTOR(S): Cragoe, Edward J., Jr.; Shepard, Kenneth L.

PATENT ASSIGNEE(S): Merck and Co., Inc.

SOURCE: Fr. Demande, 54 pp.  
 CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2034542	----	19710108	-----	-----
PRIORITY APPLN. INFO.:			US	19690212 <--

GI For diagram(s), see printed CA Issue.

AB Refluxing a mixture of I (R<sub>1</sub> = Me, R<sub>2</sub> = R<sub>3</sub> = H, R<sub>4</sub> = Cl), 5% aqueous NaOH, and iso-PrOH for 1 hr gave the carboxylic acid I (R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = H, R<sub>4</sub> = Cl) (II). A mixture of CH.tplbond.CCH<sub>2</sub>NH<sub>2</sub>, Me 3-amino-5,6-dichloropyrazinoate, and Me<sub>2</sub>SO when stirred for 1 hr gave I (R<sub>1</sub> = Me, R<sub>2</sub> = H, R<sub>3</sub> = CH.tplbond.CCH<sub>2</sub>, R<sub>4</sub> = Cl) which on hydrolysis gave the corresponding carboxylic acid, R<sub>1</sub> = H. Using similar methods, 21 I were prepared in which R<sub>1</sub> = H, R<sub>2</sub> = H, Me, allyl, cyclopentyl, Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>, 2-furylmethyl, MeO, NH<sub>2</sub>, etc., R<sub>3</sub> = H or Me, R<sub>4</sub> = Cl, Br, or iodo. To a solution of II, Et<sub>3</sub>N, and Me<sub>2</sub>NCHO was added N-tert-butyl-5-methylisoxazolium perchlorate (III) and the mixture stirred 2 hr to give IV (R<sub>2</sub> = R<sub>3</sub> = H, R<sub>4</sub> = Cl, R<sub>5</sub> = Me, R<sub>6</sub> =

Me3C) (V). Nineteen IV were similarly prepared in which R2 = H, allyl, propargyl, cyclopentyl, hydroxyalkyl, benzyl, furylmethyl, phenyl, substituted phenyl, MeO, NH2, Me, or Et; R3 = H or Me; R4 = Cl, Br, or iodo; R5 = Me or Ph; R6 = Et, CMe3, or Me. Refluxing a mixture of 1-aminopyrrolidine and V for 2 hr gave VI (R2 = R3 = H, R4 = Cl, R1 = pyrrolidino) as a high m.p. solid. Twenty-two VI were similarly prepared in which R2, R3, and R4 were as in V and R1 was a group such as MePrN(CH2)2, MeOCH2CH2, benzyl, Me2NCH2CH2, pyrrolidinoethyl, and 1-methyl-4-piperazinoethyl. VI (R2 = R3 = H, R4 = Cl, R1 = 2-pyridylamino) was prepared by refluxing a mixture of 2-hydrazinopyridine (VII) and MeCN. Reacting III, 3,5-diamino-6-chloropyrazinoic acid (VIII) with Et3N in Me2NCHO, then addition of 2-hydrazinopyrimidine in DMF and further heating gave VI (R2 = R3 = H, R4 = Cl, R1 = 2-pyrimidinylamino). In THF, under similar conditions were prepared a further 14 amides and hydrazines VI including VI (R2 = R3 = H, R4 = Cl, R1 = 4H-1,2,4-triazolyl). Stirring a mixture of benzamidine and VII in H2O for 2 hr gave IX. Five analogs were prepared using other amidines. In a similar manner using guanidine in place of benzamidine was prepared X (R = H) (XI) giving a crystalline hydrochloride. XI could also be prepared directly from

VIII


without isolation of intermediates. By similar methods were prepared X (R = OH, CH2Ph) and 39 analogs of X in which the NH2 adjacent to the Cl could also be substituted. With aminoguanidine and 2-hydrazino-2-imidazoline were prepared X (R = NH2 and 2-aminoimidazoline). A mixture of CNNH2 and Na in iso-PrOH was refluxed for 0.5 hr and then heated with N-tert-butyl-3-(3,5-diamino-6-chloropyrazinylcarbonyloxy)crotonamide to give N-cyano-3,5-diamino-6-chloropyrazinecarboxamide. Refluxing N-tert-butyl-3-methyl-3-(3,5-diamino-6-chloropyrazinylcarbonyloxy)acrylamide (XII) and benzyloxydiguanide in THF gave XIII (R = H, R1 = CH2Ph). Twelve XI in which R was H and R1 1-6C alkyl, or R was a substituent such as cyclopentyl, PhCH2, and furylmethyl, and R1 was substituted benzyl were prepared. Refluxing a mixture of 2-amino-2-thiazoline, XII, and THF gave N-(2-thiazolin-2-yl)-3,5-diamino-6-chloropyrazinecarboxamide (XIV, R = R1 = R2 = R3 = H). Three analogs were prepared in which R was cyclopentyl, benzyl and HO(CH2)2, the other substituents being H, Me, or C6H13. XIV where RNH was pyrrolidino was also prepared. The 4- and 2-pyridyl groups and 2-pyrimidinyl could be substituted for the thiazoline. Reaction of V with sulfamide and Et3N in MeCN at room-temperature gave XV (R = R1 = R2 = H, X = Cl). Eighteen XV were similarly prepared. Properties are also given for a further 19 amides XVI. containing a wide variety of substituents. The products are useful in treatment of hypertension and related conditions by causing diuresis without elimination of potassium. Daily doses are 5 mg-1 g.

IT 37804-11-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 37804-11-8 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-5-(dimethylamino)-N-2-pyridinyl-  
(CA INDEX NAME)




ACCESSION NUMBER: 1971:420438 CAPLUS  
 DOCUMENT NUMBER: 75:20438  
 ORIGINAL REFERENCE NO.: 75:3278h,3279a  
 TITLE: N-substituted 3,5-diamino-6-halopyrazinamides  
 INVENTOR(S): Shepard, Kenneth L.; Cragoe, Edward J., Jr.  
 PATENT ASSIGNEE(S): Merck and Co., Inc.  
 SOURCE: U.S., 10 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3573306	A	19710330	US 1969-804663	19690305
NL 7001141	A	19700908	NL 1970-1141	19700127 <--
BE 746816	A	19700904	BE 1970-746816	19700304 <--
PRIORITY APPLN. INFO.:			US 1969-804663	A 19690305 <--

AB Addition of diphenylcarbonyl chloride to 3,5-diamino-6-chloropyrazinoic acid and Et3N in HCONMe2 gave 3,5-diamino-6-chloropyrazinecarboxylic diphenylcarbamic anhydride (I). Refluxing Na in iso-PrOH with guanidine-HCl and addition of I gave 1-(3,5-diamino-6-chloropyrazinoyl)guanidine. Similarly prepared were 1,1,3,3-tetramethyl-2-(3,5-diamino-6-chloropyrazinoyl)guanidine, 1-(3,5-diamino-6-chloropyrazinoyl)-3-cyanoguanidine, N-methyl-N-(cyanomethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(2,2-diethoxyethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(2-morpholinoethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(4-pyridylmethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(2-pyridyl)-3,5-diamino-6-chloropyrazinecarboxamide, 3,5-diamino-6-chloropyrazinecarboxylic acid 1,2-dimethylhydrazide, 3,5-diamino-6-chloropyrazinecarboxylic acid 1-methyl-2-benzylidenehydrazide, and N-(3,5-diamino-6-chloropyrazinoyl)morpholine. These compds. had diuretic activity at 10-100 mg.

IT 33249-56-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 33249-56-8 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-2-pyridinyl- (CA INDEX NAME)



L13 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1963:53333 CAPLUS  
 DOCUMENT NUMBER: 58:53333  
 ORIGINAL REFERENCE NO.: 58:9094g-h,9095a-g  
 TITLE: 3,5-Diaminopyrazine-2,6-dicarboxamides  
 INVENTOR(S): Daglish, Anthony F.; Vonderwahl, R.; Tillotson, G. A.  
 PATENT ASSIGNEE(S): J. R. Geigy A.-G.  
 SOURCE: 8 pp.  
 DOCUMENT TYPE: Patent



LANGUAGE: Unavailable  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1087609		19600825	DE 1958-G24632	19580528 <--
CH 358807			CH	
CH 358808			CH	
US 3043780		19620710	US 1958-737215	19580523
US 3175980		19650330	US 1961-179263	19611116
US 3201315		19650817	US 1962-168868	19620115
PRIORITY APPLN. INFO.:			CH	19570529 <--

GI For diagram(s), see printed CA Issue.

AB 1,3-Diethyl-4-amino-5-nitrosouracil (I) 212 and 1,3-diethyl-4-aminouracil 183 in AcOH 750 refluxed 3 h. with stirring, cooled, and filtered yielded 3,2;5,6-bis[(1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydro)-1,4-pyrimidino] pyrazine 320 parts (II), m. 235.5-36° (75% AcOH). II 10, EtOH 200 parts, and N NaOH 300 volume parts. refluxed 2.5 h., cooled, and filtered gave 3,5-bis(ethylamino)pyrazine-2,6-bis(N-ethylcarboxamide) 7.5 parts, m. 133-4° (EtOH). In the same manner as II were prepared the following IV (R1, R2, R3, R4 and m.p. given): Pr, Pr, Pr, Pr, 150-1°; Bu, Bu, Bu, Bu (V), 115-16°; Me, Me, Me, Me (VI), 390°. Saponification of IV gave the corresponding VII (R1, R2, R3, R4, and m.p. given): Pr, Pr, Pr, Pr, 96-7°; Bu, Bu, Bu, Bu, 89-91°; Me, Me, Me, Me (VIIa), 232-3°. I 42 and 1,3-dipropyl-4-aminouracil 42 in AcOH 150 refluxed 3 h. with stirring, cooled, diluted with H2O, and filtered gave IV (R1 = R2 = Et, R3 = R4 = Pr) 70 parts, m. 150-1° (EtOH); a portion 10 saponified in the usual manner gave VII (R1 = R2 = Et, R3 = R4 = Pr) 7.2 parts, m. 91-2°. In the same manner were prepared IV (R1 = R2 = Me, R3 = R4 = Pr), m. 169-9.5°, and IV(R1 = R2 = Me, R3 = R4 = Et) (VIII), m. 253-4°, and saponified to VII (R1 = R2 = Me, R3 = R4 = Pr), m. 136-7° and VII (R1 = R2 = Me, R3 = R4 = Pr), m. 169-70°, resp. 1,3-Dimethyl-4-aminouracil (IX) 31 and 5-NO derivative 40 of IX in AcOH 200 refluxed 3 h. gave VI 51 parts, m. 390° (75% EtOH). VI 51 and a solution 152 of KOH 200 in EtOH 2400 refluxed 6 h. yielded VIIa.0.5H2O 117 parts, m. 214° (decomposition). VIIa.0.5H2O 20 and SOCl2 150 kept 45 min. at room temperature and evaporated, the residue added slowly with cooling

to

PhNH2 10 and dry C5H5N 400 parts, stirred overnight, steam distilled to remove the C5H5N, and filtered yielded X (R1 = R2 = R3 = Me, R4 = NPh), light yellow crystals, m. 198-8.5° (EtOH). Similarly were prepared the following X with R1 = R2 = R3 = Me) (R4, m.p., and color of fluorescence given): NH2, 290-2°, violet blue; NHCH2CH2OH, 210-10.5°, violet-blue; NHPr, 218-19°, violet-blue; NHet, 197-8.5°, violet-blue; NHCH2Ph, 218.5-20°, blue-violet; NHCH2CH2Ph, 76-8°, blue-violet; m-NHC6H4OMe, 126.5-27°, blue; NHBu, 194-6°, violet-blue; p-NHC6H4OPh, 252-4°, blue; NHCH2CH:CH2, 194-5.5°, violet-blue; NHC8H17, 121-21.5°, violet-blue; PhNH, 237-8°, blue-violet; NMe2, 128-9°, violet; NHCHetMe, 188-90°, violet-blue; 2-pyridylamino, 223-4°, blue-violet; NHCMe3, 204-5°, violet-blue; p-NHC6H4Me, 211-12.5°, blue-violet; o-NHC6H4Me, 194-5°, blue-violet; m-NHC6H4Me, 172-3°, blue-violet; p-ClC6H4NH, 261-2.5°, blue-violet; m-ClC6H4NH, 185-7°, blue-violet; 3,4-Cl2C6H3NH, 216-17°, violet-blue; m-HO2CC6H4NH, 268-70°; m-HO3SC6H4NH, -, violet-blue; p-HO3SC6H4NH, -, violet-blue; m-(p-MeC6NH4SO2NH)C6H4NH, 226-7° violet-blue; m-H2NO2SC6H4NH, 234-6°, violet-blue; morpholino, 155-6°, violet-blue; NHCHMe2, 175-7°, violet-blue; NH(CH2)3OH, 147-9°, violet blue; 3-pyridylamino, 209-11°, blue-violet; 3,4-dimethyl-1-phenylpyrazolylamino, 267-9°, blue-violet; 2-thiazolylamino, 262-3°, blue-violet; 1-phenyl-3-pyrazolylamino,

236-8°, blue-violet; 6-quinolylamino, 232-4°, blue-violet; NHCONHPh, 233-4°, blue; NHCONHCH2Ph, 190-1°, violet-blue; NHCONHMe, 215-17°, violet-blue. Similarly were prepared the following XII (R1, R2, R3, and m.p. given): PhCH2, PhCH2, PhCH2, 161-2°; Et, Et, Et (XIII), 174-5°. XIII was converted in the usual manner to the anilide, m. 146.5-7.5°, and to the N-(2-pyridyl)amide, m. 108-9°. VIII 57, KOH 45, and EtOH 500 refluxed 6 h. and evaporated, and the residue acidified with dilute HCl gave

XII

(R1 = R2 = Et, R3 = Me) (XIV) 43 parts, m 160-2°. XIV 20 treated 45 min. with SOCl2 100 and evaporated, and the residue stirred overnight with concentrated NH4OH 300 and EtOH 100 and filtered gave amide of XIV 16 parts, m. 223-4° (EtOH). Similarly were prepared the N-Et, N-Pr, and N-PhCH2 amides, m. 162-4°, 84-6°, and 87-9°, resp., of XIV.


VI 10 and PhCH2NH2 300 refluxed 24 h., cooled, diluted with H2O, and filtered yielded 3,2-[(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro)-1,4-pyrimidino]-5-methylamino-6 - (Ar. benzylcarboxamido)pyrazine 9 parts, m. 204-5° (EtOH). 1,3-Dibutyl-4-aminouracil (XV) 48 and 5-NO derivative 54 of XV in 2N H2SO4 300 refluxed 3 h. with stirring, cooled, and filtered, and the residue in EtOH 1200 refluxed 2 h. with N NaHCO3 1800 and filtered gave V 66 parts, needles, m. 115-16° (EtOH).

IT 94804-12-3P, 2,6-Pyrazinedicarboxamide,  
N-ethyl-3,5-bis(ethylamino)-N'-2-pyridyl-  
RL: PREP (Preparation)

(preparation of)

RN 94804-12-3 CAPLUS

CN 2,6-Pyrazinedicarboxamide, N2-ethyl-3,5-bis(ethylamino)-N6-2-pyridinyl-  
(CA INDEX NAME)



=> fil stnguide

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

116.04 682.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

-16.40 -16.40

FILE 'STNGUIDE' ENTERED AT 15:46:34 ON 25 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 20, 2009 (20090220/UP).

=>

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

1.82 684.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-16.40

FILE 'STNGUIDE' ENTERED AT 16:02:11 ON 25 FEB 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Feb 20, 2009 (20090220/UP).

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.26	685.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-16.40

FILE 'REGISTRY' ENTERED AT 16:12:46 ON 25 FEB 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 24 FEB 2009 HIGHEST RN 1111415-98-5  
 DICTIONARY FILE UPDATES: 24 FEB 2009 HIGHEST RN 1111415-98-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
 Uploading C:\Program Files\STNEXP\Queries\10589407phenyl\narrow.str




chain nodes :  
 7 8 9 17  
 ring nodes :  
 1 2 3 4 5 6 10 11 12 13 14 15  
 chain bonds :  
 2-8 7-8 7-10 7-17 8-9

ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15  
 exact/norm bonds :  
 7-8 7-10 8-9  
 exact bonds :  
 2-8 7-17  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15  
 isolated ring systems :  
 containing 1 : 10 :

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom  
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS

L14 STRUCTURE UPLOADED

=> d l14  
 L14 HAS NO ANSWERS  
 L14 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l14 sss sam  
 SAMPLE SEARCH INITIATED 16:14:54 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 598 TO ITERATE

100.0% PROCESSED 598 ITERATIONS 50 ANSWERS  
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 10493 TO 13427  
 PROJECTED ANSWERS: 2530 TO 4070

L15 50 SEA SSS SAM L14


=> s l14 sss full  
 FULL SEARCH INITIATED 16:15:01 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 12386 TO ITERATE

100.0% PROCESSED 12386 ITERATIONS 3109 ANSWERS  
 SEARCH TIME: 00.00.01

L16 3109 SEA SSS FUL L14

=> d scan


L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C13 H9 C12 N3 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20


L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(4-ethoxyphenoxy)phenyl]-  
MF C19 H18 N4 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[3-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-1,3-  
thiazin-4-yl]-4-fluorophenyl]-5-(3,5-dimethyl-4-isoxazolyl)-  
MF C21 H21 F N6 O2 S


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[3-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-1,3-  
thiazin-4-yl]phenyl]-5-chloro-  
MF C16 H16 Cl N5 O S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[3-[[ (2-methoxyphenyl)amino]sulfonyl]-4-  
methylphenyl]-5-methyl-  
MF C20 H20 N4 O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-5-  
benzoylphenyl]-  
MF C23 H24 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(1-methylethyl)phenyl]-  
MF C14 H16 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[5-(acetylamino)-2-fluorophenyl]-  
MF C13 H11 F N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[5-[[4-(4-cyanophenyl)-1-piperidinyl]carbonyl]-2-methylphenyl]-5-methyl-  
MF C26 H25 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[4-[(2,4-dimethylphenyl)thio]phenyl]-  
 MF C19 H17 N3 O S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[4-[(6-phenyl-4-pyrimidinyl)amino]phenyl]-  
 MF C21 H16 N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[2-(1,3-dimethylbutyl)phenyl]-3-(trifluoromethyl)-  
 MF C18 H20 F3 N3 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-(2-benzothiazolyl)-N-(3,5-dimethylphenyl)-  
 MF C20 H16 N4 O S






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-chloro-N-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)phenyl]-  
 MF C18 H10 Cl F2 N3 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-chloro-N-[3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]-  
 MF C18 H11 Cl F3 N3 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-(2,4-difluorophenyl)-3-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-  
 MF C24 H15 F3 N6 O2  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-[(4-chlorobenzoyl)amino]-N-[4-[cyano[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]-  
 MF C27 H31 Cl N6 O3 Si




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, N-[4-[[ (3,4-dihydro-2H-pyrrol-5-yl)amino]sulfonyl]phenyl]-  
MF C15 H15 N5 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-methyl-N-[3-(2-methylpropyl)-4-[1,1,2-trifluoro-2-(trifluoromethoxy)ethoxy]phenyl]-  
MF C19 H19 F6 N3 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxylic acid, 3-[[[3-(methylthio)phenyl]amino]carbonyl]-  
MF C13 H11 N3 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 3109 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 2-Pyrazinecarboxamide, N-[4-[(dimethylamino)sulfonyl]phenyl]-5-methyl-  
MF C14 H16 N4 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

(FILE 'HOME' ENTERED AT 15:35:13 ON 25 FEB 2009)

FILE 'REGISTRY' ENTERED AT 15:35:28 ON 25 FEB 2009

L1 STRUCTURE UPLOADED  
L2 50 S L1 SSS SAM  
L3 3685 S L1 SSS FULL  
L4 STRUCTURE UPLOADED  
L5 50 S L4 SSS SAM  
L6 3230 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:40:44 ON 25 FEB 2009

L7 187 S L6 AND (PRY<2005)

FILE 'REGISTRY' ENTERED AT 15:41:20 ON 25 FEB 2009

FILE 'REGISTRY' ENTERED AT 15:42:35 ON 25 FEB 2009

L8 STRUCTURE UPLOADED  
L9 STRUCTURE UPLOADED  
L10 11 S L9 SSS SAM  
L11 178 S L9 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:45:31 ON 25 FEB 2009

L12 50 S L11  
L13 20 S L12 AND (PRY<2005)

FILE 'STNGUIDE' ENTERED AT 15:46:34 ON 25 FEB 2009

FILE 'STNGUIDE' ENTERED AT 16:02:11 ON 25 FEB 2009

FILE 'REGISTRY' ENTERED AT 16:12:46 ON 25 FEB 2009

L14 STRUCTURE UPLOADED  
L15 50 S L14 SSS SAM  
L16 3109 S L14 SSS FULL

=> fil cap

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

187.80

TOTAL

SESSION

873.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-16.40

FILE 'CAPLUS' ENTERED AT 16:15:33 ON 25 FEB 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Feb 2009 VOL 150 ISS 9  
 FILE LAST UPDATED: 24 Feb 2009 (20090224/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.


```
=> s l16 and (pry<2005)
      345 L16
      4600131 PRY<2005
L17      173 L16 AND (PRY<2005)
```

```
=> d 1-20,160-173 ibib abs hitstr
```

```
L17 ANSWER 1 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1042502 CAPLUS
DOCUMENT NUMBER: 149:307845
TITLE: Preparation of imidazolidin-2-imines and their analogs
as aspartyl protease inhibitors for treating various
diseases
INVENTOR(S): Zhu, Zhaoning; McKittrick, Brian; Sun, Zhong-Yue; Ye,
Yuanzan C.; Voigt, Johannes H.; Strickland, Corey;
Smith, Elizabeth M.; Stamford, Andrew; Greenlee,
William J.; Mazzola, Robert D., Jr.; Caldwell, John;
Cumming, Jared N.; Wang, Lingyan; Wu, Yusheng;
Iserloh, Ulrich; Liu, Xiaoxiang; Huang, Ying; Li,
Guoqing; Pan, Jianping; Misiaszek, Jeffrey A.; Guo,
Tao; Le, Thuy X. H.; Saionz, Kurt W.; Babu, Suresh D.;
Hunter, Rachael C.; Morris, Michelle L.; Gu, Huizhong;
Qian, Gang; Tadesse, Dawit; Lai, Gaifa; Duo, Jingqi;
Qu, Chuanxing; Shao, Yuefei
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE: PCT Int. Appl., 702 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
```

FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008103351	A2	20080828	WO 2008-US2182	20080220
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20080200445	A1	20080821	US 2007-710582	20070223 <--
PRIORITY APPLN. INFO.:			US 2007-710582	A 20070223
			US 2003-529535P	P 20031215 <--
			US 2004-10772	A2 20041213 <--
			US 2005-149027	A2 20050609
OTHER SOURCE(S):	MARPAT 149:307845			
GI				



AB Disclosed are compds. I [W = a bond, C(S), S(O), etc.; X = O, NR5 or CR6R7; U = a bond, S(O), SO2, C(O), etc.; R1, R2, R5 = H, alkyl, cycloalkyl, etc.; R3, R4, R6, R7 = H, alkyl, cycloalkyl, etc.; with provisos] or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof; and the pharmaceutical compns. comprising the compds. I. Over 1000 compds. I were prepared E.g., synthesis of imidazolidin-2-imine II, starting from III, was described. Compds. I were tested in various assays (data given for selected compds. I). Also disclosed is the method of inhibiting aspartyl protease, and in

particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting Human Immunodeficiency Virus, plasmepsin, cathepsin D, and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compds. I in combination with a cholinesterase inhibitor or a muscarinic M1 agonist or M2 antagonist. This abstract record is one of 2 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.


IT 887911-28-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic aspartyl protease inhibitors for treating various diseases)

RN 887911-28-6 CAPLUS

CN 2-Pyrazinecarboxamide, N-[3-(2-amino-4,5-dihydro-1-methyl-5-oxo-4-phenyl-1H-imidazol-4-yl)phenyl]- (CA INDEX NAME)



L17 ANSWER 2 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1011066 CAPLUS

DOCUMENT NUMBER: 149:307842

TITLE: Preparation of imidazolidin-2-imines and their analogs as aspartyl protease inhibitors for treating various diseases

INVENTOR(S): Zhu, Zhaoning; McKittrick, Brian; Sun, Zhong-Yue; Ye, Yuanzan C.; Voigt, Johannes H.; Strickland, Corey O.; Smith, Elizabeth M.; Stamford, Andrew; Greenlee, William J.; Mazzola, Robert D.; Caldwell, John P.; Cumming, Jared N.; Wang, Lingyan; Wu, Yusheng; Iserloh, Ulrich; Liu, Xiaoxiang; Guo, Tao; Le, Thuy X. E.; Saionz, Kurt W.; Babu, Suresh D.; Hunter, Rachael C.; Morris, Michelle L.; Gu, Huizhong; Qian, Gang; Tadesse, Dawit; Huang, Ying; Li, Guoqing; Pan, Jianping; Misiaszek, Jeffrey A.; Lai, Gaifa; Duo, Jingqi; Qu, Chuanxing; Shao, Yuefei

PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia Drug Discovery, Inc.

SOURCE: U.S. Pat. Appl. Publ., 1209pp., Cont.-in-part of U.S. Ser. No. 149,027.  
CODEN: USXXCO

DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080200445	A1	20080821	US 2007-710582	20070223 <--
US 20070072852	A1	20070329	US 2004-10772	20041213 <--
US 20060111370	A1	20060525	US 2005-149027	20050609 <--

AU 2005317204	A1	20060622	AU 2005-317204	20050609 <--
CA 2591033	A1	20060622	CA 2005-2591033	20050609 <--
WO 2006065277	A2	20060622	WO 2005-US20446	20050609 <--
WO 2006065277	A3	20070125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1838304	A2	20071003	EP 2005-766007	20050609 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
JP 2008523059	T	20080703	JP 2007-545436	20050609 <--
IN 2007CN02535	A	20070907	IN 2007-CN2535	20070613 <--
KR 2007106689	A	20071105	KR 2007-713310	20070613 <--
MX 2007007058	A	20071211	MX 2007-7058	20070613 <--
NO 2007003616	A	20070912	NO 2007-3616	20070712 <--
CN 101115482	A	20080130	CN 2005-80047939	20070809 <--
WO 2008103351	A2	20080828	WO 2008-US2182	20080220
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
JP 2008174570	A	20080731	JP 2008-79293	20080325 <--
PRIORITY APPLN. INFO.:			US 2003-529535P	P 20031215 <--
			US 2004-10772	A2 20041213 <--
			US 2005-149027	A2 20050609
			JP 2006-544081	A3 20041213 <--
			WO 2005-US20446	W 20050609
			US 2007-710582	A 20070223

GI





AB Disclosed are compds. I [W = a bond, C(S), S(O), etc.; X = O, NR<sub>5</sub> or CR<sub>6</sub>R<sub>7</sub>; U = a bond, S(O), SO<sub>2</sub>, C(O), etc.; R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub> = H, alkyl, cycloalkyl, etc.; R<sub>3</sub>, R<sub>4</sub>, R<sub>6</sub>, R<sub>7</sub> = H, alkyl, cycloalkyl, etc.; with provisos] or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof; and the pharmaceutical compns. comprising the compds. I. Over 1000 compds. I were prepared E.g., synthesis of imidazolidin-2-imine II, starting from III, was described. Compds. I were tested in various assays (data given for selected compds. I). Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepsin, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compds. I in combination with a cholinesterase inhibitor or a muscarinic M<sub>1</sub> agonist or M<sub>2</sub> antagonist.


IT 887911-28-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic aspartyl protease inhibitors for treating various diseases)


RN 887911-28-6 CAPLUS

CN 2-Pyrazinecarboxamide, N-[3-(2-amino-4,5-dihydro-1-methyl-5-oxo-4-phenyl-1H-imidazol-4-yl)phenyl]- (CA INDEX NAME)




ACCESSION NUMBER: 2006:982164 CAPLUS  
 DOCUMENT NUMBER: 145:356811  
 TITLE: Preparation of fused heterocyclic kinase inhibitors  
 INVENTOR(S): Borzilleri, Robert M.; Chen, Zhong; Huynh, Tram N.;  
 Vaccaro, Wayne; Chen, Xiao-Tao; Kim, Kyoung S.; Cai,  
 Zhen-Wei  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: U.S. Pat. Appl. Publ., 141 pp., Cont.-in-part of U.S.  
 Ser. No. 167,043.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060211695	A1	20060921	US 2005-292358	20051201 <--
US 7439246	B2	20081021		
US 20050288290	A1	20051229	US 2005-167043	20050624 <--
AU 2005259894	A1	20060112	AU 2005-259894	20050628 <--
AU 2005260056	A1	20060112	AU 2005-260056	20050628 <--
CA 2571680	A1	20060112	CA 2005-2571680	20050628 <--
EP 1761268	A2	20070314	EP 2005-791275	20050628 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU				
EP 1768983	A2	20070404	EP 2005-764291	20050628 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU				
EP 1771177	A2	20070411	EP 2005-790229	20050628 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU				
CN 1993130	A	20070704	CN 2005-80025519	20050628 <--
CN 101005843	A	20070725	CN 2005-80027728	20050628 <--
CN 101027305	A	20070829	CN 2005-80027173	20050628 <--
JP 2008504366	T	20080214	JP 2007-519322	20050628 <--
JP 2008504367	T	20080214	JP 2007-519390	20050628 <--
JP 2008504368	T	20080214	JP 2007-519416	20050628 <--
BR 2005012722	A	20080401	BR 2005-12722	20050628 <--
IN 2006DN07597	A	20070803	IN 2006-DN7597	20061215 <--
IN 2006DN07602	A	20070803	IN 2006-DN7602	20061215 <--
MX 2006015032	A	20070208	MX 2006-15032	20061219 <--
MX 2006015192	A	20070228	MX 2006-15192	20061220 <--
IN 2006DN07759	A	20070817	IN 2006-DN7759	20061220 <--
KR 2007028458	A	20070312	KR 2006-727376	20061227 <--
KR 2007037448	A	20070404	KR 2006-727370	20061227 <--
NO 2007000453	A	20070124	NO 2007-453	20070124 <--
NO 2007000506	A	20070214	NO 2007-506	20070126 <--
NO 2007000514	A	20070312	NO 2007-514	20070126 <--
PRIORITY APPLN. INFO.:			US 2004-583459P	P 20040628 <--
			US 2004-612563P	P 20040923 <--
			US 2005-167043	A2 20050624
			WO 2005-US22682	W 20050628
			WO 2005-US23099	W 20050628
			WO 2005-US23198	W 20050628
OTHER SOURCE(S):		MARPAT 145:356811		
GI				



I



II



III

AB The title compds. I and II [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; B = O, NR8, S, SO, SO2, CR9C10; V = NR11 or (CR47R48)p; W or X = C or N; Y = O, S, NR12; Z = CR13R14, (CR13R14)mNR15; m = 0-2; n = 0-4; p = 0-4, provided that if p = 0, R1 is not Ph; A = substituted pyrrolo[2,1-f][1,2,4]triazin-4-yl, pyrrolo[1,2-b]pyridazin-4-yl, pyrrolo[2,3-b]pyridin-4-yl, etc.; R3, R8, R11, R15 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl, heterocycloalkyl; R9, R10 = H, halo, alkyl, etc.; R12 = H, alkyl, CN, etc.; R13-R15, R47, R48 = H, halo, alkyl, etc.; and their pharmaceutically acceptable salts], useful as protein kinase inhibitors for treating cancer and other protein kinase mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from Et 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylate, was given. Compds. I and II inhibit the Met kinase with IC50 values between 0.01 to 100  $\mu$ M. Pharmaceutical compns. comprising the compound I or II alone or in combination with other antitumor agent are disclosed.


IT 888717-17-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer)

RN 888717-17-7 CAPLUS

CN 2-Pyrazinecarboxamide, N-[3-fluoro-4-[(5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy]phenyl]- (CA INDEX NAME)




L17 ANSWER 4 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:710810 CAPLUS  
 DOCUMENT NUMBER: 145:159773  
 TITLE: Benzimidazole derivative transcription  
 factor-modulating compounds for use as antiinfective  
 agents  
 INVENTOR(S): Alekshun, Michael N.; Amoo, Victor; Kim, Oak K.;  
 Verma, Atul K.  
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 405 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006076009	A2	20060720	WO 2005-US14345	20050425 <--
WO 2006076009	A3	20071227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2005324492	A1	20060720	AU 2005-324492	20050425 <--
CA 2562763	A1	20060720	CA 2005-2562763	20050425 <--
US 20060160799	A1	20060720	US 2005-115024	20050425 <--
EP 1742637	A2	20070117	EP 2005-856651	20050425 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,				

HR, LV, MK, YU  
 JP 2008504233 T 20080214 JP 2007-509742 20050425 <--  
 PRIORITY APPLN. INFO.: US 2004-565047P P 20040423 <--  
 US 2004-569032P P 20040507 <--  
 US 2004-623251P P 20041028 <--  
 WO 2005-US14345 W 20050425

OTHER SOURCE(S): MARPAT 145:159773  
 AB The invention provides substituted benzimidazole compds. useful as  
 antiinfectives that decrease resistance, virulence, or growth of microbes.  
 Also provided are methods for making and using the substituted  
 benzimidazole compds., as well as pharmaceutical preps. for e.g. reducing  
 antibiotic resistance and inhibiting biofilms.  
 IT 900142-29-2  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (benzimidazole derivative transcription factor-modulating compds. for use  
 as antiinfective agents)  
 RN 900142-29-2 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-[4-(1-hydroxy-6-nitro-1H-benzimidazol-2-  
 yl)phenyl]- (CA INDEX NAME)



L17 ANSWER 5 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:656503 CAPLUS  
 DOCUMENT NUMBER: 145:124568  
 TITLE: Preparation of benzimidazole derivatives for treatment  
 of prostatic hypertrophy  
 INVENTOR(S): Haruno, Akihiro; Miyoshi, Kazuhisa; Oda, Nobuyuki;  
 Hagiwara, Yuichi; Yamashita, Tomohiro; Konno, Yasuo;  
 Kazuno, Hideki  
 PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 147 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006070806	A1	20060706	WO 2005-JP23906	20051227 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

JP 2004-381951


A 20041228 <--

JP 2005-69693

A 20050311

OTHER SOURCE(S): MARPAT 145:124568

GI



AB 5-[(Pyridin-5-ylcarbonyl)amino]-1H-benzimidazole compds. represented by the general formula [I; wherein R1 and R2 each represents H, (un)substituted C1-6 alkyl, or (un)substituted C3-7 cycloalkyl, provided that R1 and R2 may form, in cooperation with the adjacent nitrogen atom, a 4- to 8-membered (un)substituted heterocycle optionally having N or O besides that nitrogen atom in the ring structure; and R3 represents a 5- or 6-membered monocyclic unsatd. heterocyclic group having, in the ring structure, one to three heteroatoms selected among N, O, and S, benzofuryl, dihydrobenzofuryl, methylenedioxyphenyl (these groups are (un)substituted)] or pharmaceutically acceptable salts thereof are prepared. These compds. or salts thereof are useful in the prevention or treatment of diseases attributable to abnormal proliferation of prostatic interstitial cells, in particular, prostatic hypertrophy (benign prostatic hyperplasia). Thus, N-(3,4-diaminophenyl)-6-morpholinonicotinamide was cyclocondensed with 2-dimethylaminomethylpyridine-5-carboxaldehyde to give 2-[(2-dimethylaminomethyl)pyridin-5-yl]-5-[[2-(morpholino)pyridin-5-yl]carbonylamino]-1H-benzimidazole (II). II showed IC50 of 0.025  $\mu$ M against the proliferation of prostatic interstitial cells. Pharmaceutical formulation containing specific compds. I were described.

IT 897399-92-7P, N-[3-Amino-4-[(pyrazin-2-ylcarbonyl)amino]phenyl]-6-(pyrrolidin-1-yl)nicotinamide 897399-93-8P, N-[4-Amino-3-[(pyrazin-2-ylcarbonyl)amino]phenyl]-6-(pyrrolidin-1-yl)nicotinamide


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of benzimidazole derivs. as inhibitors for abnormal proliferation of prostatic interstitial cells in treatment of prostatic hypertrophy)


RN 897399-92-7 CAPLUS

CN 2-Pyrazinecarboxamide, N-[2-amino-4-[[[6-(1-pyrrolidinyl)-3-pyridinyl]carbonyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 897399-93-8 CAPLUS

CN 2-Pyrazinecarboxamide, N-[2-amino-5-[[[6-(1-pyrrolidinyl)-3-pyridinyl]carbonyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:655920 CAPLUS

DOCUMENT NUMBER: 145:124613

TITLE: Preparation of carboxylic acid derivatives having three cyclic moieties as anticoagulants

INVENTOR(S): Ishihara, Tsukasa; Miura, Masanori; Ohne, Kazuhiko; Takuwa, Tomofumi; Shirakami, Shohei; Ibuka, Ryotaro; Ohnuki, Kei; Seki, Norio; Shigenaga, Takeshi; Hirayama, Fukushi; Hirabayashi, Akihito; Kai, Yuichiro; Kobayashi, Junichi; Hirasawa, Hideaki; Kondou, Atsushi; Yamada, Ken

PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan

SOURCE: PCT Int. Appl., 198 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006070878	A1	20060706	WO 2005-JP24096	20051228 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: JP 2004-380131 A 20041228 <--

OTHER SOURCE(S): MARPAT 145:124613

GI



I

AB The title compds. [I; ring A = aryl or heteroaryl ring; ring B = benzene, naphthalene, or monocyclic or bicyclic heteroaryl ring; ring C = cycloalkyl, aryl, or heterocyclic ring; m, n, p = an integer of 0-3; R<sup>1</sup> = NH<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CONH<sub>2</sub>, C(:NH)NH<sub>2</sub>, C(:NOH)NH<sub>2</sub>, C(:NH)NH-CO<sub>2</sub>-(optionally substituted lower alkyl), 5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl; R<sup>2</sup>, R<sup>3</sup> = lower alkyl, halo-lower alkyl, halo, oxo, cyano, NO<sub>2</sub>, halo-lower alkoxy, NR<sup>0</sup>R<sup>0</sup>, SR<sup>0</sup>, S(O)R<sup>0</sup>, SO<sub>2</sub>R<sup>0</sup>, SO<sub>2</sub>NR<sup>0</sup>R<sup>0</sup>, NR<sup>0</sup>SO<sub>2</sub>R<sup>0</sup>, COR<sup>0</sup>, CO<sub>2</sub>R<sup>0</sup>, CONR<sup>0</sup>R<sup>0</sup>, NR<sup>0</sup>COR<sup>0</sup>, NR<sup>0</sup>CO-(halo-lower alkyl), cycloalkyl, aryl, heterocyclyl, etc.;



R0, R00 = H, lower alkyl; R4 = lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl, halo, oxo, cyano, NO2, OR6, NR6R6a, SR6, SOR6, SO2R6, SO2NR6R6a, NR6SO2R6a, NR6SO2NR6R6a, NR6SO2NR6aCO2R6a, COR6, CO2R6, CONR6R6a, cycloalkyl, aryl, heterocyclyl, etc.; R6, R6a = H, each (un)substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, or heterocyclyl; R5 = OR0, NR0R00, N(R0)-lower alkylene-OR00; J = NR0CO, CONR0, NR0CONR0, NR0-lower alkylene, lower alkylene-NR0CO; L = NR0-lower alkylene, NR0-lower alkenylene, lower alkylene, lower alkenylene; X = a single bond, (un)substituted NH, S, CO, SO, SO2, lower alkylene-O, lower alkylene-(un)substituted NH; Y = a single bond, each (un)substituted lower alkylene or lower alkenylene] or pharmaceutically acceptable salt thereof are prepared These compds. such as phenoxyacetic acid and phenylpropanoic acid derivs. or salts thereof have an anticoagulant effect based on the inhibition of the activated blood coagulation factor VII and, therefore, are useful as blood coagulation inhibitors or preventives/remedies for diseases caused by thrombus or embolus. They are also selective inhibitors of activated blood coagulation factor VII over activated blood coagulation factor X and thrombin. The above diseases include ischemic heart diseases, restenosis after angioplasty, cerebral thrombosis, transient cerebral ischemia, peripheral arterial obstruction, Charcot's syndrome (intermittent claudication), deep venous thrombosis, pulmonary embolism, disseminated intravascular coagulation (DIC), thrombogenesis after heart valve replacement surgery, coagulation or inflammation of circulating blood during external blood circulation, arteriosclerosis, and cancer. For example, [(3-([(2-([(2-amino-1H-benzimidazol-5-yl)amino]carbonyl)-4-chlorophenyl)amino]methyl)biphenyl-2-yl)oxy]acetic acid in vitro inhibited activated blood coagulation factor VII over activated blood coagulation factor X and thrombin with IC50 of 0.36, ≥100, and ≥100 μM, resp.

IT 897639-50-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carboxylic acid derivs. having three cyclic moieties as activated blood coagulation factor VII inhibitors and anticoagulants)


RN 897639-50-8 CAPLUS

CN Acetic acid, 2-[2-[[[3-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-2-pyrazinyl]amino]methyl]-6-ethoxyphenoxy]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 897639-49-5

CMF C23 H24 N6 O5



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2006:634786 CAPLUS  
DOCUMENT NUMBER: 145:103692  
TITLE: Preparation of  
4H-spiro[1,3]benzodioxine-2,4'-piperidine derivatives  
and related compounds  
INVENTOR(S): Barker, Emma; Jenmalm Jensen, Annika; Nordling, Erik;  
Proud, Andrew; Slater, Martin; Weber, Mikael  
PATENT ASSIGNEE(S): Biovitrum AB, Swed.  
SOURCE: PCT Int. Appl., 83 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006067224	A2	20060629	WO 2005-EP57132	20051222 <--
WO 2006067224	A3	20061102		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20060217375	A1	20060928	US 2005-318126	20051222 <--
PRIORITY APPLN. INFO.:			SE 2004-3160	A 20041223 <--
			US 2005-653803P	P 20050217
OTHER SOURCE(S):	MARPAT 145:103692			
GI				




AB The invention relates to compds. I [m, n are 0 or 1; A, Y are independently CH<sub>2</sub>, O, NH or alkylimino; R<sub>1</sub> is Ph, naphthyl or aza analogs (with provisos)] for use in the prophylaxis or treatment of orexin-1 or orexin-2 receptor-related disorders such as obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, drug addiction, and sleeping disorders. Thus, I (m, n = 1, A = NH, Y = CH<sub>2</sub>, R<sub>1</sub> = 5-quinolinyl), prepared by condensation of 5-bromo-2-hydroxybenzyl alc. with N-carboethoxy-4-piperidone, followed by deprotection and arylation reaction, showed K<sub>i</sub> = 349 nM for inhibition of the orexin-1 receptor.

IT 895525-09-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of spirobenzodioxinepiperidine derivs. and related compds. for inhibition of orexin receptor)

RN 895525-09-4 CAPLUS

CN 2-Pyrazinecarboxamide, N-(3-spiro[4H-1,3-benzodioxin-2,4'-piperidin]-6-ylphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:631033 CAPLUS

DOCUMENT NUMBER: 145:103956

TITLE: Preparation of peptides as Myd88 homodimerization inhibitors

INVENTOR(S): Carminati, Paolo; Gallo, Grazia; Fanto', Nicola; Ruggiero, Vito; Sassano, Marica; Mastroianni, Domenico

PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy

SOURCE: PCT Int. Appl., 122 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2006067091	A1	20060629	WO 2005-EP56847	20051216 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005318226	A1	20060629	AU 2005-318226	20051216 <--
CA 2590750	A1	20060629	CA 2005-2590750	20051216 <--
EP 1828246	A1	20070905	EP 2005-823931	20051216 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
CN 101084240	A	20071205	CN 2005-80043762	20051216 <--
JP 2008524167	T	20080710	JP 2007-546073	20051216 <--
MX 200707259	A	20070814	MX 2007-7259	20070615 <--
IN 2007KN02236	A	20070817	IN 2007-KN2236	20070618 <--
KR 2007094802	A	20070921	KR 2007-716815	20070720 <--
US 20080064643	A1	20080313	US 2007-793516	20070720 <--
PRIORITY APPLN. INFO.:			EP 2004-425929	A 20041220 <--
			WO 2005-EP56847	W 20051216

OTHER SOURCE(S): MARPAT 145:103956

AB The invention relates to peptidic and peptidomimetic compds. AA1-AA2-AA3-AA4-AA5-AA6-AA7 [AA1-AA7 are L- or D-amino acid residues (defined), at least one of which is not a natural amino acid (if all are natural amino acids, the sequence is reversed); AA1, AA2, AA7 may be absent; AA2-AA3-AA4 may be a spacer group; AA5-AA6 may be a  $\beta$ -turn mimetic; a disulfide bond may exist between AA4 = AA7 = Cys or D-Cys; the N-terminal amine group may be acylated and the terminal carboxyl may be in the acid or amide form] or their pharmaceutically-acceptable salts, which mimic a particular protein portion of MyD88, preventing its homodimerization and interfering with its interaction with the TIR domain. The compds. are useful as medicaments, particularly for the treatment of inflammatory and autoimmune diseases. Thus, Ac-D-Thr-Gly-D-Pro-D-Leu-D-Val-D-Asp-D-Arg-NH<sub>2</sub> was prepared by the solid-phase method and assayed for inhibition of homodimerization of Myd88 (30% in the NF-kB assay).

IT 894787-19-0P 894787-23-6P 894787-31-6P  
894787-33-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides as Myd88 homodimerization inhibitors)

RN 894787-19-0 CAPLUS

CN Spiro[pyrrolidine-2,7'-(6'H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-3'-carboxamide, 1-[4-chloro-3-[(2-pyrazinylcarbonyl)amino]benzoyl]tetrahydro-6'-oxo-, (2R,3'S,8'aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 894787-23-6 CAPLUS

CN Spiro[pyrrolidine-2, 7' (6'H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-3'-carboxamide, tetrahydro-1-[3-[[4-[[ (5-methyl-2-pyrazinyl)carbonyl]amino]benzoyl]amino]-1-oxopropyl]-6'-oxo-, (2R, 3'S, 8'aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 894787-31-6 CAPLUS

CN Spiro[pyrrolidine-2, 7' (6'H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide, tetrahydro-1-[3-[[4-[[ (5-methyl-2-pyrazinyl)carbonyl]amino]benzoyl]amino]-1-oxopropyl]-6'-oxo-, (2R, 4'R, 8'aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 894787-33-8 CAPLUS

CN Spiro[pyrrolidine-2, 7' (6'H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide, 1-[4-chloro-3-[(2-pyrazinylcarbonyl)amino]benzoyl]tetrahydro-6'-oxo-, (2R,4'R,8'aR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:558961 CAPLUS

DOCUMENT NUMBER: 145:62922

TITLE: Preparation of pyrazinedicarboxamides and related compounds for the treatment of thromboembolic diseases

INVENTOR(S): Roehrig, Susanne; Jeske, Mario; Akbaba, Metin; Rosentreter, Ulrich; Boyer, Stephen; Fischer, Karin; Pohlmann, Jens; Tuch, Arounarith; Perzborn, Elisabeth; Gerdes, Christoph; Schlemmer, Karl-Heinz; Burkhardt, Nils; Allerheiligen, Swen; Nell, Peter; Arndt, Sabine; Lobell, Mario

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006061116	A1	20060615	WO 2005-EP12681	20051128 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004059219	A1	20060614	DE 2004-102004059219	20041209
CA 2594102	A1	20060615	CA 2005-2594102	20051128 <--
EP 1824844	A1	20070829	EP 2005-815232	20051128 <--
EP 1824844	B1	20081105		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008522992	T	20080703	JP 2007-544770	20051128 <--
AT 413396	T	20081115	AT 2005-815232	20051128 <--
US 20060287315	A1	20061221	US 2005-299342	20051208 <--
PRIORITY APPLN. INFO.:			DE 2004-102004059219A	20041209 <--
			WO 2005-EP12681	W 20051128
OTHER SOURCE(S):			CASREACT 145:62922; MARPAT 145:62922	
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [A = substituted pyrrolidinonyl, imidazolidinonyl, 2-oxazolidinonyl, etc.; R1, R2 = H, F, Cl, etc.; R3 = H, alkyl, OH, etc.; Z = Ph, pyridyl, pyrimidinyl, etc.] and their pharmaceutically acceptable salts and their formulations were prepared For example, 1,1'-Carbonyldiimidazole mediated cyclization of aminoalc. II afforded pyrazinedicarboxamide III in 19% yield. In blood-coagulation factor Xa inhibition assays, 8-examples of compds. I exhibited IC50 values ranging from 0.16-16 nM.

IT 890822-15-8P 890822-23-8P 890822-31-8P  
 890822-39-6P 890822-47-6P 890822-55-6P  
 890822-63-6P 890822-71-6P 890822-79-4P  
 890822-87-4P 890822-95-4P 890823-03-7P  
 890823-11-7P 890823-19-5P 890823-27-5P  
 890823-35-5P 890823-43-5P 890823-51-5P  
 890823-59-3P 890823-67-3P 890823-75-3P  
 890823-83-3P 890823-91-3P 890823-99-1P  
 890824-07-4P 890824-15-4P 890824-22-3P  
 890824-29-0P 890824-36-9P 890824-43-8P  
 890824-50-7P 890824-58-5P 890824-65-4P  
 890824-73-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazinedicarboxamides and related compds. for the treatment of thromboembolic diseases)

RN 890822-15-8 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(4-chlorophenyl)-N3-[4-(2-oxo-1-

pyrrolidinyl)phenyl]- (CA INDEX NAME)



RN 890822-23-8 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (CA INDEX NAME)



RN 890822-31-8 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(6-chloro-3-pyridinyl)-N3-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (CA INDEX NAME)






RN 890822-39-6 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-fluorophenyl)-N3-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (CA INDEX NAME)




RN 890822-47-6 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-methylphenyl)-N3-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (CA INDEX NAME)




RN 890822-55-6 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-chlorophenyl)-N3-[4-(2-oxo-3-oxazolidinyl)phenyl]- (CA INDEX NAME)




RN 890822-63-6 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-oxo-3-oxazolidinyl)phenyl]- (CA INDEX NAME)




RN 890822-71-6 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-chlorophenyl)-N3-[4-(2-oxo-1-imidazolidinyl)phenyl]- (CA INDEX NAME)



RN 890822-79-4 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-(3-hydroxy-2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 890822-87-4 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-[(3S)-3-hydroxy-2-oxo-1-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 890822-95-4 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-[(3R)-3-hydroxy-2-oxo-1-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 890823-03-7 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-[4-(3-amino-2-oxo-1-piperidinyl)phenyl]-N3-(4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 890823-11-7 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-chlorophenyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 890823-19-5 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 890823-27-5 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 890823-35-5 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(6-chloro-3-pyridinyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 890823-43-5 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(2-chlorophenyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 890823-51-5 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(3,5-dichlorophenyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 890823-59-3 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-fluorophenyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 890823-67-3 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-methylphenyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 890823-75-3 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-[4-(3-oxo-4-morpholinyl)phenyl]-N3-phenyl- (CA INDEX NAME)



RN 890823-83-3 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(4-ethynylphenyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)






RN 890823-91-3 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-chlorophenyl)-N3-[4-[2-(2-hydroxyethyl)-3-oxo-4-morpholinyl]phenyl]- (CA INDEX NAME)




RN 890823-99-1 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-chlorophenyl)-N3-[4-(tetrahydro-3-methyl-2-oxo-1(2H)-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 890824-07-4 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(tetrahydro-3-methyl-2-oxo-1(2H)-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 890824-15-4 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(6-chloro-3-pyridinyl)-N3-[4-(tetrahydro-3-methyl-2-oxo-1(2H)-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 890824-22-3 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-fluorophenyl)-N3-[4-(tetrahydro-3-methyl-2-oxo-1(2H)-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 890824-29-0 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-methylphenyl)-N3-[4-(tetrahydro-3-methyl-2-oxo-1(2H)-pyrimidinyl)phenyl]- (CA INDEX NAME)



RN 890824-36-9 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[tetrahydro-3-(2-hydroxyethyl)-2-oxo-1(2H)-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 890824-43-8 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[tetrahydro-2-oxo-3-[2-(1-pyrrolidinyl)ethyl]-1(2H)-pyrimidinyl]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 890824-50-7 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-[3-(hydroxymethyl)-2-oxo-1(2H)-pyridinyl]phenyl]- (CA INDEX NAME)




RN 890824-58-5 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[3-(hydroxymethyl)-2-oxo-1(2H)-pyridinyl]phenyl]-

[(cyclopropylamino)methyl]-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 890824-57-4


CMF C26 H21 Cl F N7 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 890824-65-4 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(4-cyanophenyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 890824-73-4 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-[2-(2-aminoethoxy)-4-(3-oxo-4-morpholinyl)phenyl]-N3-(5-chloro-2-pyridinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 890824-72-3  
 CMF C23 H22 Cl N7 O5




CM 2


CRN 76-05-1  
 CMF C2 H F3 O2




IT 278610-25-6P 693252-02-7P 890052-00-3P  
 890052-06-9P 890826-85-4P 890826-92-3P  
 890826-99-0P 890827-06-2P 1096601-39-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of pyrazinedicarboxamides and related compds. for the treatment  
 of thromboembolic diseases)  
 RN 278610-25-6 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 3-[[ (4-chlorophenyl)amino]carbonyl]- (CA INDEX  
 NAME)



RN 693252-02-7 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 3-[[ (4-cyanophenyl)amino]carbonyl]- (CA INDEX  
 NAME)




RN 890052-00-3 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 3-[[ (4-ethynylphenyl)amino]carbonyl]- (CA  
 INDEX NAME)




RN 890052-06-9 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[[2-[[ (1,1-  
 dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (CA INDEX NAME)






RN 890826-85-4 CAPLUS

CN Carbamic acid, [1-[4-[[[3-[[4-chlorophenyl]amino]carbonyl]pyrazinyl]carbonyl]amino]phenyl]-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 890826-92-3 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-chlorophenyl)-N3-[4-[2-[2-[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-3-oxo-4-morpholinyl]phenyl]- (CA INDEX NAME)




RN 890826-99-0 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-fluoro-4-(3-formyl-2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 890827-06-2 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[2-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]-4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 1096601-39-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:542131 CAPLUS

DOCUMENT NUMBER: 145:46051

TITLE: Preparation of 2-imino-3-phenyloxazolidines and related compounds for the treatment of thromboembolic diseases

INVENTOR(S): Roehrig, Susanne; Pohlmann, Jens; Arndt, Sabine; Jeske, Mario; Akbaba, Metin; Perzborn, Elisabeth; Gerdes, Christoph; Schlemmer, Karl-Heinz; Tuch, Arounarith; Lobell, Mario; Nell, Peter; Burkhardt, Nils

PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006058630	A1	20060608	WO 2005-EP12465	20051122 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004058062	A1	20060608	DE 2004-102004058062	20041202
CA 2589740	A1	20060608	CA 2005-2589740	20051122 <--
EP 1819701	A1	20070822	EP 2005-815274	20051122 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008521844	T	20080626	JP 2007-543733	20051122 <--
US 20080214533	A1	20080904	US 2007-792108	20071213 <--
PRIORITY APPLN. INFO.:			DE 2004-102004058062A	20041202 <--
			WO 2005-EP12465	W 20051122
OTHER SOURCE(S):		MARPAT 145:46051		
GI				



I



II



III

AB Title compds. I [Y = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R<sub>1</sub> = H, alkyl, CN, etc.; R<sub>2</sub>, R<sub>3</sub> = H, halo, CN, etc.; A = phenylene, 5 or 6-membered heteroaryl ring with provisos; Z = Ph, pyridyl, pyrimidinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, methanesulfonic acid mediated cyclization of cyanoamine II afforded the methanesulfonic acid salt of claimed phenyloxazolidine III in 81% yield. In blood-coagulation factor Xa inhibition assays, 4-examples of compds. I

exhibited IC50 values ranging 0.3-4.4 nM.


IT 890051-67-9P 890051-68-0P 890051-71-5P  
890051-72-6P 890051-73-7P 890051-74-8P  
890051-75-9P 890051-76-0P 890051-77-1P  
890051-78-2P 890051-79-3P 890051-80-6P  
890051-81-7P 890051-82-8P 890051-95-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-imino-3-phenyloxazolidines and related compds. for the treatment of thromboembolic diseases)


RN 890051-67-9 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]- (CA INDEX NAME)



RN 890051-68-0 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(dihydro-2-imino-2H-1,3-oxazin-3(4H)-yl)phenyl]- (CA INDEX NAME)




RN 890051-71-5 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 890051-67-9


CMF C20 H16 Cl N7 O3



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 890051-72-6 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, hydrobromide (1:?) (CA INDEX NAME)



●x HBr

RN 890051-73-7 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 890051-74-8 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(dihydro-2-imino-2H-1,3-oxazin-3(4H)-yl)phenyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 890051-68-0  
 CMF C21 H18 Cl N7 O3



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 890051-75-9 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-[4-(2-imino-3-oxazolidinyl)phenyl]-N3-(5-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 890051-76-0 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-[4-(2-imino-3-oxazolidinyl)phenyl]-N3-(5-methyl-2-pyridinyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1




CRN 890051-75-9  
CMF C21 H19 N7 O3




CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 890051-77-1 CAPLUS  
CN 2,3-Pyrazinedicarboxamide, N2-(5-cyano-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]- (CA INDEX NAME)



RN 890051-78-2 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(5-cyano-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 890051-77-1  
 CMF C21 H16 N8 O3




CM 2

CRN 75-75-2  
 CMF C H4 O3 S



RN 890051-79-3 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(4-cyanophenyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]- (CA INDEX NAME)




RN 890051-80-6 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(4-cyanophenyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 890051-79-3


CMF C22 H17 N7 O3




CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 890051-81-7 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(4-ethynylphenyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]- (CA INDEX NAME)



RN 890051-82-8 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-(4-ethynylphenyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 890051-81-7  
 CMF C23 H18 N6 O3



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 890051-95-3 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[(2Z)-2-(hydroxyimino)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




IT 693252-02-7P 890052-00-3P 890052-06-9P  
890052-07-0P 890052-08-1P 890052-09-2P  
890052-10-5P 890052-11-6P 890052-12-7P  
890052-13-8P 890052-14-9P 890052-15-0P  
890052-16-1P 890052-34-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of 2-imino-3-phenyloxazolidines and related compds. for the treatment of thromboembolic diseases)


RN 693252-02-7 CAPLUS

CN 2-Pyrazinecarboxylic acid, 3-[[[4-cyanophenyl]amino]carbonyl]- (CA INDEX NAME)




RN 890052-00-3 CAPLUS

CN 2-Pyrazinecarboxylic acid, 3-[[[4-ethynylphenyl]amino]carbonyl]- (CA INDEX NAME)




RN 890052-06-9 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (CA INDEX NAME)




RN 890052-07-0 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[[cyano[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (CA INDEX NAME)




RN 890052-08-1 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]propyl]amino]phenyl]- (CA INDEX NAME)




RN 890052-09-2 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[cyano[3-[(1,1-dimethylethyl)dimethylsilyl]oxy]propyl]amino]phenyl]- (CA INDEX NAME)




RN 890052-10-5 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-[4-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]-N3-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 890052-11-6 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-[4-[cyano[2-[[[1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]-N3-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 890052-12-7 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-[4-[cyano[2-[[[1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]-N3-(5-cyano-2-pyridinyl)- (CA INDEX NAME)







RN 890052-13-8 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-(4-cyanophenyl)-N3-[4-[[2-[[1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (CA INDEX NAME)



RN 890052-14-9 CAPLUS


CN 2,3-Pyrazinedicarboxamide, N2-[4-[cyano[2-[[1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]-N3-(4-cyanophenyl)- (CA INDEX NAME)





RN 890052-34-3 CAPLUS

CN 2,3-Pyrazinedicarboxamide, N2-(5-cyano-2-pyridinyl)-N3-[4-[[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:534761 CAPLUS

DOCUMENT NUMBER: 145:28024

TITLE: Preparation of fused heterocyclic kinase inhibitors

INVENTOR(S): Borzilleri, Robert M.; Chen, Zhong; Huynh, Tram N.; Vaccaro, Wayne; Chen, Xiao-Tao; Kim, Kyoung S.; Cai, Zhen-Wei

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 141 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

US 20050288290	A1	20051229	US 2005-167043	20050624 <--
AU 2005259894	A1	20060112	AU 2005-259894	20050628 <--
AU 2005260056	A1	20060112	AU 2005-260056	20050628 <--
CA 2571680	A1	20060112	CA 2005-2571680	20050628 <--
WO 2006004636	A2	20060112	WO 2005-US22682	20050628 <--
WO 2006004636	A3	20060526		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006004833	A2	20060112	WO 2005-US23099	20050628 <--
WO 2006004833	A3	20060713		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006004884	A2	20060112	WO 2005-US23198	20050628 <--
WO 2006004884	A3	20060323		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1761268	A2	20070314	EP 2005-791275	20050628 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU			
EP 1768983	A2	20070404	EP 2005-764291	20050628 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU			
EP 1771177	A2	20070411	EP 2005-790229	20050628 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU			
CN 1993130	A	20070704	CN 2005-80025519	20050628 <--
CN 101005843	A	20070725	CN 2005-80027728	20050628 <--
CN 101027305	A	20070829	CN 2005-80027173	20050628 <--
JP 2008504366	T	20080214	JP 2007-519322	20050628 <--



compound I or II alone or in combination with other antitumor agent are disclosed.


IT 888717-17-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer)

RN 888717-17-7 CAPLUS

CN 2-Pyrazinecarboxamide, N-[3-fluoro-4-[(5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy]phenyl]- (CA INDEX NAME)



L17 ANSWER 12 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:534671 CAPLUS

DOCUMENT NUMBER: 145:28023

TITLE: Preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer

INVENTOR(S): Borzilleri, Robert M.; Chen, Zhong; Hunt, John T.; Huynh, Tram; Poss, Michael A.; Schroeder, Gretchen M.; Vaccaro, Wayne; Wong, Tai W.; Chen, Xiao-Tao; Kim, Kyoung S.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 135 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060004006	A1	20060105	US 2005-167049	20050624 <--
US 7173031	B2	20070206		
AU 2005259894	A1	20060112	AU 2005-259894	20050628 <--
AU 2005260056	A1	20060112	AU 2005-260056	20050628 <--
CA 2571680	A1	20060112	CA 2005-2571680	20050628 <--
WO 2006004636	A2	20060112	WO 2005-US22682	20050628 <--
WO 2006004636	A3	20060526		


	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006004833	A2	20060112	WO 2005-US23099	20050628	<--
WO 2006004833	A3	20060713			
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006004884	A2	20060112	WO 2005-US23198	20050628	<--
WO 2006004884	A3	20060323			
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1761268	A2	20070314	EP 2005-791275	20050628	<--
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU			
EP 1768983	A2	20070404	EP 2005-764291	20050628	<--
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU			
EP 1771177	A2	20070411	EP 2005-790229	20050628	<--
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU			
CN 1993130	A	20070704	CN 2005-80025519	20050628	<--
CN 101005843	A	20070725	CN 2005-80027728	20050628	<--
CN 101027305	A	20070829	CN 2005-80027173	20050628	<--
JP 2008504366	T	20080214	JP 2007-519322	20050628	<--
JP 2008504367	T	20080214	JP 2007-519390	20050628	<--
JP 2008504368	T	20080214	JP 2007-519416	20050628	<--
BR 2005012722	A	20080401	BR 2005-12722	20050628	<--
IN 2006DN07597	A	20070803	IN 2006-DN7597	20061215	<--
IN 2006DN07602	A	20070803	IN 2006-DN7602	20061215	<--
MX 2006015032	A	20070208	MX 2006-15032	20061219	<--

MX 2006015192	A	20070228	MX 2006-15192	20061220	<--
IN 2006DN07759	A	20070817	IN 2006-DN7759	20061220	<--
KR 2007028458	A	20070312	KR 2006-727376	20061227	<--
KR 2007037448	A	20070404	KR 2006-727370	20061227	<--
NO 2007000453	A	20070124	NO 2007-453	20070124	<--
NO 2007000506	A	20070214	NO 2007-506	20070126	<--
NO 2007000514	A	20070312	NO 2007-514	20070126	<--
PRIORITY APPLN. INFO.:			US 2004-583459P	P	20040628 <--
			US 2004-612563P	P	20040923 <--
			WO 2005-US22682	W	20050628
			WO 2005-US23099	W	20050628
			WO 2005-US23198	W	20050628


OTHER SOURCE(S): MARPAT 145:28023  
GI



I



II



III

AB The title compds. I and II [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; B = O, NR8, S, SO, SO2, CR9C10; V = NR11 or (CR47R48)p; W or X = C or N; Y = O, S, NR12; Z = CR13R14, (CR13R14)mNR15; m = 0-2; n = 0-4; p = 0-4, provided that if p = 0, R1 is not Ph; A = substituted pyrrolo[2,1-f][1,2,4]triazin-4-yl, pyrrolo[1,2-b]pyridazin-4-yl, pyrrolo[2,3-b]pyridin-4-yl, etc.; R3, R8, R11, R15 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl, heterocycloalkyl; R9, R10 = H, halo, alkyl, etc.; R12 = H, alkyl, CN, etc.; R13-R15, R47, R48 = H, halo, alkyl, etc.; and their pharmaceutically acceptable salts], useful as protein kinase inhibitors for treating cancer and other protein kinase mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from Et 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylate, was given. Compds. I and II inhibit the Met kinase with IC50 values between 0.01 to 100  $\mu$ M. Pharmaceutical compns. comprising the compound I or II alone or in combination with other antitumor agent are disclosed.


IT 888717-17-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors



for treating cancer)  
 RN 888717-17-7 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-[3-fluoro-4-[(5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 205 THERE ARE 205 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:513602 CAPLUS

DOCUMENT NUMBER: 145:46271

TITLE: Preparation of glycopeptide antibiotic monomer derivatives having antibacterial activity against vancomycin-resistant bacteria

INVENTOR(S): Arimoto, Hirokazu; Lu, Jun; Yamano, Yoshinori; Yasukata, Tatsuro; Yoshida, Osamu; Iwaki, Tsutomu; Yoshida, Yutaka; Kato, Issei; Morimoto, Kenji; Yasoshima, Kayo

PATENT ASSIGNEE(S): National University Corporation Nagoya University, Japan; Shionogi & Co., Ltd.

SOURCE: PCT Int. Appl., 244 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006057303	A1	20060601	WO 2005-JP21587	20051124 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

AU 2005308160	A1	20060601	AU 2005-308160	20051124 <--
CA 2588285	A1	20060601	CA 2005-2588285	20051124 <--
EP 1818340	A1	20070815	EP 2005-809139	20051124 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
BR 2005016657	A	20080916	BR 2005-16657	20051124 <--
US 20080097078	A1	20080424	US 2007-791446	20070524 <--
MX 200706319	A	20070725	MX 2007-6319	20070528 <--
IN 2007CN02297	A	20070907	IN 2007-CN2297	20070529 <--
KR 2007092719	A	20070913	KR 2007-714842	20070628 <--
CN 101111513	A	20080123	CN 2005-80047421	20070730 <--
PRIORITY APPLN. INFO.:			JP 2004-344231	A 20041129 <--
			JP 2005-212471	A 20050722
			WO 2005-JP21587	W 20051124
OTHER SOURCE(S):			MARPAT 145:46271	
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. A-(Sac-NH)-RA [A = a part formed by removing the sugar part from a known glycopeptide antibiotic derivative; (Sac-NH) = an amino sugar part or a sugar chain part containing an amino sugar; RA = -X1-Ar1-X2-Y-X3-Ar2; X1, X2, X3 = single bond, -O-, -S-, etc.; Y = -NR2CO-, -CONR2-, Q1, etc.; R2 = H, alkyl; Ar1, Ar2 = (un)substituted, (un)saturated carbocycle or heterocycle] and their pharmaceutically acceptable salts were prepared For example, reductive amination of 3-benzyloxy-N-(4-formylphenyl)-4-methyl-2-nitrobenzamide, e.g., prepared from 3-hydroxy-4-methyl-2-nitrobenzoic acid in 4 steps, with vancomycin hydrochloride afforded compound I in 62% yield. In antibacterial test against *E. faecalis* SR7914 (VRE: VanA), MIC values of compound I and vancomycin were 4 and >64 µg/mL (sic), resp.


IT 889680-06-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of glycopeptide antibiotic monomer derivs. having antibacterial activity against vancomycin-resistant bacteria)

RN 889680-06-2 CAPLUS


CN Vancomycin, N3'''-[[3-[(pyrazinylcarbonyl)amino]phenyl]methyl]-, hydrochloride (5:6) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl



● 6/5 HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 14 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:493876 CAPLUS

DOCUMENT NUMBER: 145:8167

TITLE: Preparation of imidazolidin-2-imines and their analogs as aspartyl protease inhibitors for treating various diseases

INVENTOR(S): Zhu, Zhaoning; McKittrick, Brian A.; Sun, Zhong-Yue; Ye, Yuanzan C.; Voigt, Johannes H.; Strickland, Corey; Smith, Elizabeth M.; Stamford, Andrew; Greenlee, William J.; Mazzola, Robert; Caldwell, John; Cumming, Jared N.; Wang, Lingyan; Wu, Yusheng; Iserloh, Ulrich; Guo, Tao; Le, Thuy X. H.; Saionz, Kurt W.; Babu, Suresh D.; Hunter, Rachael C.; Morris, Michelle L.; Gu, Huizhong; Qian, Gang; Tadesse, Dawit

PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacoepia Drug Discovery, Inc.

SOURCE: U.S. Pat. Appl. Publ., 568 pp., Cont.-in-part of U.S. Ser. No. 10,772.

CODEN: USXXCO



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060111370	A1	20060525	US 2005-149027	20050609 <--
US 20070072852	A1	20070329	US 2004-10772	20041213 <--
AU 2005317204	A1	20060622	AU 2005-317204	20050609 <--
CA 2591033	A1	20060622	CA 2005-2591033	20050609 <--
WO 2006065277	A2	20060622	WO 2005-US20446	20050609 <--
WO 2006065277	A3	20070125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1838304	A2	20071003	EP 2005-766007	20050609 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2008523059	T	20080703	JP 2007-545436	20050609 <--
US 20080200445	A1	20080821	US 2007-710582	20070223 <--
IN 2007CN02535	A	20070907	IN 2007-CN2535	20070613 <--
KR 2007106689	A	20071105	KR 2007-713310	20070613 <--
MX 2007007058	A	20071211	MX 2007-7058	20070613 <--
NO 2007003616	A	20070912	NO 2007-3616	20070712 <--
CN 101115482	A	20080130	CN 2005-80047939	20070809 <--
JP 2008174570	A	20080731	JP 2008-79293	20080325 <--
PRIORITY APPLN. INFO.:			US 2003-529535P	P 20031215 <--
			US 2004-10772	A2 20041213 <--
			JP 2006-544081	A3 20041213 <--
			US 2005-149027	A2 20050609
			WO 2005-US20446	W 20050609
OTHER SOURCE(S):		MARPAT 145:8167		
GI				



AB Disclosed are compds. I [W = a bond, C(S), S(O), etc.; X = O, NR<sup>5</sup> or CR<sup>6</sup>R<sup>7</sup>; U = a bond, S(O), SO<sub>2</sub>, C(O), etc.; R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub> = H, alkyl, cycloalkyl, etc.; R<sub>3</sub>, R<sub>4</sub>, R<sub>6</sub>, R<sub>7</sub> = H, alkyl, cycloalkyl, etc.] or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof; and the pharmaceutical compns. comprising the compds. I. Over 1000 compds. I were prepared E.g., synthesis of imidazolidin-2-imine II, starting from III, was described. Compds. I were tested in various assays (data given for selected compds. I). Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepsin, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compds. I in combination with a cholinesterase inhibitor or a muscarinic M<sub>1</sub> agonist or M<sub>2</sub> antagonist.


IT 887911-28-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic aspartyl protease inhibitors for treating various diseases)

RN 887911-28-6 CAPLUS

CN 2-Pyrazinecarboxamide, N-[3-(2-amino-4,5-dihydro-1-methyl-5-oxo-4-phenyl-1H-imidazol-4-yl)phenyl]- (CA INDEX NAME)



ACCESSION NUMBER: 2006:437125 CAPLUS  
 DOCUMENT NUMBER: 144:468165  
 TITLE: Preparation of benzimidazole derivatives containing  
 aryloxy moiety as glucokinase activators  
 INVENTOR(S): Hashimoto, Noriaki; Takahashi, Keiji; Nakama, Chisato;  
 Ogino, Yoshio; Sakai, Fumiko; Nishimura, Teruyuki;  
 Eiki, Junichi  
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd, Japan  
 SOURCE: PCT Int. Appl., 162 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006049304	A1	20060511	WO 2005-JP20483	20051101 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005301608	A1	20060511	AU 2005-301608	20051101 <--
CA 2586056	A1	20060511	CA 2005-2586056	20051101 <--
EP 1810969	A1	20070725	EP 2005-803447	20051101 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
CN 101094847	A	20071226	CN 2005-80045688	20051101 <--
BR 2005017232	A	20081007	BR 2005-17232	20051101 <--
MX 2007005289	A	20070719	MX 2007-5289	20070430 <--
KR 2007083939	A	20070824	KR 2007-710065	20070502 <--
IN 2007DN03926	A	20070831	IN 2007-DN3926	20070525 <--
NO 2007002806	A	20070727	NO 2007-2806	20070601 <--
US 20080125429	A1	20080529	US 2007-666555	20070618 <--
PRIORITY APPLN. INFO.:			JP 2004-319339	A 20041102 <--
			JP 2005-178628	A 20050617
			WO 2005-JP20483	W 20051101
OTHER SOURCE(S):		MARPAT 144:468165		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1, R2 = H, halo, alkyl, etc.; R3 = H, halo, alkyl, etc.; R4 = H, alkyl, alkoxy, etc.; Q = carbon, nitrogen, , sulfur atom with the proviso that the sulfur atom may be mono- or di-substituted with oxo; R5, R6 = H, alkyl, halo, etc.; X1-X4 = carbon, nitrogen; Z = oxygen, sulfur, nitrogen; Ar = optionally substituted aryl with alkyl, alkoxy, halo, etc., optionally substituted heteroaryl with alkyl, alkoxy, halo, etc.; ring A = aromatic heterocycle containing nitrogen represented by Q1; X = carbon; m = 1-6;  
 n = 0-3; p = 0-2 with the proviso that at least two of X1 to X4 are each

carbon; q = 0, 1] and their pharmaceutically acceptable salts were prepared. For example, DEAD mediated reaction of a mixture of compound II [R = OH; R' = CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>SiMe<sub>3</sub>] and compound III [R = OH; R' = CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>SiMe<sub>3</sub>], e.g., prepared from 4-bromo-3-fluoroaniline in 9 steps, with succinimide followed by treatment with trifluoroacetic acid and silica-gel purification afforded compound II [R = 2,5-dioxopyrrolidin-1-yl; R' = H]. In glucokinase activation assays, the EC<sub>50</sub> value of compound II [R = 2,5-dioxopyrrolidin-1-yl; R' = H] was 0.12  $\mu$ M. Comps. I are claimed useful for the treatment of diabetes and obesity.

IT 886977-03-3P 886978-99-0P 886979-01-7P

886979-96-0P 886979-97-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of benzimidazole derivs. containing aryloxy moiety as

glucokinase activators for treatment of diabetes and obesity)


RN 886977-03-3 CAPLUS

CN Benzoic acid, 2-fluoro-5-nitro-4-[(2-pyrazinylcarbonyl)amino]-, methyl ester (CA INDEX NAME)



RN 886978-99-0 CAPLUS


CN 2-Pyrazinecarboxamide, N-[5-fluoro-2-nitro-4-[(2-oxo-1-pyrrolidinyl)methyl]phenyl]- (CA INDEX NAME)



RN 886979-01-7 CAPLUS


CN Benzoic acid, 4-[[5-bromo-2-pyrazinyl)carbonyl]amino]-2-fluoro-, methyl ester (CA INDEX NAME)






RN 886979-96-0 CAPLUS

CN Benzoic acid, 5-[[6-(ethylsulfonyl)-3-pyridinyl]oxy]-3-nitro-2-[(2-pyrazinylcarbonyl)amino]-, methyl ester (CA INDEX NAME)



RN 886979-97-1 CAPLUS

CN Benzoic acid, 5-[[6-(ethylsulfonyl)-3-pyridinyl]oxy]-2-[(2-pyrazinylcarbonyl)amino]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 16 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:367034 CAPLUS

DOCUMENT NUMBER: 144:412543

TITLE: Preparation of quinoxalines as B Raf inhibitors

INVENTOR(S): Aquila, Brian; Dakin, Les; Deegan, Tracey; Ioannidis, Stephanos; Lee, Stephen; Lyne, Paul; Pontz, Timothy; Su, Mei

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Ltd.

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006040568	A1	20060420	WO 2005-GB3953	20051013 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005293384	A1	20060420	AU 2005-293384	20051013 <--
CA 2583096	A1	20060420	CA 2005-2583096	20051013 <--
EP 1828147	A1	20070905	EP 2005-792991	20051013 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
CN 101080396	A	20071128	CN 2005-80042973	20051013 <--
JP 2008516939	T	20080522	JP 2007-536261	20051013 <--
BR 2005018126	A	20081028	BR 2005-18126	20051013 <--
NO 2007001776	A	20070425	NO 2007-1776	20070403 <--
US 20080207616	A1	20080828	US 2007-577132	20070412 <--
MX 200704480	A	20070508	MX 2007-4480	20070413 <--
IN 2007DN02812	A	20070803	IN 2007-DN2812	20070416 <--
KR 2007063044	A	20070618	KR 2007-711025	20070515 <--
PRIORITY APPLN. INFO.:			US 2004-619373P	P 20041015 <--
			WO 2005-GB3953	W 20051013
OTHER SOURCE(S):			CASREACT 144:412543; MARPAT 144:412543	
GI				




AB The title compds. I [A = carbocyclyl or heterocyclyl; R1 is a substituent on carbon and is selected from halo, nitro, cyano, etc.; n = 0-4; Z = CONH, NHCO, CH2NH; R2 = H, halo, nitro, etc.; R3 = halo, hydroxy, Me, methoxy or hydroxymethyl; X = NR18CO, NR19, NR20CH2; R4-R8 = H, halo, nitro, etc.; R18-R20 = H, alkyl, alkanoyl, etc.] which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity, were prepared Thus, amidation of N-(5-amino-2-methylphenyl)quinoxaline-6-carboxamide (preparation given) with 3-(methylthio)benzoic acid afforded 73% N-(2-methyl-5-{[3-(methylthio)benzoyl]amino}phenyl)quinoxaline-6-carboxamide. The compds. I exhibited activity less than 30  $\mu$ M when tested in B-Raf in vitro ELISA assay. The invention also relates to processes for the manufacture of compds. I, to pharmaceutical compns. containing them and to their use in the manufacture of medicaments of use in the production of

an anti-cancer effect in a warm blooded animal such as man.

IT 884000-09-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of quinoxalines as B Raf inhibitors for treating cancer)

RN 884000-09-3 CAPLUS

CN 6-Quinoxalinecarboxamide, N-[2-methyl-5-[(2-pyrazinylcarbonyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 17 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:353676 CAPLUS

DOCUMENT NUMBER: 144:369921

TITLE: Preparation of phenylaminopyridines for treatment of neoplastic and autoimmune disease.

INVENTOR(S): Eberle, Martin; Bachmann, Felix; Strebel, Alessandro; Roy, Subho; Saha, Goutam; Nandi, Godhuli

PATENT ASSIGNEE(S): Basilea Pharmaceutica A.-G., Switz.

SOURCE: PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006027348	A1	20060316	WO 2005-EP54371	20050905 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1634871	A1	20060315	EP 2004-405552	20040906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CA 2578047	A1	20060316	CA 2005-2578047	20050905 <--
EP 1789044	A1	20070530	EP 2005-787155	20050905 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20080221171	A1	20080911	US 2008-662047	20080111 <--
PRIORITY APPLN. INFO.: EP 2004-405552 A 20040906 <-- WO 2005-EP54371 W 20050905				

OTHER SOURCE(S): CASREACT 144:369921; MARPAT 144:369921  
GI



AB Title compds. [I; A = CH, N, CX; X = alkyl; R1 = COR9, SO2R10, PO(OR11)2, (substituted) Ph, heteroaryl; R2 = H, alkyl; R3 = 1-2 of H, alkyl, cycloalkyl heterocyclyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, (substituted) alkenyl, alkynyl, aryl, heteroaryl, aryloxy, etc.; R4, R5 = H, alkyl, haloalkyl, alkoxy, amino, halo; R6 = H, alkyl, alkylcarbonyl, alkoxyalkyl; R7 = 1-2 of H, alkyl, cycloalkyl, heterocyclyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, (substituted) alkenyl, alkynyl, aryl, heteroaryl, etc.; R8 = H, OH, alkoxy, alkylcarbonyloxy, alkoxyalkyl, aminocarbonyl, halo, cyano, NO2, etc.; R9 = alkyl, haloalkyl, cycloalkylalkyl, heterocyclylalkyl, hydroxyalkyl, alkoxyalkyl, etc.; R10 = alkyl, haloalkyl, cycloalkylalkyl, heterocyclylalkyl, hydroxyalkyl, alkoxyalkyl, alkylcarbonyl, (substituted) alkenyl, heterocyclyl, aryl, heteroaryl, etc.; R11 = alkyl, haloalkyl, alkoxyalkyl, aryl, aralkyl], were prepared Thus, 3,5-dibromopyridine, p-anisidine, (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, NaOCMe3, and Pd2(dba)3 were heated together in PhMe at 70° for 16 h to give 3-bromo-5-(p-methoxyphenylamino)pyridine. The latter was refluxed with 3-aminophenylboronic acid, Na2CO3, and Pd(PPh3)4 in dimethoxyethane for 16 h to give 3-(m-aminophenyl)-5-(p-methoxyphenylamino)pyridine. This was stirred with MsCl in pyridine at -20° to room temperature to give 3-(m-mesyaminophenyl)-5-(p-methoxyphenylamino)pyridine. I induced apoptosis in various cancer cell lines.


IT 882183-54-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylaminopyridines for treatment of neoplastic and autoimmune disease)

RN 882183-54-2 CAPLUS

CN 2-Pyrazinecarboxamide, N-[3-[5-[(4-methoxyphenyl)amino]-3-pyridinyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 18 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:318485 CAPLUS

DOCUMENT NUMBER: 144:370081

TITLE: Carbostyryl compounds and their preparation, pharmaceutical compositions, and their transcription promoting activity of TFF2 for treatment and/or prevention of various diseases

INVENTOR(S): Kuroda, Takeshi; Yamauchi, Takahito; Shinohara, Tomoichi; Oshima, Kunio; Kitajima, Chiharu; Nagao, Hitoshi; Fukushima, Tae; Tomoyasu, Takahiro; Ishiyama, Hironobu; Ohta, Kazuhide; Takano, Masaaki; Sumida, Takumi

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 468 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006035954	A1	20060406	WO 2005-JP18217	20050926 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005288080	A1	20060406	AU 2005-288080	20050926 <--
CA 2580811	A1	20060406	CA 2005-2580811	20050926 <--
JP 3906471	B1	20070418	JP 2006-519041	20050926 <--
JP 2007512220	T	20070517		
EP 1797082	A1	20070620	EP 2005-788152	20050926 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

CN 101068810	A	20071107	CN 2005-80037090	20050926 <--
BR 2005016219	A	20080826	BR 2005-16219	20050926 <--
US 20070179173	A1	20070802	US 2006-582014	20060607 <--
IN 2007DN01824	A	20070817	IN 2007-DN1824	20070308 <--
MX 200703735	A	20070423	MX 2007-3735	20070328 <--
KR 2007061902	A	20070614	KR 2007-709483	20070426 <--
KR 823414	B1	20080417		
KR 2007072632	A	20070704	KR 2007-714064	20070621 <--
KR 840465	B1	20080620		
PRIORITY APPLN. INFO.:			JP 2004-282814	A 20040928 <--
			WO 2005-JP18217	W 20050926
			KR 2007-709483	A3 20070426
OTHER SOURCE(S):			CASREACT 144:370081; MARPAT 144:370081	
GI				



AB The invention provides carbostyryl compds. represented by formula I or salts thereof, and their pharmaceutical compns., prepns. and use for transcription promotion activity of TFF2. The carbostyryl compds. or salts thereof, of the invention, induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds. Compds. of formula I wherein A is a bond, a lower alkylene group, or a lower alkylidene group; X is O or S; the dotted line is a single or a double bond; R4 and R5 are independently H, with the provision that dotted line is a double bond; or R4-R5 may be linked together to form a CH=CH-CH=CH group; R1 is H, lower alkyl, (un)substituted Ph lower alkyl, cycloalkyl lower alkyl, phenoxy lower alkyl, naphthyl lower alkyl, lower alkoxy lower alkyl, carboxyl lower alkyl, lower alkoxy carbonyl lower alkyl, (un)substituted pyridyl lower alkyl, cyano lower alkyl, etc.; R2 is H, lower alkoxy, lower alkyl, carboxy lower alkyl, lower alkoxy carbonyl lower

alkoxy, HO, (un)substituted Ph lower alkoxy, (un)substituted piperidinyl(oxy) lower alkyl, lower alkenyloxy, (un)substituted pyridyl lower alkoxy, lower alkynyloxy, Ph lower alkenyloxy, Ph lower alkynyloxy, (un)substituted furyl lower alkoxy, (un)substituted oxadiazolyl lower alkyl, or (un)substituted thiazolyl lower alkoxy, etc.; R3 is H, lower (HO-substituted) alkyl, cycloalkyl lower alkyl, carboxyl lower alkyl, lower alkoxy carbonyl lower alkyl, (un)substituted Ph lower alkyl, naphthyl lower alkyl, (un)substituted furyl lower alkyl, (un)substituted thiazolyl lower alkyl, (un)substituted tetrazolyl, or (un)substituted benzothienyl, etc.; and their pharmaceutically acceptable salts are claimed. Example compound II was prepared by heterocyclization of 2-chloro-3-(8-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-5-yl)propionic acid with thiourea. All the invention compds. were evaluated for the transcription promoting activity of hTFF2. From the assay, it was determined that some invention compds., including compound III, showed TFF2 production activity of 1000% or higher at a test compound concentration of 10<sup>-6</sup>M

concentration Some

invention compds. showed a TFF2 production promoting activity of 300% or higher at a test compound concentration is less than 10<sup>-5</sup>M and preferably more than

10<sup>-6</sup>M. Example compound III and a few other compds. showed >20% healing ratio of the ulcerated area, which indicated that these compds. may be effective in preventing and/or treating mucosal injury.

IT 882009-63-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of carbostyryl compds. and their transcription promoting activity of TFF2 for treatment and/or prevention of various diseases)

RN 882009-63-4 CAPLUS

CN 2-Pyrazinecarboxamide, N-[4-[[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-3,4-dihydro-8-methoxy-2-oxo-1(2H)-quinolinyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A





REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 19 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:273658 CAPLUS  
 DOCUMENT NUMBER: 144:331457  
 TITLE: Preparation of substituted pyrazolo[1,5-a]pyrimidines and methods of their use as antiproliferative agents  
 INVENTOR(S): Wang, Yanong Daniel; Gopalsamy, Ariamala; Honores, Erick Eduardo; Jennings, Lee Dalton; Johnson, Steven Lawrence; Powell, Dennis William; Sum, Fuk-Wah; Tsou, Hwei-Ru; Wu, Biqi; Zhang, Nan  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 83 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060063784	A1	20060323	US 2005-221846	20050909 <--
WO 2006033795	A2	20060330	WO 2005-US31087	20050901 <--
WO 2006033795	A3	20060810		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-610550P P 20040917 <--  
 OTHER SOURCE(S): CASREACT 144:331457; MARPAT 144:331457  
 GI





AB The invention is related to novel methods of use of pyrazolo[1,5-a]pyrimidines I [R1 = H, CN, halo, CHO, CO2H, etc.; R2-R4 = H, CF3, alkyl; R5 = (un)substituted hetero/aryl], and their therapeutically acceptable salts and prodrugs, as antiproliferative agents, particularly antitumor agents, in mammals, including humans. The use of pyrazolopyrimidines I in regulating the expression of p21 in cells, and the preparation of certain I are given. Thus, reacting (3-Amino-1H-pyrazol-4-yl)(thien-2-yl)methanone (preparation given) with 3-(Dimethylamino)-1-(2-thienyl)-2-propen-1-one (preparation given) gave pyrazolopyrimidine II. In a cytotoxicity test against 80S14 (p21-deficient) cells, II had an IC50 in the range of 1-10  $\mu$ M.


IT 879372-18-6P, N-[3-[3-[(Thien-2-yl)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]pyrazine-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted pyrazolo[1,5-a]pyrimidines as antitumor agents)

RN 879372-18-6 CAPLUS


CN 2-Pyrazinecarboxamide, N-[3-[3-(2-thienylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]- (CA INDEX NAME)



L17 ANSWER 20 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:273618 CAPLUS  
 DOCUMENT NUMBER: 144:312112  
 TITLE: Preparation of substituted pyrazolo[1,5-a]pyrimidines  
 as antiproliferative agents  
 INVENTOR(S): Wang, Yanong Daniel; Gopalsamy, Ariamala; Powell,  
 Dennis William; Tsou, Hwei-Ru; Zhang, Nan  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 84 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060063785	A1	20060323	US 2005-221847	20050909 <--
WO 2006033796	A1	20060330	WO 2005-US31088	20050901 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.: US 2004-610520P P 20040917 <--  
 OTHER SOURCE(S): MARPAT 144:312112  
 GI



AB This invention relates to novel pyrazolo[1,5-a]pyrimidine compds. I (wherein R1 = H, cyano, halogen, carbamoyl, formyl, carboxy, C(O)O-alkyl, C(O)O-cycloalkyl, C(O)cycloalkyl, R6, C(O)R6, and C(S)R6; R6 = (un)substituted, aryl or heteroaryl; R2, R3, and R4 = H, CF3, or alkyl; R5 = (un)substituted aryl or heteroaryl) and the therapeutically acceptable salts thereof. These compds. are useful as anti-proliferative agents in mammals, including humans. The compds., their use in regulating the expression of p21 in cells, as well as a method of preparation are claimed. For example, II is prepared from (3-amino-1H-pyrazol-4-yl)-2-


thienylmethanone and 3-(dimethylamino)-1-[3-(cyclopentyloxy)phenyl]-2-propen-1-one, which in turn was prepared from 3-cyclopentyloxyacetophenone and DMF-di-Me acetal. In a cytotoxicity test against 80S14 (p21-deficient) cells, II had an IC50 in the range of 1-10  $\mu$ M.

IT 879372-18-6P, N-[3-[3-[(Thien-2-yl)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]pyrazine-2-carboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of substituted pyrazolo[1,5-a]pyrimidines as antiproliferative agents)  
 RN 879372-18-6 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-[3-[3-(2-thienylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]- (CA INDEX NAME)



L17 ANSWER 160 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1981:532666 CAPLUS  
 DOCUMENT NUMBER: 95:132666  
 ORIGINAL REFERENCE NO.: 95:22215a,22218a  
 TITLE: Aminopropanol derivatives and their pharmaceutical use  
 INVENTOR(S): Friebe, Walter Gunar; Kampe, Wolfgang; Bartsch, Wolfgang; Sponer, Gisbert; Dietmann, Karl  
 PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H. , Fed. Rep. Ger.  
 SOURCE: Ger. Offen., 22 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2948056	A1	19810604	DE 1979-2948056	19791129
US 4378363	A	19830329	US 1980-207527	19801117 <--
EP 29992	A1	19810610	EP 1980-107337	19801125 <--
EP 29992	B1	19830629		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT 3977	T	19830715	AT 1980-107337	19801125 <--
JP 56092863	A	19810727	JP 1980-166857	19801128 <--
PRIORITY APPLN. INFO.:			DE 1979-2948056	A 19791129 <--
			EP 1980-107337	A 19801125 <--
OTHER SOURCE(S):	CASREACT 95:132666; MARPAT 95:132666			
GI				




AB The  $\beta$ -adrenergic blocking agents (no data) I [R = H, acyl, aroyl; R1 = alkyl optionally substituted by Z1R4 (Z1 = bond, O, S; R4 = optionally substituted aryl or heteroaryl); R2 = H, acyl; R3 = optionally substituted heterocyclyl; Z = bond, CH2] and their salts were prepared Thus, 4-H2NC6H4OCH2CH(OH)CH2N(CH2Ph)CHMe reacted with 2-indolecarbonyl chloride in CH2Cl2 containing NaHCO3, and the product was hydrogenated over Pd-C to give I.HCl (R = H, R1 = Me2CH, R2 = H, R3Z = 2-indolyl).

IT 79112-24-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 79112-24-6 CAPLUS

CN 2-Pyrazinecarboxamide, N-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-5-methyl- (CA INDEX NAME)



L17 ANSWER 161 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1981:3857 CAPLUS

DOCUMENT NUMBER: 94:3857

ORIGINAL REFERENCE NO.: 94:715a,718a

TITLE: Carboxylic acid derivatives

INVENTOR(S): Noda, Kanji; Nakagawa, Akira; Motomura, Toshiharu; Tsuji, Masayoshi; Amano, Hidetoshi; Ide, Hiroyuki

PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.  
 CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55040650	A	19800322	JP 1978-114394	19780916 <--
PRIORITY APPLN. INFO.:			JP 1978-114394	A 19780916 <--

GI For diagram(s), see printed CA Issue.


AB Sixteen carboxylic acid derivs. I (the ring is a benzene, cyclohexane, pyridine, or pyrazine ring; R = H, halo, alkyl, alkoxy, NO2; R1 = substituted Ph) were prepared by reaction of II with R1NH2. The data of homologous passive dermal reaction were given in rats. Thus, reaction of 2.96 g phthalic anhydride with 3.66 g 3,4,5-(MeO)3C6H2NH2 in EtOH 24 h at room temperature gave 5.7 g N-(3,4,5-trimethoxyphenyl)phthalamidic acid.

IT 75893-58-2P 75893-59-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 75893-58-2 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 3-[[ (3,4,5-trimethoxyphenyl)amino]carbonyl]-  
 (CA INDEX NAME)




RN 75893-59-3 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 3-[[ (3,5-dichloro-4-hydroxyphenyl)amino]carbonyl]- (CA INDEX NAME)



L17 ANSWER 162 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1979:151840 CAPLUS  
 DOCUMENT NUMBER: 90:151840  
 ORIGINAL REFERENCE NO.: 90:24125a,24128a  
 TITLE: Methyl N-acylanthranilates  
 INVENTOR(S): Kirino, Osamu; Yamamoto, Shigeo; Kato, Hisao  
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53130655	A	19781114	JP 1977-45269	19770419 <--
JP 58048560	B	19831028		

PRIORITY APPLN. INFO.: JP 1977-45269 A 19770419 <--  
 AB 2-RCONHC6H4CO2Me (I; R = 2- or 3-furyl, 2-thienyl, 2-, 3-, or 4-pyridyl, pyrazinyl) were prepared by treating 2-H2NC6H4CO2Me (II) with RCO2H or their reactive derivs. Antibacterial test data of I against Sphaerotheca fuliginea and Erysiphe graminis are given. Thus, stirring 15.1 g II, pyrazinecarboxylic acid, and dicyclohexylcarbodiimide in C6H6 4 h at room temperature gave 21.5 g I (R = pyrazinyl).  
 IT 69873-69-4P  
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and bactericidal activity of)  
 RN 69873-69-4 CAPLUS  
 CN Benzoic acid, 2-[(2-pyrazinylcarbonyl)amino]-, methyl ester (CA INDEX NAME)



L17 ANSWER 163 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1977:140042 CAPLUS  
 DOCUMENT NUMBER: 86:140042  
 ORIGINAL REFERENCE NO.: 86:21993a,21996a  
 TITLE: 1,5-Diphenylpyrazoles  
 INVENTOR(S): Reis, Hermann; Vilhuber, Heinz G.; Schulz, Lothar;  
 Lenke, Dieter  
 PATENT ASSIGNEE(S): BASF A.-G., Fed. Rep. Ger.  
 SOURCE: Ger. Offen., 13 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2525024	A1	19761230	DE 1975-2525024	19750605 <--
PRIORITY APPLN. INFO.: GI			DE 1975-2525024	A 19750605 <--




AB Antiinflammatory (carboxamidophenyl)pyrazoles (I; R = 2-, 3-, and 4-pyridinyl, 2-chloro-3-pyridinyl, 2,6-dichloro-4-methyl-3-pyridinyl, 4-pyrimidinyl, 2-pyrazinyl) are prepared by acylation of 5-(4-aminophenyl)-1-phenylpyrazole (II) with the appropriate acyl chlorides. Thus, reaction of ClCH:CHCOC6H4NO2-4 with PhNH2 gives 94% PhNHCH:CHCOC6H4NO2-4 which on condensation with PhNHNH2 gives 63% 5-(4-nitrophenyl)-1-phenylpyrazole (III). Hydrogenation of III gives 87% II. Nicotinic acid is converted with SOCl2 to the acid chloride which reacts with II in PhMe in the presence of Et3N at 60° to give 76% I (R = 3-pyridinyl) (IV). IV has 87% of the activity of phenylbutazone with <20% of its toxicity.

IT 62089-25-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 62089-25-2 CAPLUS


CN 2-Pyrazinecarboxamide, N-[4-(1-phenyl-1H-pyrazol-5-yl)phenyl]- (CA INDEX NAME)




L17 ANSWER 164 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1976:542990 CAPLUS  
 DOCUMENT NUMBER: 85:142990  
 ORIGINAL REFERENCE NO.: 85:22917a,22920a  
 TITLE: N-monosubstituted-2,3-pyridinedicarboxamides, and related compounds  
 INVENTOR(S): Jacobs, Richard L.  
 PATENT ASSIGNEE(S): Sherwin-Williams Co., USA  
 SOURCE: U.S., 10 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3960877	A	19760601	US 1974-536947	19741223 <--
PRIORITY APPLN. INFO.:			US 1968-740046	A1 19680626 <--
			US 1970-82804	A1 19701021 <--
			US 1973-381770	A1 19730723 <--

GI



AB Amides I-III (R or R1 = alkyl, cycloalkyl, substituted benzyl, etc.) were prepared by treating dicarboximides with RNH2 or N-substituted dicarboximides with NH3. The amides are intermediates for herbicidal condensed pyrimidines. Thus I (R = CHMe2, R1 = H) on heating with base gave pyridopyrimidinedione IV.  
 IT 60554-71-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 60554-71-4 CAPLUS  
 CN 2,3-Pyrazinedicarboxamide, N2-phenyl- (CA INDEX NAME)




L17 ANSWER 165 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1973:492284 CAPLUS  
 DOCUMENT NUMBER: 79:92284  
 ORIGINAL REFERENCE NO.: 79:14995a,14998a  
 TITLE: Anticonvulsive and tranquilizing pyrrolopyrazines  
 INVENTOR(S): Cotrel, Claude; Jeanmart, Claude; Messer, Mayer N.  
 PATENT ASSIGNEE(S): Rhone-Poulenc S. A.  
 SOURCE: Ger. Offen., 18 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2300491	A1	19730719	DE 1973-2300491	19730105 <--
DE 2300491	B2	19770908		
FR 2166314	A1	19730817	FR 1972-505	19720107
FR 2205318	A2	19740531	FR 1972-39731	19721109
DD 102698	A5	19731220	DD 1972-167951	19721228 <--
PL 82478	B1	19751031	PL 1972-159840	19721228 <--
PL 91759	B1	19770331	PL 1972-174539	19721228 <--
PL 91760	B1	19770331	PL 1972-174540	19721228 <--
NL 7217852	A	19730710	NL 1972-17852	19721229 <--
US 3862149	A	19750121	US 1972-319876	19721229 <--
ZA 7300072	A	19730926	ZA 1973-72	19730104 <--
HU 164821	B	19740411	HU 1973-RO691	19730104 <--
AU 7350754	A	19740704	AU 1973-50754	19730104 <--
BE 793730	A1	19730705	BE 1973-126194	19730105 <--
JP 48076892	A	19731016	JP 1973-69	19730105 <--
JP 52003952	B	19770131		
GB 1358680	A	19740703	GB 1973-796	19730105 <--
CH 560702	A5	19750415	CH 1974-11606	19730105 <--
CH 560703	A5	19750415	CH 1974-11607	19730105 <--
AT 323181	B	19750625	AT 1973-100	19730105 <--
CH 564558	A5	19750731	CH 1973-113	19730105 <--
CA 991183	A1	19760615	CA 1973-160620	19730105 <--
SU 548212	A3	19770225	SU 1973-1873290	19730105 <--
NO 136843	B	19770808	NO 1973-62	19730105 <--
CS 180649	B1	19770831	CS 1976-4995	19730105 <--
CS 180650	B2	19770831	CS 1976-4996	19730105 <--
SE 398503	B	19771227	SE 1973-159	19730105 <--
SE 398503	C	19780406		
CS 180610	B2	19780131	CS 1973-122	19730105 <--
FI 54124	B	19780630	FI 1973-27	19730105 <--
FI 54124	C	19781010		
DK 139359	B	19790205	DK 1973-69	19730105 <--
DK 139359	C	19790709		
SU 507240	A3	19760315	SU 1974-1993903	19740206 <--
SU 504484	A3	19760225	SU 1974-1995434	19740213 <--



JP 52048687 A 19770418 JP 1976-106831 19760908 <--  
 JP 52031358 B 19770813  
 JP 52048688 A 19770418 JP 1976-106832 19760908 <--  
 PRIORITY APPLN. INFO.: FR 1972-505 A 19720107 <--  
 FR 1972-39731 A 19721109 <--

GI For diagram(s), see printed CA Issue.  
 AB Five pyrrolopyrazines (I; R = 3-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 5-chloro-2-pyridyl, 6-methyl-3-pyridazinyl, or 7-chloro-2-quinolyl; n = 0 or 1), useful as tranquilizers and anticonvulsants, were prepared by reaction of II with YCl or successively with ClCO<sub>2</sub>Ph and 1-methylpiperazine, optionally followed by oxidation II were prepared by reaction of RNH<sub>2</sub> with 2,3-pyrazinedicarboxylic anhydride, followed by ring closure, and KBH<sub>4</sub> reduction of the resulting 5,7-dioxopyrrolopyrazine derivs.  
 IT 43200-87-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
 RN 43200-87-9 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 3-[[[(3-nitrophenyl)amino]carbonyl]- (CA INDEX NAME)



L17 ANSWER 166 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1973:99069 CAPLUS  
 DOCUMENT NUMBER: 78:99069  
 ORIGINAL REFERENCE NO.: 78:15905a,15908a  
 TITLE: Azo dyes for color photography  
 INVENTOR(S): Piller, Bernhard; Lenoir, John; Froehlich, Alfred; Stauner, Thomas; Tschopp, Paul  
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G.  
 SOURCE: Ger. Offen., 104 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2216592	A	19721019	DE 1972-2216592	19720406 <--
DE 2216592	C2	19820930		
CH 572230	A5	19760130	CH 1971-5058	19710407
CH 566029	A5	19750829	CH 1971-7208	19710514
CH 572231	A5	19760130	CH 1971-13605	19710916
AU 7240352	A	19730927	AU 1972-40352	19720323 <--
AU 7240651	A	19731004	AU 1972-40651	19720330 <--
CA 985675	A1	19760316	CA 1972-138612	19720330 <--
CA 987310	A1	19760413	CA 1972-138614	19720330 <--
IT 958675	B	19731030	IT 1972-89525	19720405 <--
IT 958676	B	19731030	IT 1972-89526	19720405 <--
GB 1372448	A	19741030	GB 1972-15612	19720405 <--
BE 781728	A1	19721006	BE 1972-115988	19720406 <--
BE 781729	A1	19721006	BE 1972-115989	19720406 <--
NL 7204615	A	19721010	NL 1972-4615	19720406 <--

NL 7204616	A	19721010	NL 1972-4616	19720406 <--
FR 2132697	A5	19721124	FR 1972-12026	19720406 <--
FR 2132697	B1	19740913		
FR 2132734	A5	19721124	FR 1972-12183	19720406 <--
FR 2132734	B1	19740802		
JP 56011941	B	19810318	JP 1972-33985	19720406 <--
AT 317672	B	19740910	AT 1972-3022	19720407 <--
JP 56011942	B	19810318	JP 1972-34511	19720407 <--
US 4118232	A	19781003	US 1977-777867	19770315 <--
PRIORITY APPLN. INFO.:			CH 1971-5058	A 19710407 <--
			CH 1971-7208	A 19710514 <--
			CH 1971-13605	A 19710916 <--
			US 1972-238944	A1 19720328 <--
			US 1975-606395	A3 19750821 <--

AB Approx. 300 disazo dyes (I, R=H, Me, alkylaryl; X = halogen, Me, OMe, SMe, CF<sub>3</sub>, NHBz; Q = aromatic or heterocyclic dicarboxylic acid residue) were prepared by the reaction of an amino azo compound with a diacyl chloride and are especially useful for diffusion transfer Ag-dye bleach processes. Thus, 5,4,2-Me(O<sub>2</sub>N)(H<sub>2</sub>N)C<sub>6</sub>H<sub>2</sub>SO<sub>3</sub>NH<sub>4</sub> was diazotized and coupled with ZH (R = 2,6-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>), reduced with Na<sub>2</sub>S, and acylated with m-C<sub>6</sub>H<sub>4</sub>(COCl)<sub>2</sub> to give disazo dye (II R = 2,6-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub> in Z) [38215-20-2], λ<sub>maximum</sub> 524 and 542 nm in DMF. In another example, 4,3-Cl(H<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>CO<sub>2</sub>Me was acylated with 4-MeC<sub>6</sub>H<sub>4</sub>COCl to give 2,5-Cl(MeO<sub>2</sub>C)C<sub>6</sub>H<sub>3</sub>NHCOC<sub>6</sub>H<sub>4</sub>Me-4, followed by hydrolysis, oxidation with KMnO<sub>4</sub>, and treatment with SOCl<sub>2</sub> to give 2,5-Cl(ClCO)C<sub>6</sub>H<sub>3</sub>NHCOC<sub>6</sub>H<sub>4</sub>COCl-4 which was condensed with 5,4,2-Me(H<sub>2</sub>N)(HO<sub>3</sub>S)C<sub>6</sub>H<sub>2</sub>N:NZ (R = 2,6-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub> in Z) to give disazo dye (III R = 2,6-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>) [38359-32-9], λ<sub>maximum</sub> 526 and 545 in DMF-H<sub>2</sub>O.


IT 41522-66-1 41522-67-2 41522-68-3  
41675-97-2

RL: USES (Uses)


(photog. sensitization maximum of)

RN 41522-66-1 CAPLUS


CN 2-Naphthalenesulfonic acid, 5,5'-[(3,6-dimethyl-2,5-pyrazinediyl)bis[carbonylimino(4-methoxy-6-sulfo-3,1-phenylene)azo]]bis[6-(2,6-dimethylphenyl)amino]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 41522-67-2 CAPLUS  
 CN 2-Naphthalenesulfonic acid, 5,5'-[(3,6-dimethyl-2,5-pyrazinediyl)bis[carbonylimino(4-methyl-6-sulfo-3,1-phenylene)azo]]bis[6-[(2,6-dimethylphenyl)amino]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 41522-68-3 CAPLUS  
 CN 2-Naphthalenesulfonic acid, 5,5'-[2,5-pyrazinediylbis[carbonylimino(4-methoxy-6-sulfo-3,1-phenylene)azo]]bis[6-[(2,6-dimethylphenyl)amino]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 41675-97-2 CAPLUS  
 CN 2-Naphthalenesulfonic acid, 5,5'-[(3,6-dimethyl-2,5-pyrazinediyl)bis[carbonylimino[2-sulfo-5-(trifluoromethyl)-4,1-phenylene]azo]]bis[6-(2,6-dimethylphenyl)-4-hydroxy- (9CI) (CA INDEX NAME)



L17 ANSWER 167 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1972:434570 CAPLUS

DOCUMENT NUMBER: 77:34570

ORIGINAL REFERENCE NO.: 77:5763a,5766a

TITLE: Pyrazinamide derivatives as diuretics and natriuretics

INVENTOR(S): Cragoe, Edward J., Jr.; Shepard, Kenneth L.

PATENT ASSIGNEE(S): Merck and Co., Inc.

SOURCE: Fr. Demande, 54 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2034542		19710108		
PRIORITY APPLN. INFO.:			US	19690212 <--

GI For diagram(s), see printed CA Issue.

AB Refluxing a mixture of I (R1 = Me, R2 = R3 = H, R4 = Cl), 5% aqueous NaOH, and iso-PrOH for 1 hr gave the carboxylic acid I (R1 = R2 = R3 = H, R4 = Cl) (II). A mixture of CH.tplbond.CCH2NH2, Me 3-amino-5,6-dichloropyrazinoate, and Me2SO when stirred for 1 hr gave I (R1 = Me, R2 = H, R3 = CH.tplbond.CCH2, R4 = Cl) which on hydrolysis gave the corresponding carboxylic acid, R1 = H. Using similar methods, 21 I were prepared in which R1 = H, R2 = H, Me, allyl, cyclopentyl, Me2NCH2CH2, 2-furylmethyl, MeO, NH2, etc., R3 = H or Me, R4 = Cl, Br, or iodo. To a solution of II, Et3N, and Me2NCHO was added N-tert-butyl-5-methylisoxazolium perchlorate (III) and the mixture stirred 2 hr to give IV (R2 = R3 = H, R4 = Cl, R5 = Me, R6 = Me3C) (V). Nineteen IV were similarly prepared in which R2 = H, allyl, propargyl, cyclopentyl, hydroxyalkyl, benzyl, furylmethyl, phenyl, substituted phenyl, MeO, NH2, Me, or Et; R3 = H or Me; R4 = Cl, Br, or iodo; R5 = Me or Ph; R6 = Et, CMe3, or Me. Refluxing a mixture of 1-aminopyrrolidine and V for 2 hr gave VI (R2 = R3 = H, R4 = Cl, R1 = pyrrolidino) as a high m.p. solid. Twenty-two VI were similarly prepared in which R2, R3, and R4 were as in V and R1 was a group such as MePrN(CH2)2, MeOCH2CH2, benzyl, Me2NCH2CH2, pyrrolidinoethyl, and 1-methyl-4-piperazinoethyl. VI (R2 = R3 = H, R4 = Cl, R1 = 2-pyridylamino) was prepared by refluxing a mixture of 2-hydrazinopyridine (VII) and MeCN. Reacting III, 3,5-diamino-6-chloropyrazinoic acid (VIII) with Et3N in Me2NCHO, then addition of 2-hydrazinopyrimidine in DMF and further heating gave VI (R2 = R3 = H, R4 = Cl, R1 = 2-pyrimidinylamino).

In THF, under similar conditions were prepared a further 14 amides and hydrazines VI including VI (R<sub>2</sub> = R<sub>3</sub> = H, R<sub>4</sub> = Cl, R<sub>1</sub> = 4H-1,2,4-triazolyl). Stirring a mixture of benzamidine and VII in H<sub>2</sub>O for 2 hr gave IX. Five analogs were prepared using other amidines. In a similar manner using guanidine in place of benzamidine was prepared X (R = H) (XI) giving a crystalline hydrochloride. XI could also be prepared directly from

VIII


without isolation of intermediates. By similar methods were prepared X (R = OH, CH<sub>2</sub>Ph) and 39 analogs of X in which the NH<sub>2</sub> adjacent to the Cl could also be substituted. With aminoguanidine and 2-hydrazino-2-imidazoline were prepared X (R = NH<sub>2</sub> and 2-aminoimidazoline). A mixture of CNNH<sub>2</sub> and Na in iso-PrOH was refluxed for 0.5 hr and then heated with N-tert-butyl-3-(3,5-diamino-6-chloropyrazinylcarbonyloxy)crotonamide to give N-cyano-3,5-diamino-6-chloropyrazinecarboxamide. Refluxing N-tert-butyl-3-methyl-3-(3,5-diamino-6-chloropyrazinylcarbonyloxy)acrylamide (XII) and benzyloxydiguanide in THF gave XIII (R = H, R<sub>1</sub> = CH<sub>2</sub>Ph). Twelve XI in which R was H and R<sub>1</sub> 1-6C alkyl, or R was a substituent such as cyclopentyl, PhCH<sub>2</sub>, and furylmethyl, and R<sub>1</sub> was substituted benzyl were prepared. Refluxing a mixture of 2-amino-2-thiazoline, XII, and THF gave N-(2-thiazolin-2-yl)-3,5-diamino-6-chloropyrazinecarboxamide (XIV, R = R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = H). Three analogs were prepared in which R was cyclopentyl, benzyl and HO(CH<sub>2</sub>)<sub>2</sub>, the other substituents being H, Me, or C<sub>6</sub>H<sub>13</sub>. XIV where RNH was pyrrolidino was also prepared. The 4- and 2-pyridyl groups and 2-pyrimidinyl could be substituted for the thiazoline. Reaction of V with sulfamide and Et<sub>3</sub>N in MeCN at room-temperature gave XV (R = R<sub>1</sub> = R<sub>2</sub> = H, X = Cl). Eighteen XV were similarly prepared. Properties are also given for a further 19 amides XVI. containing a wide variety of substituents. The products are useful in treatment of hypertension and related conditions by causing diuresis without elimination of potassium. Daily doses are 5 mg-1 g.

IT 32209-55-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 32209-55-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-phenyl- (CA INDEX NAME)



L17 ANSWER 168 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:420438 CAPLUS

DOCUMENT NUMBER: 75:20438

ORIGINAL REFERENCE NO.: 75:3278h,3279a

TITLE: N-substituted 3,5-diamino-6-halopyrazinamides

INVENTOR(S): Shepard, Kenneth L.; Cragoe, Edward J., Jr.

PATENT ASSIGNEE(S): Merck and Co., Inc.

SOURCE: U.S., 10 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------


-----	-----	-----	-----	-----
US 3573306	A	19710330	US 1969-804663	19690305
NL 7001141	A	19700908	NL 1970-1141	19700127 <--
BE 746816	A	19700904	BE 1970-746816	19700304 <--
PRIORITY APPLN. INFO.:			US 1969-804663	A 19690305 <--

AB Addition of diphenylcarbonyl chloride to 3,5-diamino-6-chloropyrazinoic acid and Et3N in HCONMe2 gave 3,5-diamino-6-chloropyrazinecarboxylic diphenylcarbamic anhydride (I). Refluxing Na in iso-PrOH with guanidine-HCl and addition of I gave 1-(3,5-diamino-6-chloropyrazinoyl)guanidine. Similarly prepared were 1,1,3,3-tetramethyl-2-(3,5-diamino-6-chloropyrazinoyl)guanidine, 1-(3,5-diamino-6-chloropyrazinoyl)-3-cyanoguanidine, N-methyl-N-(cyanomethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(2,2-diethoxyethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(2-morpholinoethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(4-pyridylmethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(2-pyridyl)-3,5-diamino-6-chloropyrazinecarboxamide, 3,5-diamino-6-chloropyrazinecarboxylic acid 1,2-dimethylhydrazide, 3,5-diamino-6-chloropyrazinecarboxylic acid 1-methyl-2-benzylidenehydrazide, and N-(3,5-diamino-6-chloropyrazinoyl)morpholine. These compds. had diuretic activity at 10-100 mg.

IT 32209-55-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 32209-55-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-phenyl- (CA INDEX NAME)



L17 ANSWER 169 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1969:78013 CAPLUS

DOCUMENT NUMBER: 70:78013

ORIGINAL REFERENCE NO.: 70:14573a,14576a

TITLE: 2-Methyl-3-phenyl-4(3H)-pteridinones

INVENTOR(S): Nakanishi, Michio; Tahara, Tetsuya; Maruyama, Yutaka

PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd.

SOURCE: U.S., 2 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 3426022	A	19690204	US 1967-641143	19670525 <--
SE 307365	B	19690107	SE 1967-7240	19670523 <--
FR 6890	M	19690421	FR 1967-6890	19670526 <--
GB 1181284	A	19700211	GB 1967-1181284	19670530 <--
PRIORITY APPLN. INFO.:			JP 1966-34445	A 19660528 <--

OTHER SOURCE(S): MARPAT 70:78013

GI For diagram(s), see printed CA Issue.

AB The title compds. (I), are prepared by treating

3-(acetamido)pyrazine-2-carboxylic acid (II) or its cyclized derivs.  
 2-methyl-4H-pyrazino[2,3-d]-1,3-oxazin-4-one (III) with an aniline in the  
 presence of a dehydrating agent. Thus, 2 g. PhNH<sub>2</sub> and 2 ml. PCl<sub>3</sub> were  
 added to 4 g. II in 100 ml. toluene, and refluxed 3 hrs. giving 3.2 g. I  
 (R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = H), m. 230-2° (EtOH). I (R<sub>1</sub> = R<sub>2</sub> = H, R<sub>3</sub> = MeO),  
 m. 209-11°, was prepared by stirring 4.5 g. III, 3.5 g. p-anisidine,  
 in 70 ml. tetrahydrofuran (THF) with 6 g. dicyclohexylcarbodiimide (IV) 6  
 hrs. at room temperature. Similarly prepared were the following I (R<sub>1</sub> R<sub>2</sub>, R<sub>3</sub>,

and


m.p. given): Me, H, H, 184-6°; H, H, Br, 224-5°; H, F<sub>3</sub>C, H,  
 201-4°; Me, H, Me, 183-4°; H, H, Cl, 190-1°; H, H, F,  
 233-4°. A solution of 5 g. III and 5 g. 3,4-dichloroaniline in 50 ml.  
 THF was stirred 30 min. at room temperature and filtered, giving 9.5 g.  
 3-(acetamido)pyrazine-2-carboxy-3',4'-dichloroanilide (V), m.  
 120-2°. A suspension of 6 g. V in 5; ml. THF was stirred 5.5 hrs.  
 at room temp with 2.5 g. IV, filtered, and the filtrate evaporated to give 5.2  
 g. I (R<sub>1</sub> = H, R<sub>2</sub> = R<sub>3</sub> = Cl), m. 293-4°.  
 3-(Acetamido)pyrazine-2-carboxy-3'-(trifluoromethyl)-anilide, m.  
 154-5° (decomposition) was similarly prepared and cyclized. These compds.  
 are useful as antiinflammatory agents.

IT 21635-46-1P 21635-48-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 21635-46-1 CAPLUS

CN 2-Pyrazinecarboxamide, 3-(acetylamino)-N-(3,4-dichlorophenyl)- (CA INDEX  
 NAME)



RN 21635-48-3 CAPLUS

CN 2-Pyrazinecarboxamide, 3-(acetylamino)-N-[3-(trifluoromethyl)phenyl]- (CA  
 INDEX NAME)



L17 ANSWER 170 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1966:52786 CAPLUS

DOCUMENT NUMBER: 64:52786

ORIGINAL REFERENCE NO.: 64:9905f-g

TITLE: Poly(oxymethylene) articles

PATENT ASSIGNEE(S): J. R. Geigy A. -G.

SOURCE: 13 pp.


DOCUMENT TYPE: Patent

LANGUAGE: Unavailable


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 652264		19641216	BE	19640825 <--
PRIORITY APPLN. INFO.:			CH	19640604 <--
AB	Poly(oxymethylenes) or their copolymers are treated with 0.005-0.05% 3-phenyl-7-triazolyl (or triazinylamino)coumarin, or a 2(or 3 or 4)-chloro-2'-cyano-4'-(1,2-naphthotriazolyl)stilbene, or a 4,4'-bis [4-(substituted amino)-6-anilino-s-triazin-2-ylamino] stilbene-2,2'-disulfonic acid, or 3,5-bis(alkylamino)-2-benzamido-6-alkanoylamino-1,4-diazine as optical brighteners. Thus, a mixture of 500 g. Delrin and 0.045 g. 3-phenyl-7-(3-methylpyrazol-1-yl)coumarin is injection-molded at 120-250° to give pure white plaques, as compared with yellowish plaques for the control.			
IT	6994-55-4, 2,6-Pyrazinedicarboxamide, N-methyl-3,5-bis(methylamino)-N'-phenyl- 6994-56-5, Benzoic acid, m-[3,5-bis(methylamino)-6-(methylcarbamoyl)pyrazinecarboxamido]-, methyl ester (as optical brightening agent for polyoxymethylenes)			
RN	6994-55-4 CAPLUS			
CN	2,6-Pyrazinedicarboxamide, N2-methyl-3,5-bis(methylamino)-N6-phenyl- (CA INDEX NAME)			



RN 6994-56-5 CAPLUS  
CN Benzoic acid, 3-[[[3,5-bis(methylamino)-6-[(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



L17 ANSWER 171 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1965:499120 CAPLUS  
DOCUMENT NUMBER: 63:99120  
ORIGINAL REFERENCE NO.: 63:18317f-h,18318a  
TITLE: Fluorescent brightening agents  
INVENTOR(S): Tanaka, Tosbiki  
PATENT ASSIGNEE(S): Japan Chemical Works Co., Ltd.  
SOURCE: 3 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: Unavailable  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 40006100	B4	19650326	JP	19620904 <--

PRIORITY APPLN. INFO.: JP 19620904 <--


GI For diagram(s), see printed CA Issue.

AB Compds. of the formula I, where R, R1, R2, and R3 are H, alkyl, or alkylene radicals and X and Z are O, S, or NH, and A, A1, and Y are H, are fluorescent brightening agents for polyesters and polyolefins. Thus, 24 parts 2-(paminophenyl)-6-methylbenzothiazole was diazotized and added at 0-5° to a stirred solution of 10 parts maleic anhydride in aqueous Me2CO in the presence of 40 parts NaOAc. The mixture was treated with 20 parts 10% HCl containing 0.5 part CuCl, stirred 30 min. at <10°, and kept 1 h. at 50° to give p-(6-methylbenzothiazol-2-yl)cinnamic acid (II), which was purified by dissoln. in 3% aqueous Na2CO3. A mixture of 30 parts II and 12 parts 2,5-HO(Me)C6H3NH2 (III) was heated under N at 160-70° for 6 h. and at 200-10° for 2 h. to give pale yellow I (R R2 Me, R1 R3 Y A A1 H, X S, Z O), m. 240° (PhCl). ZnCl2 or H3BO3 may be used as a condensing agent. Similarly, the following I (A Y Y1 H) were prepared (R, R1, R2, R3, X, Z, color, and m.p. given): Me, Me, H, H, S, S, pale yellow, 263-5°; Me, H, H, H, S, NH, pale yellow-green, 270-2°; H, H, H, H, S, O, pale yellow, >300°; H, H, H, H, S, S, pale yellow, >300°; H, H, H, H, S, NH, pale yellow, >300°; H, H, R2R3 = CH:CHCH:CH, S, O, pale yellow, >300°. Cf. following abstract

IT 4086-36-6P, Ammonium, benzyl[3-[p-[3,5-bis(methylamino)-6-(methylcarbamoyl)-2-pyrazinecarboxamido]benzamido]propyl]dimethyl, chloride 4129-06-0P, Ammonium, benzyl[3-[m-[3,5-bis(methylamino)-6-(methylcarbamoyl)-2-pyrazinecarboxamido]benzamido]propyl]dimethyl, chloride 6820-71-9P, Ammonium, triethyl(2-hydroxyethyl), ethyl sulfate, p-[3,5-bis(methylamino)-6-(methylcarbamoyl)pyrazinecarboxamido]benzoate RL: PREP (Preparation) (preparation of)

RN 4086-36-6 CAPLUS


CN Benzenemethanaminium, N-[3-[[4-[[[3,5-bis(methylamino)-6-(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]benzoyl]amino]propyl]-N,N-dimethyl-, chloride (1:1) (CA INDEX NAME)



● Cl<sup>-</sup>

RN 4129-06-0 CAPLUS


CN Benzenemethanaminium, N-[3-[[3-[[[3,5-bis(methylamino)-6-(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]benzoyl]amino]propyl]-N,N-dimethyl-, chloride (1:1) (CA INDEX NAME)



RN 6820-71-9 CAPLUS  
 CN Ethanaminium, 2-[[4-[[[3,5-bis(methylamino)-6-[(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]benzoyl]oxy]-N,N,N-triethyl-, ethyl sulfate (1:1)  
 (CA INDEX NAME)


CM 1

CRN 48028-76-8  
 CMF C2 H5 O4 S



CM 2

CRN 47766-06-3  
 CMF C24 H36 N7 O4



L17 ANSWER 172 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1965:499119 CAPLUS  
 DOCUMENT NUMBER: 63:99119  
 ORIGINAL REFERENCE NO.: 63:18317b-f  
 TITLE: Fluorescent brightening agents for polyacrylonitrile  
 PATENT ASSIGNEE(S): J. R. Geigy A.-G.  
 SOURCE: 18 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
NL 6412539		19650503	NL 1964-12539	19641028 <--
BE 654991			BE	

FR 1412795

FR

GB 1031548

GB

PRIORITY APPLN. INFO.:

CH

19631029 &lt;--

GI For diagram(s), see printed CA Issue.


AB Compds. of the general formula I are prepared and quaternized to give II. A suspension of 25.7 g. AC1 (III) in 500 mL. PhCl is added dropwise at -5° to a stirred solution of 25.7 g. m-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>NH(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub> in 300 mL. C<sub>5</sub>H<sub>5</sub>N and 200 mL. PhCl. The mixture is stirred 12-16 h. at 0°, briefly at 50°, and steam distilled, the residue neutralized with .apprx. 20 g. Na<sub>2</sub>CO<sub>3</sub>, and steam distilled again, to yield I (X = H, Y = 3-SO<sub>2</sub>NH, n = 3, R = Me) (IV), yellow crystals, m. 161-3° (1:1 PhCl-ligroine). Similarly are obtained the following I (X, Y, n, R, and m.p. given): H, 3-CONH, 3, Me, 214-16° (EtOAc) (V); H, 4-CONH, 3, Me, 192-5° (VI); H, 3-CONH, 2, Et, 158-60°; H, 4-CONH, 2, Et, 153-6°; H, 3-CONH, 3, Et, 176-7°; H, 4-CONH, 3, Et, 168-70°; 3-Cl, 4-CONH, 3, Me, 197-9°; 4-Me, 3-CONH, 3, Me, 203-5°; H, 4-CO<sub>2</sub>, 2, Et, 91-2° (VII); H, 3-CO<sub>2</sub>, 2, PhCH<sub>2</sub>, 110-.14° (VIII); H, 4-CO<sub>2</sub>, 2, PhCH<sub>2</sub>, 91-6° (IX); H, 4-CO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>O, 2, Et, 144-5° (X). Compds. VII-X, before crystallization from 1:1 Me<sub>2</sub>COC<sub>5</sub>H<sub>12</sub>, are dissolved in Me<sub>2</sub>CO and filtered through an Al<sub>2</sub>O<sub>3</sub> column. Me<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub> (XI) (20.4 g.) is added dropwise to a suspension of 41.2 g. ANHC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>Cl-4 in 500 mL. PhCl, the mixture is stirred 6 h. at 90°, steam distilled, and the residue in Me<sub>2</sub>CO filtered through Al<sub>2</sub>O<sub>3</sub> to yield I (X = H, Y = 4-SO<sub>2</sub>NH, n = 3, R = Me), m. 204-7°; similarly V is prepared from XI and ANHC<sub>6</sub>H<sub>4</sub>COC1. A solution of 47.8 g. IV in 300 mL. PhCl is stirred and reacted slowly at 90-5° with 13.8 g. PhCH<sub>2</sub>Cl (XII), stirred 7 h. at 90-5°, and cooled to yield II (X = H, Y = 3-SO<sub>2</sub>NH, n = 3, R = Me, R' = PhCH<sub>2</sub>, Z = Cl), white powder, m. 193-5° (iso-BuOH). Similarly, other II (X = H) are prepared (starting amine, quaternizing agent, and m.p. given): V, Me<sub>2</sub>SO<sub>4</sub> (XIII), 208-10°; V, XII, 234-6°; VI, XIII, 226-7°; VI, XII, 170-1°; VII, Et<sub>2</sub>SO<sub>4</sub>, 230-3°. Compds. I and II in 0.01-0.2% acid or neutral solns. with nonionic detergents, develop a strong bleaching effect on polyacrylonitrile fibers.

IT 3991-89-7P, 2,6-Pyrazinedicarboxamide, N-[m-[3-(diethylamino)propyl]carbamoyl]phenyl]-N'-methyl-3,5-bis(methylamino)- 3991-90-0P, 2,6-Pyrazinedicarboxamide, N-[p-[3-(diethylamino)propyl]carbamoyl]phenyl]-N'-methyl-3,5-bis(methylamino)- 3991-95-5P, 2,6-Pyrazinedicarboxamide, N-[p-[3-(dimethylamino)propyl]carbamoyl]phenyl]-N'-methyl-3,5-bis(methylamino)- 4037-74-5P, Benzoic acid, p-[3,5-bis(methylamino)-6-(methylcarbamoyl)pyrazinecarboxamido]-, 2-[2-(diethylamino)ethoxy]ethyl ester 4046-41-7P, 2,6-Pyrazinedicarboxamide, N-[m-[3-(dimethylamino)propyl]sulfamoyl]phenyl]-N'-methyl-3,5-bis(methylamino)- 4046-42-8P, 2,6-Pyrazinedicarboxamide, N-[p-[2-(diethylamino)ethyl]carbamoyl]phenyl]-N'-methyl-3,5-bis(methylamino)- 4086-34-4P, 2,6-Pyrazinedicarboxamide, N-[p-[3-(dimethylamino)propyl]sulfamoyl]phenyl]-N'-methyl-3,5-bis(methylamino)- 4086-35-5P, Ammonium, [3-[m-[3,5-bis(methylamino)-6-(methylcarbamoyl)pyrazinecarboxamido]benzamido]propyl]trimethyl, methyl sulfate 4086-36-6P, Ammonium, benzyl [3-[p-[3,5-bis(methylamino)-6-(methylcarbamoyl)-2-pyrazinecarboxamido]benzamido]propyl]dimethyl, chloride 4108-49-0P, 2,6-Pyrazinedicarboxamide, N-[m-[2-(diethylamino)ethyl]carbamoyl]phenyl]-N'-methyl-3,5-bis(methylamino)- 4129-05-9P, Benzoic acid, m-[3,5-bis(methylamino)-6-(methylcarbamoyl)pyrazinecarboxamido]-, 2-(dibenzylamino)ethyl ester 4129-06-0P, Ammonium, benzyl [3-[m-[3,5-bis(methylamino)-6-(methylcarbamoyl)-2-pyrazinecarboxamido]benzamido]propyl]dimethyl, chloride 4129-07-1P, Ammonium, [3-[p-[3,5-bis(methylamino)-6-

(methylcarbamoyl)pyrazinecarboxamido]benzamido]propyl]trimethyl, methyl sulfate 4168-67-6P, Benzoic acid, p-[3,5-bis(methylamino)-6-(methylcarbamoyl)pyrazinecarboxamido]-, 2-(dibenzylamino)ethyl ester 4180-46-5P, 2,6-Pyrazinedicarboxamide, N-[m-[3-(dimethylamino)propyl]carbamoyl]phenyl]-N'-methyl-3,5-bis(methylamino)- 4180-47-6P, Ammonium, benzyl[3-[N3-[(3,5-bis(methylamino)-6-(methylcarbamoyl)pyrazinyl)carbonyl]metanilamido]propyl]dimethyl, chloride 4189-28-0P, Benzoic acid, p-[3,5-bis(methylamino)-6-(methylcarbamoyl)pyrazinecarboxamido]-, 2-(diethylamino)ethyl ester 4193-51-5P, 2,6-Pyrazinedicarboxamide, N-[3-chloro-4-[3-(dimethylamino)propyl]carbamoyl]phenyl]-N'-methyl-3,5-bis(methylamino)- 4366-29-4P, 2,6-Pyrazinedicarboxamide, N-[3-[[3-(dimethylamino)propyl]carbamoyl]-p-tolyl]-N'-methyl-3,5-bis(methylamino)- 6820-71-9P, Benzoic acid, p-[3,5-bis(methylamino)-6-(methylcarbamoyl)pyrazinecarboxamido]-, ester with triethyl(2-hydroxyethyl)ammonium ethyl sulfate  
 RL: PREP (Preparation)  
 (preparation of)


RN 3991-89-7 CAPLUS

CN 2,6-Pyrazinedicarboxamide, N2-[3-[[[3-(diethylamino)propyl]amino]carbonyl]phenyl]-N6-methyl-3,5-bis(methylamino)-  
 (CA INDEX NAME)




RN 3991-90-0 CAPLUS

CN 2,6-Pyrazinedicarboxamide, N2-[4-[[[3-(diethylamino)propyl]amino]carbonyl]phenyl]-N6-methyl-3,5-bis(methylamino)-  
 (CA INDEX NAME)




RN 3991-95-5 CAPLUS

CN 2,6-Pyrazinedicarboxamide, N2-[4-[[[3-(dimethylamino)propyl]amino]carbonyl]phenyl]-N6-methyl-3,5-bis(methylamino)-  
 (CA INDEX NAME)




RN 4037-74-5 CAPLUS

CN Benzoic acid, 4-[[[3,5-bis(methylamino)-6-[(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]-, 2-[2-(diethylamino)ethoxy]ethyl ester (CA INDEX NAME)




RN 4046-41-7 CAPLUS

CN 2,6-Pyrazinedicarboxamide, N2-[3-[[[3-(dimethylamino)propyl]amino]sulfonyl]phenyl]-N6-methyl-3,5-bis(methylamino)- (CA INDEX NAME)




RN 4046-42-8 CAPLUS

CN 2,6-Pyrazinedicarboxamide, N2-[4-[[[2-(diethylamino)ethyl]amino]carbonyl]phenyl]-N6-methyl-3,5-bis(methylamino)- (CA INDEX NAME)



RN 4086-34-4 CAPLUS

CN 2,6-Pyrazinedicarboxamide, N2-[4-[[[3-(dimethylamino)propyl]amino]sulfonyl]phenyl]-N6-methyl-3,5-bis(methylamino)- (CA INDEX NAME)




RN 4086-35-5 CAPLUS

CN Ammonium, [3-[m-[3,5-bis(methylamino)-6-(methylcarbamoyl)pyrazinecarboxamido]benzamido]propyl]trimethyl-, methyl sulfate (8CI) (CA INDEX NAME)

CM 1

CRN 47731-82-8

CMF C22 H33 N8 O3



CM 2


CRN 21228-90-0

CMF C H3 O4 S

Me-O-SO<sub>3</sub><sup>-</sup>


RN 4086-36-6 CAPLUS

CN Benzenemethanaminium, N-[3-[[4-[[[3,5-bis(methylamino)-6-(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]benzoyl]amino]propyl]-N,N-dimethyl-, chloride (1:1) (CA INDEX NAME)




● Cl<sup>-</sup>


RN 4108-49-0 CAPLUS  
 CN 2,6-Pyrazinedicarboxamide, N2-[3-[[[2-(diethylamino)ethyl]amino]carbonyl]phenyl]-N6-methyl-3,5-bis(methylamino)-  
 (CA INDEX NAME)



RN 4129-05-9 CAPLUS  
 CN Benzoic acid, 3-[[[3,5-bis(methylamino)-6-[(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]-, 2-[bis(phenylmethyl)amino]ethyl ester (CA INDEX NAME)



RN 4129-06-0 CAPLUS  
 CN Benzenemethanaminium, N-[3-[[3-[[[3,5-bis(methylamino)-6-[(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]benzoyl]amino]propyl]-N,N-dimethyl-, chloride (1:1) (CA INDEX NAME)




● Cl<sup>-</sup>

RN 4129-07-1 CAPLUS  
 CN 1-Propanaminium, 3-[[4-[[[3,5-bis(methylamino)-6-[(methylamino)carbonyl]pyrazinyl]carbonyl]amino]benzoyl]amino]-N,N,N-trimethyl-, methyl sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 50567-59-4


CMF C22 H33 N8 O3



CM 2


CRN 21228-90-0

CMF C H3 O4 S




RN 4168-67-6 CAPLUS

CN Benzoic acid, 4-[[[3,5-bis(methylamino)-6-[(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]-, 2-[bis(phenylmethyl)amino]ethyl ester (CA INDEX NAME)



RN 4180-46-5 CAPLUS


CN 2,6-Pyrazinedicarboxamide, N2-[3-[[[3-(dimethylamino)propyl]amino]carbonyl]phenyl]-N6-methyl-3,5-bis(methylamino)- (CA INDEX NAME)




RN 4180-47-6 CAPLUS

CN Benzenemethanaminium, N-[3-[[[3-[[[3,5-bis(methylamino)-6-[(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]phenyl]sulfonyl]amino]propyl]-N,N-dimethyl-, chloride (1:1) (CA INDEX NAME)







RN 4189-28-0 CAPLUS  
 CN Benzoic acid, 4-[[[3,5-bis(methylamino)-6-[(methylamino)carbonyl]-2-pyrazinyl]carbonyl]amino]-, 2-(diethylamino)ethyl ester (CA INDEX NAME)



RN 4193-51-5 CAPLUS  
 CN 2,6-Pyrazinedicarboxamide, N2-[3-chloro-4-[[[3-(dimethylamino)propyl]amino]carbonyl]phenyl]-N6-methyl-3,5-bis(methylamino)- (CA INDEX NAME)



RN 4366-29-4 CAPLUS  
 CN 2,6-Pyrazinedicarboxamide, N2-[3-[[[3-(dimethylamino)propyl]amino]carbonyl]-4-methylphenyl]-N6-methyl-3,5-bis(methylamino)- (CA INDEX NAME)



RN 6820-71-9 CAPLUS  
 CN Ethanaminium, 2-[[4-[[[3,5-bis(methylamino)-6-[(methylamino)carbonyl]-2-

pyrazinyl]carbonyl]amino]benzoyl]oxy]-N,N,N-triethyl-, ethyl sulfate (1:1)  
(CA INDEX NAME)


CM 1

CRN 48028-76-8  
CMF C2 H5 O4 S

Et-O-SO<sub>3</sub><sup>-</sup>

CM 2

CRN 47766-06-3  
CMF C24 H36 N7 O4



L17 ANSWER 173 OF 173 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1963:53333 CAPLUS  
DOCUMENT NUMBER: 58:53333  
ORIGINAL REFERENCE NO.: 58:9094g-h,9095a-g  
TITLE: 3,5-Diaminopyrazine-2,6-dicarboxamides  
INVENTOR(S): Daglish, Anthony F.; Vonderwahl, R.; Tillotson, G. A.  
PATENT ASSIGNEE(S): J. R. Geigy A.-G.  
SOURCE: 8 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: Unavailable  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 1087609		19600825	DE 1958-G24632	19580528 <--
CH 358807			CH	
CH 358808			CH	
US 3043780		19620710	US 1958-737215	19580523
US 3175980		19650330	US 1961-179263	19611116
US 3201315		19650817	US 1962-168868	19620115
PRIORITY APPLN. INFO.:			CH	19570529 <--

GI For diagram(s), see printed CA Issue.

AB 1,3-Diethyl-4-amino-5-nitrosouracil (I) 212 and 1,3-diethyl-4-aminouracil 183 in AcOH 750 refluxed 3 h. with stirring, cooled, and filtered yielded 3,2;5,6-bis[(1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydro)-1,4-pyrimidino]pyrazine 320 parts (II), m. 235.5-36° (75% AcOH). II 10, EtOH 200 parts, and N NaOH 300 volume parts. refluxed 2.5 h., cooled, and filtered gave 3,5-bis(ethylamino)pyrazine-2,6-bis(N-ethylcarboxamide) 7.5 parts, m. 133-4° (EtOH). In the same manner as II were prepared the following IV (R1, R2, R3, R4 and m.p. given): Pr, Pr, Pr, Pr, 150-1°; Bu, Bu, Bu, Bu (V), 115-16°; Me, Me, Me, Me (VI), 390°. Saponification of IV gave the corresponding VII (R1, R2, R3, R4, and m.p. given): Pr, Pr,

Pr, Pr, 96-7°; Bu, Bu, Bu, Bu, 89-91°; Me, Me, Me, Me (VIIa), 232-3°. I 42 and 1,3-dipropyl-4-aminouracil 42 in AcOH 150 refluxed 3 h. with stirring, cooled, diluted with H<sub>2</sub>O, and filtered gave IV (R<sub>1</sub> = R<sub>2</sub> = Et, R<sub>3</sub> = R<sub>4</sub> = Pr) 70 parts, m. 150-1° (EtOH); a portion 10 saponified in the usual manner gave VII (R<sub>1</sub> = R<sub>2</sub> = Et, R<sub>3</sub> = R<sub>4</sub> = Pr) 7.2 parts, m. 91-2°. In the same manner were prepared IV (R<sub>1</sub> = R<sub>2</sub> = Me, R<sub>3</sub> = R<sub>4</sub> = Pr), m. 169-9.5°, and IV (R<sub>1</sub> = R<sub>2</sub> = Me, R<sub>3</sub> = R<sub>4</sub> = Et) (VIII), m. 253-4°, and saponified to VII (R<sub>1</sub> = R<sub>2</sub> = Me, R<sub>3</sub> = R<sub>4</sub> = Pr), m. 136-7° and VII (R<sub>1</sub> = R<sub>2</sub> = Me, R<sub>3</sub> = R<sub>4</sub> = Pr), m. 169-70°, resp. 1,3-Dimethyl-4-aminouracil (IX) 31 and 5-NO derivative 40 of IX in AcOH 200 refluxed 3 h. gave VI 51 parts, m. 390° (75% EtOH). VI 51 and a solution 152 of KOH 200 in EtOH 2400 refluxed 6 h. yielded VIIa.0.5H<sub>2</sub>O 117 parts, m. 214° (decomposition). VIIa.0.5H<sub>2</sub>O 20 and SOCl<sub>2</sub> 150 kept 45 min. at room temperature and evaporated, the residue added slowly with cooling

to

PhNH<sub>2</sub> 10 and dry C<sub>5</sub>H<sub>5</sub>N 400 parts, stirred overnight, steam distilled to remove the C<sub>5</sub>H<sub>5</sub>N, and filtered yielded X (R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = Me, R<sub>4</sub> = NPh), light yellow crystals, m. 198-8.5° (EtOH). Similarly were prepared the following X with R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = Me) (R<sub>4</sub>, m.p., and color of fluorescence given): NH<sub>2</sub>, 290-2°, violet blue; NHCH<sub>2</sub>CH<sub>2</sub>OH, 210-10.5°, violet-blue; NHPr, 218-19°, violet-blue; NH<sub>2</sub>Et, 197-8.5°, violet-blue; NHCH<sub>2</sub>Ph, 218.5-20°, blue-violet; NHCH<sub>2</sub>CH<sub>2</sub>Ph, 76-8°, blue-violet; m-NHC<sub>6</sub>H<sub>4</sub>OMe, 126.5-27°, blue; NHBu, 194-6°, violet-blue; p-NHC<sub>6</sub>H<sub>4</sub>OPh, 252-4°, blue; NHCH<sub>2</sub>CH:CH<sub>2</sub>, 194-5.5°, violet-blue; NHC<sub>8</sub>H<sub>17</sub>, 121-21.5°, violet-blue; PhNH, 237-8°, blue-violet; NMe<sub>2</sub>, 128-9°, violet; NHCH<sub>2</sub>Me, 188-90°, violet-blue; 2-pyridylamino, 223-4°, blue-violet; NHCMe<sub>3</sub>, 204-5°, violet-blue; p-NHC<sub>6</sub>H<sub>4</sub>Me, 211-12.5°, blue-violet; o-NHC<sub>6</sub>H<sub>4</sub>Me, 194-5°, blue-violet; m-NHC<sub>6</sub>H<sub>4</sub>Me, 172-3°, blue-violet; p-ClC<sub>6</sub>H<sub>4</sub>NH, 261-2.5°, blue-violet; m-ClC<sub>6</sub>H<sub>4</sub>NH, 185-7°, blue-violet; 3,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>NH, 216-17°, violet-blue; m-HO<sub>2</sub>CC<sub>6</sub>H<sub>4</sub>NH, 268-70°; m-HO<sub>3</sub>SC<sub>6</sub>H<sub>4</sub>NH, -, violet-blue; p-HO<sub>3</sub>SC<sub>6</sub>H<sub>4</sub>NH, -, violet-blue; m-(p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>NH)C<sub>6</sub>H<sub>4</sub>NH, 226-7° violet-blue; m-H<sub>2</sub>NO<sub>2</sub>SC<sub>6</sub>H<sub>4</sub>NH, 234-6°, violet-blue; morpholino, 155-6°, violet-blue; NHCHMe<sub>2</sub>, 175-7°, violet-blue; NH(CH<sub>2</sub>)<sub>3</sub>OH, 147-9°, violet blue; 3-pyridylamino, 209-11°, blue-violet; 3,4-dimethyl-1-phenylpyrazolylamino, 267-9°, blue-violet; 2-thiazolylamino, 262-3°, blue-violet; 1-phenyl-3-pyrazolylamino, 236-8°, blue-violet; 6-quinolylamino, 232-4°, blue-violet; NHCONHPh, 233-4°, blue; NHCONHCH<sub>2</sub>Ph, 190-1°, violet-blue; NHCONHMe, 215-17°, violet-blue. Similarly were prepared the following XII (R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and m.p. given): PhCH<sub>2</sub>, PhCH<sub>2</sub>, PhCH<sub>2</sub>, 161-2°; Et, Et, Et (XIII), 174-5°. XIII was converted in the usual manner to the anilide, m. 146.5-7.5°, and to the N-(2-pyridyl)amide, m. 108-9°. VIII 57, KOH 45, and EtOH 500 refluxed 6 h. and evaporated, and the residue acidified with dilute HCl gave


XII

(R<sub>1</sub> = R<sub>2</sub> = Et, R<sub>3</sub> = Me) (XIV) 43 parts, m 160-2°. XIV 20 treated 45 min. with SOCl<sub>2</sub> 100 and evaporated, and the residue stirred overnight with concentrated NH<sub>4</sub>OH 300 and EtOH 100 and filtered gave amide of XIV 16 parts, m. 223-4° (EtOH). Similarly were prepared the N-Et, N-Pr, and N-PhCH<sub>2</sub> amides, m. 162-4°, 84-6°, and 87-9°, resp., of XIV. VI 10 and PhCH<sub>2</sub>NH<sub>2</sub> 300 refluxed 24 h., cooled, diluted with H<sub>2</sub>O, and filtered yielded 3,2-[(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro)-1,4-pyrimidino]-5-methylamino-6 - (Ar. benzylcarboxamido)pyrazine 9 parts, m. 204-5° (EtOH). 1,3-Dibutyl-4-aminouracil (XV) 48 and 5-NO derivative 54 of XV in 2N H<sub>2</sub>SO<sub>4</sub> 300 refluxed 3 h. with stirring, cooled, and filtered, and the residue in EtOH 1200 refluxed 2 h. with N NaHCO<sub>3</sub> 1800 and filtered gave V 66 parts, needles, m. 115-16° (EtOH).

IT

93997-91-2P, 2,6-Pyrazinedicarboxamide, N-ethyl-3,5-bis(ethylamino)-N'-phenyl-

RL: PREP (Preparation)  
 (preparation of)  
 RN 93997-91-2 CAPLUS  
 CN 2,6-Pyrazinedicarboxamide, N2-ethyl-3,5-bis(ethylamino)-N6-phenyl- (CA  
 INDEX NAME)



=> fil stnguide  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
195.50	1069.26

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-27.88	-44.28

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 16:17:07 ON 25 FEB 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Feb 20, 2009 (20090220/UP).

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.84	1070.10

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-44.28

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:24:19 ON 25 FEB 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic  
substances identified in English-, French-, German-,  
and Japanese-language basic patents from 2004-present  
NEWS 3 NOV 26 MARPAT enhanced with FSORT command  
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 5 NOV 26 Two new SET commands increase convenience of STN  
searching  
NEWS 6 DEC 01 ChemPort single article sales feature unavailable  
NEWS 7 DEC 12 GBFULL now offers single source for full-text  
coverage of complete UK patent families  
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS  
NEWS 9 JAN 06 The retention policy for unread STNmail messages  
will change in 2009 for STN-Columbus and STN-Tokyo  
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent  
Classification Data  
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added  
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE  
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING  
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE  
NEWS 14 FEB 10 COMPENDEX reloaded and enhanced  
NEWS 15 FEB 11 WTEXTILES reloaded and enhanced  
NEWS 16 FEB 19 New patent-examiner citations in 300,000 CA/CAPLUS  
patent records provide insights into related prior  
art  
NEWS 17 FEB 19 Increase the precision of your patent queries -- use  
terms from the IPC Thesaurus, Version 2009.01  
NEWS 18 FEB 23 Several formats for image display and print options  
discontinued in USPATFULL and USPAT2  
NEWS 19 FEB 23 MEDLINE now offers more precise author group fields  
and 2009 MeSH terms  
NEWS 20 FEB 23 TOXCENTER updates mirror those of MEDLINE - more  
precise author group fields and 2009 MeSH terms  
NEWS 21 FEB 23 Three million new patent records blast AEROSPACE into  
STN patent clusters  
NEWS 22 FEB 25 USGENE enhanced with patent family and legal status  
display data from INPADOCDB  
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:05:15 ON 25 FEB 2009

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 18:05:21 ON 25 FEB 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 FEB 2009 HIGHEST RN 1111415-98-5  
DICTIONARY FILE UPDATES: 24 FEB 2009 HIGHEST RN 1111415-98-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10589407specieclaim33.str



chain nodes :

7 8 9 17 18

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

2-8 3-18 7-8 7-10 7-17 8-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

3-18 7-8 7-10 8-9

exact bonds :

2-8 7-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :

containing 1 : 10 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS 18:CLASS

L1           STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1           STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 18:05:38 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -       196 TO ITERATE

100.0% PROCESSED       196 ITERATIONS

13 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*

BATCH   \*\*COMPLETE\*\*

PROJECTED ITERATIONS:       3081 TO       4759

PROJECTED ANSWERS:         44 TO       476

L2           13 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 18:05:43 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -       4135 TO ITERATE

100.0% PROCESSED       4135 ITERATIONS

250 ANSWERS

SEARCH TIME: 00.00.01


L3           250 SEA SSS FUL L1

=> d scan

L3   250 ANSWERS   REGISTRY   COPYRIGHT 2009 ACS on STN

IN   2-Pyrazinecarboxamide, N-[5-acetyl-2-(3-amino-1-piperidinyl)phenyl]-3-amino-


MF   C18 H22 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):200

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(5,6,7,8,9,10-hexahydro-1,2,4-triazolo[4,3-a]azocin-3-yl)phenyl]-  
MF C19 H21 N7 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 3-Pyridinepropanoic acid,  $\beta$ -[[[3-[[[3-amino-6-[(aminoiminomethyl)amino]-5-cyano-2-pyrazinyl]carbonyl]amino]phenyl]sulfonyl]amino]-  
MF C21 H20 N10 O5 S  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-(2-hydroxy-4-methylphenyl)-  
MF C12 H12 N4 O2






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[(6-amino-3,4-dihydro-2,5,7,8-  
 tetramethyl-4-oxo-2H-1-benzopyran-2-yl)methoxy]phenyl]-  
 MF C25 H27 N5 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-5-  
 (cyclopropylcarbonyl)phenyl]-  
 MF C20 H24 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[[[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]amino]carbonyl]-5-methoxyphenyl]-  
 MF C27 H30 F3 N7 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(1,3-benzodioxol-5-ylcarbonyl)amino]phenyl]-  
 MF C19 H15 N5 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-(aminocarbonyl)-2-(1-piperidinyl)phenyl]-  
 MF C17 H20 N6 O2  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-(3-acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1)

MF C24 H26 N6 O4 S . Cl H




● HCl

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)phenyl]-6-(4-methoxyphenyl)-  
 MF C23 H26 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[[4-(4-fluorophenyl)sulfonyl]amino]phenyl]-  
 MF C17 H14 F N5 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl]-  
 MF C14 H13 N7 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidiny1)-4-fluorophenyl]-  
 MF C16 H19 F N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-N-phenyl-  
 MF C18 H16 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-(2-fluoro-5-methoxyphenyl)-N-[2-(1-piperazinyl)phenyl]-  
 MF C22 H23 F N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[(3-methyl-1-oxobutyl)amino]phenyl]-  
 MF C16 H19 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(1-methylethyl)phenyl]-  
 MF C14 H16 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-5-(trifluoromethyl)phenyl]-  
 MF C17 H19 F3 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[[2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]phenyl]-  
 MF C19 H17 N5 O5 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[(4-methoxyphenyl)amino]phenyl]-  
 MF C18 H17 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-fluorophenyl)-  
 MF C11 H9 F N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N,6-diphenyl-  
 MF C17 H14 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1-Piperazinecarboxylic acid, 4-[2-[[3-amino-6-bromo-2-pyrazinyl]carbonyl]amino]-4-benzoylphenyl]-, 1,1-dimethylethyl ester  
 MF C27 H29 Br N6 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(1-methylpropyl)phenyl]-  
 MF C15 H18 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(diethylamino)phenyl]-  
 MF C15 H19 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-cyano-2-(1-piperidinyl)phenyl]-,  
 2,2,2-trifluoroacetate (1:?)  
 MF C17 H18 N6 O . x C2 H F3 O2

CM 1






CM 2




L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-bromo-N-(3-methoxyphenyl)-  
 MF C12 H11 Br N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-[3-(aminocarbonyl)phenyl]-N-[2-(1-piperazinyl)phenyl]-  
 MF C22 H23 N7 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[3-chloro-4-[[3-(methylsulfonyl)benzoyl]amino]phenyl]-  
MF C19 H16 Cl N5 O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[4-methoxy-3-(3-pyridinylmethoxy)phenyl]-  
MF C18 H17 N5 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidiny)-5-chlorophenyl]-  
MF C16 H19 Cl N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[5-[[3-(1-cyano-1-methylethyl)benzoyl]amino]-2-methylphenyl]-  
MF C20 H22 N4 O

MF C23 H22 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-5-methoxyphenyl]-6-phenyl-  
 MF C23 H26 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[[4-ethoxyphenyl]amino]sulfonyl]-4-methoxyphenyl]-  
 MF C20 H21 N5 O5 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-butoxyphenyl)-  
 MF C15 H18 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-4-methylphenyl]-  
 MF C17 H22 N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]-  
 MF C13 H12 N8 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl]-4-fluorophenyl]-5-(2-methoxyethoxy)-  
 MF C19 H23 F N6 O3 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3,4-dimethoxyphenyl)-  
 MF C13 H14 N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1)  
 MF C23 H26 N6 O4 S . Cl H




● HCl

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)phenyl]-6-(2-fluorophenyl)-  
 MF C22 H23 F N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 4-Morpholineacetamide, N-[4-[[ (3-amino-2-pyrazinyl)carbonyl]amino]phenyl]-  
 MF C17 H20 N6 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[2-(ethylamino)-2-oxoethoxy]phenyl]-  
 MF C15 H17 N5 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)phenyl]-  
 MF C16 H20 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-  
 1-piperazinyl)sulfonyl]phenyl]-  
 MF C23 H25 N7 O4 S  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-(1-naphthalenyl)-N-[2-(1-  
 piperazinyl)phenyl]-  
 MF C25 H24 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(2-benzothiazolylmethyl)phenyl]-  
 MF C19 H15 N5 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C13 H12 Cl N5 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-5-methylphenyl]-  
 MF C17 H22 N6 O






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Thieno[2,3-b]quinoline-2-carboxamide,  
 N-[(1S)-2-amino-1-[3-[[ (3-amino-2-pyrazinyl)carbonyl]amino]phenyl]ethyl]-6-  
 (1,1-dimethylpropyl)-5,6,7,8-tetrahydro-, (6S)-  
 MF C30 H35 N7 O2 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-benzoyl-2-(1-piperazinyl)phenyl]-6-(4-  
 methoxyphenyl)-  
 MF C29 H28 N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-(2-hydroxyphenyl)-  
MF C11 H10 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-(4-chlorophenyl)-  
MF C11 H9 Cl N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidiny)-5-benzoylphenyl]-  
MF C23 H24 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[3-methoxy-5-[[[3-

(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-  
 MF C20 H16 F3 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[(2,2,2-  
 trifluoroethyl)amino]carbonyl]phenyl]-  
 MF C14 H12 F3 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3,5-dimethoxyphenyl)-  
 MF C13 H14 N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(2-bromophenyl)-6-[4-[(4-methyl-1-  
 piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1)  
 MF C22 H23 Br N6 O3 S . Cl H




● HCl

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)phenyl]-6-  
 methyl-  
 MF C17 H22 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(4-morpholinyl)phenyl]-  
 MF C15 H17 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C29 H30 N6 O5 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-5-(1H-pyrazol-3-yl)phenyl]-  
 MF C19 H22 N8 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-(3-acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-  
 MF C24 H26 N6 O4 S  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)phenyl]-6-(2-  
 fluoro-5-methoxyphenyl)-  
 MF C23 H25 F N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-methyl-4-(2-oxo-1-pyrrolidinyl)phenyl]-  
 MF C16 H17 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-methylphenyl)-  
 MF C12 H12 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-5-methoxyphenyl]-  
 MF C17 H22 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(4-ethyl-1-piperazinyl)-3-methylphenyl]-  
 MF C18 H24 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C21 H20 N10 O5 S . C2 H F3 O2


CM 1



CM 2




L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(1-methylethyl)phenyl]-  
 MF C14 H16 N4 O






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[[6-amino-3,4-dihydro-4-(methoxyimino)-  
2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl]methoxy]phenyl]-  
MF C26 H30 N6 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[5-(cyclopropylcarbonyl)-2-(1-  
piperazinyl)phenyl]-  
MF C19 H22 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[3-methyl-4-(1-pyrrolidinyl)phenyl]-  
MF C16 H19 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(4-fluorophenyl)methoxy]phenyl]-  
 MF C18 H15 F N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-(aminocarbonyl)-2-(1-piperidinyl)phenyl]-6-bromo-  
 MF C17 H19 Br N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]-, hydrochloride (1:1)  
 MF C23 H23 F3 N6 O3 S . Cl H




● HCl

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-phenyl-N-[2-(1-piperazinyl)phenyl]-  
 MF C21 H22 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylphenyl)-  
 MF C21 H24 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(2-aminophenyl)-6-(4-hydroxy-3-methoxyphenyl)-  
 MF C18 H17 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-5-methoxyphenyl]-6-bromo-  
 MF C17 H21 Br N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]phenyl]-  
 MF C20 H19 N5 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)phenyl]-6-phenyl-  
 MF C22 H24 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3,4-dimethylphenyl)-  
 MF C13 H14 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(2-ethoxyphenyl)-  
 MF C13 H14 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-5-(trifluoromethyl)phenyl]-  
 MF C17 H19 F3 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-imidazo[1,2-a]pyridin-2-ylphenyl)-  
 MF C18 H14 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(hexahydro-1H-azepin-1-yl)phenyl]-  
 MF C17 H21 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[(3-pyridinylmethyl)thio]phenyl]-  
 MF C17 H15 N5 O S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 6-Quinolinecarboxamide, 4-amino-N-[4-[[3-amino-2-pyrazinyl)carbonyl]amino]phenyl]-2-methyl-  
 MF C22 H19 N7 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Carbamic acid, N-[1-[2-[[3-amino-6-bromo-2-pyrazinyl)carbonyl]amino]-4-methoxyphenyl]-4-piperidinyl]-, 1,1-dimethylethyl ester  
 MF C22 H29 Br N6 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-phenoxyphenyl)-  
 MF C17 H14 N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(cyclopentyloxy)phenyl]-  
 MF C16 H18 N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)phenyl]-  
 MF C16 H20 N6 O






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-  
 MF C23 H26 N6 O4 S  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-N-[2-(1-piperazinyl)phenyl]-  
 MF C22 H24 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-[[ (3-chlorophenyl)amino]sulfonyl]-2-hydroxyphenyl]-  
 MF C17 H14 Cl N5 O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C11 H9 F N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-5-chlorophenyl]-  
 MF C16 H19 Cl N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-5-[(3S)-4-[1-[(2-amino-6-chloro-3-pyridinyl)carbonyl]-4-piperidinyl]-3-ethyl-1-piperazinyl]-6-chloro-N-(4-chlorophenyl)-  
 MF C28 H32 Cl3 N9 O2

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-benzoyl-2-(1-piperazinyl)phenyl]-6-(2-fluorophenyl)-  
 MF C28 H25 F N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-ethylphenyl)-  
 MF C13 H14 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-bromo-N-phenyl-  
 MF C11 H9 Br N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-5-cyanophenyl]-  
 MF C17 H19 N7 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-imidazo[2,1-b]thiazol-6-ylphenyl)-  
 MF C16 H12 N6 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl]-4-fluorophenyl]-5-methoxy-  
 MF C17 H19 F N6 O2 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(1H-benzimidazol-1-yl)phenyl]-  
 MF C18 H14 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1)  
 MF C23 H25 N7 O4 S . Cl H




● HCl

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)phenyl]-6-(4-methoxyphenyl)-  
 MF C23 H26 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(phenylmethoxy)phenyl]-  
MF C18 H16 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[2-(dimethylamino)-2-oxoethoxy]phenyl]-  
MF C15 H17 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)phenyl]-6-bromo-  
MF C16 H19 Br N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-  
 MF C23 H23 N7 O3 S  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-(2-methoxy-3-pyridinyl)-N-[2-(1-piperazinyl)phenyl]-  
 MF C21 H23 N7 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(2-methoxyphenoxy)phenyl]-  
 MF C18 H16 N4 O3






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-phenyl-  
 MF C11 H10 Cl N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[5-acetyl-2-(1-piperazinyl)phenyl]-3-amino-  
 MF C17 H20 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Thieno[2,3-b]quinoline-2-carboxamide,  
 N-[(1S)-2-amino-1-[3-[[ (3-amino-2-pyrazinyl)carbonyl]amino]phenyl]ethyl]-6-(  
 (1,1-dimethylethyl)-  
 MF C29 H29 N7 O2 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-[3-(4-morpholinylcarbonyl)phenyl]-N-[2-(1-piperazinyl)phenyl]-  
 MF C26 H29 N7 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-methoxy-4-(2-oxo-1-pyrrolidinyl)phenyl]-  
 MF C16 H17 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-(2-chlorophenyl)-  
MF C11 H9 Cl N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidiny)-5-(methylsulfonyl)phenyl]-  
MF C17 H22 N6 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[2-methyl-5-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-  
MF C20 H16 F3 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(4-ethoxyphenoxy)phenyl]-  
 MF C19 H18 N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[2-[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]-2-oxoethyl]phenyl]-  
 MF C20 H22 N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1)  
 MF C22 H23 Br N6 O3 S . Cl H




● HCl

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)phenyl]-6-(3-furanyl)-  
 MF C20 H22 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[2-(2-pyridinyl)ethenyl]phenyl]-  
 MF C18 H15 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(2-methyl-4-pyrimidinyl)phenyl]-  
 MF C16 H14 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-5-fluorophenyl]-  
 MF C16 H19 F N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]-  
 MF C23 H23 F3 N6 O3 S  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)phenyl]-6-(3,4,5-trimethoxyphenyl)-  
 MF C25 H30 N6 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(1,1-dimethylethyl)phenyl]-  
 MF C15 H18 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-methylphenyl)-  
 MF C12 H12 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-5-methoxyphenyl]-  
 MF C17 H22 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl)phenyl]-5-methoxy-  
 MF C17 H20 N6 O2 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C16 H21 N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(methylethylthio)phenyl]-  
 MF C12 H12 N4 O S






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(2-aminophenyl)-  
 MF C11 H11 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Carbamic acid, N-[1-[2-[[[(3-amino-6-bromo-2-pyrazinyl)carbonyl]amino]-4-benzoylphenyl]-4-piperidiny]-, 1,1-dimethylethyl ester  
 MF C28 H31 Br N6 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-chloro-4-methylphenyl)-  
 MF C12 H11 Cl N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(2-methyl-4-oxazolyl)phenyl]-  
 MF C15 H13 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-(aminocarbonyl)-2-(1-piperidinyl)phenyl]-, 2,2,2-trifluoroacetate (1:?)  
 MF C17 H20 N6 O2 . x C2 H F3 O2

CM 1




CM 2




L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[3-(acetlamino)phenyl]-3-amino-6-[4-[(4-methyl-1-

MF      piperazinyl)sulfonyl]phenyl]-  
 C24 H27 N7 O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3      250 ANSWERS      REGISTRY      COPYRIGHT 2009 ACS on STN  
 IN      2-Pyrazinecarboxamide, 3-amino-6-(2-fluorophenyl)-N-[2-(1-  
 piperazinyl)phenyl]-  
 MF      C21 H21 F N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3      250 ANSWERS      REGISTRY      COPYRIGHT 2009 ACS on STN  
 IN      2-Pyrazinecarboxamide, 3-amino-N-[2-methyl-4-(1-pyrrolidinyl)phenyl]-  
 MF      C16 H19 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-[(dimethylamino)methyl]phenyl]-  
 MF C14 H17 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-5-methoxyphenyl]-6-bromo-  
 MF C17 H21 Br N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[[[5-(1,1-dimethylethyl)-3-  
 isoxazolyl]amino]carbonyl]amino]phenyl]-  
 MF C19 H21 N7 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-5-  
 benzoylphenyl]-6-phenyl-  
 MF C29 H28 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-ethylphenyl)-  
 MF C13 H14 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-ethoxyphenyl)-  
 MF C13 H14 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-methyl-2-(1-piperazinyl)phenyl]-  
 MF C16 H20 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(trifluoromethoxy)phenyl]-  
 MF C12 H9 F3 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(dimethylamino)sulfonyl]phenyl]-  
 MF C13 H15 N5 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3,5-dimethylphenyl)-  
 MF C13 H14 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-nitrophenyl)-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-  
 MF C21 H20 N6 O5 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)phenyl]-6-phenyl-  
 MF C22 H24 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-methoxy-3-(4-methoxyphenoxy)phenyl]-  
 MF C19 H18 N4 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[(2-methyl-1-oxopropyl)amino]phenyl]-  
 MF C15 H17 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-[(3S)-3-amino-1-piperidinyl]phenyl]-  
 MF C16 H20 N6 O


Absolute stereochemistry.






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-  
 MF C23 H26 N6 O4 S  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-(2-phenoxyphenyl)-N-[2-(1-piperazinyl)phenyl]-  
 MF C27 H26 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[3-(acetamido)-4-fluorophenyl]-3-amino-  
 MF C13 H12 F N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C15 H17 N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-methyl-2-(1-piperazinyl)phenyl]-  
 MF C16 H20 N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Thieno[2,3-b]quinoline-2-carboxamide,  
 N-[(1S)-2-amino-1-[3-[[ (3-amino-2-pyrazinyl)carbonyl]amino]phenyl]ethyl]-6-  
 (1,1-dimethylethyl)-5,6,7,8-tetrahydro-, (6R)-  
 MF C29 H33 N7 O2 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-5-  
 benzoylphenyl]-6-(2-fluorophenyl)-  
 MF C29 H27 F N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(4-methylphenoxy)phenyl]-  
 MF C18 H16 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-bromo-N-(2-methylphenyl)-  
 MF C12 H11 Br N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-5-benzoylphenyl]-  
 MF C23 H24 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(1-cyclopropyl-1H-tetrazol-5-yl)phenyl]-  
 MF C15 H14 N8 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(2-amino-2-oxoethoxy)phenyl]-  
 MF C13 H13 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(methylthio)phenyl]-  
 MF C12 H12 N4 O S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1)  
 MF C23 H25 N7 O4 S . Cl H




● HCl

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidiny)phenyl]-6-methyl-  
 MF C17 H22 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-(4-pentylphenyl)-  
MF C16 H20 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[(tetrahydro-2-furanyl)carbonyl]amino]phenyl]-  
MF C16 H17 N5 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidiny)phenyl]-6-bromo-  
MF C16 H19 Br N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-(2-bromophenyl)-6-[4-(4-methyl-1-

piperazinyl)sulfonyl]phenyl]-  
 MF C22 H23 Br N6 O3 S  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-(2-methoxy-5-pyrimidinyl)-N-[2-(1-  
 piperazinyl)phenyl]-  
 MF C20 H22 N8 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-propylphenyl)-  
 MF C14 H16 N4 O






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-phenyl-  
 MF C11 H10 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[5-acetyl-2-(4-amino-1-piperidiny)phenyl]-3-  
 amino-  
 MF C18 H22 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-methoxy-3-(phenylmethyl)phenyl]-  
 MF C19 H18 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C32 H38 N10 O9 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(2-amino-2-oxoethoxy)phenyl]-  
 MF C13 H13 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-  
 MF C24 H27 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(3-amino-1-piperidinyl)-5-(cyclopropylcarbonyl)phenyl]-  
 MF C20 H24 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-[[[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]amino]carbonyl]-2-methylphenyl]-  
 MF C27 H30 F3 N7 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-  
 MF C12 H12 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(tetrahydro-2-furanyl)methoxy]phenyl]-  
 MF C16 H18 N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1)  
 MF C23 H26 N6 O4 S . Cl H




● HCl

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-[3-(aminocarbonyl)phenyl]-N-[2-(4-amino-1-piperidinyl)phenyl]-  
 MF C23 H25 N7 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(cyclopropylamino)carbonyl]phenyl]-  
 MF C15 H15 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(1H-imidazol-1-ylmethyl)phenyl]-  
 MF C15 H14 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-6-  
 fluorophenyl]-  
 MF C16 H19 F N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(2-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-  
 MF C23 H26 N6 O4 S  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(1-piperazinyl)phenyl]-6-(3,4,5-trimethoxyphenyl)-  
 MF C24 H28 N6 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(2-chlorophenoxy)phenyl]-  
 MF C17 H13 Cl N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(1-methylethyl)phenyl]-  
 MF C14 H16 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(1-piperazinyl)-5-(trifluoromethyl)phenyl]-  
 MF C16 H17 F3 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-amino-3,5-dichlorophenyl)-  
 MF C11 H9 Cl2 N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(1-piperidinyl)phenyl]-  
 MF C16 H19 N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3,4,5-trimethoxyphenyl)-  
 MF C14 H16 N4 O4







\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[2-[(1-naphthalenylmethyl)amino]-2-oxoethyl]phenyl]-  
 MF C24 H21 N5 O2

PAGE 1-A




PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Carbamic acid, N-[1-[2-[[[3-amino-6-bromo-2-pyrazinyl)carbonyl]amino]-4-benzoylphenyl]-3-piperidiny]-, 1,1-dimethylethyl ester  
 MF C28 H31 Br N6 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(phenylamino)phenyl]-  
 MF C17 H15 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-ethynylphenyl)-  
 MF C13 H10 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-cyano-2-(1-piperidiny)phenyl]-  
 MF C17 H18 N6 O  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-(aminosulfonyl)phenyl]-6-[4-[(4-methyl-  
 1-piperazinyl)sulfonyl]phenyl]-  
 MF C22 H25 N7 O5 S2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):100

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-(3-furanyl)-N-[2-(1-piperazinyl)phenyl]-  
 MF C19 H20 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-chloro-4-fluorophenyl)-  
 MF C11 H8 Cl F N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[[1-oxo-2-(1H-1,2,4-triazol-1-yl)propyl]amino]phenyl]-  
 MF C16 H16 N8 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[5-chloro-2-(1-piperazinyl)phenyl]-  
 MF C15 H17 Cl N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-chloro-N-phenyl-  
 MF C11 H9 Cl N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-5-  
 benzoylphenyl]-6-phenyl-  
 MF C29 H28 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-chloro-4-methoxyphenyl)-  
 MF C12 H11 Cl N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(4-ethoxyphenyl)-  
 MF C13 H14 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-4-methylphenyl]-  
 MF C17 H22 N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(2,2,2-trifluoroethoxy)phenyl]-  
 MF C13 H11 F3 N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(4S)-2-amino-5,6-dihydro-4-methyl-4H-  
 1,3-thiazin-4-yl]phenyl]-5-methoxy-  
 MF C17 H20 N6 O2 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-fluoro-4-methylphenyl)-  
 MF C12 H11 F N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(2-methoxyphenyl)-6-[4-[(4-methyl-1-  
 piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1)  
 MF C23 H26 N6 O4 S . Cl H




● HCl

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-[3-(aminocarbonyl)phenyl]-N-[2-(3-amino-1-  
 piperidinyl)phenyl]-  
 MF C23 H25 N7 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(butylamino)sulfonyl]phenyl]-  
 MF C15 H19 N5 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[[ (3,4-  
 dimethylphenyl)sulfonyl]amino]phenyl]-  
 MF C19 H19 N5 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(1-piperazinyl)phenyl]-  
 MF C15 H18 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-  
 1-piperazinyl)sulfonyl]phenyl]-  
 MF C23 H25 N7 O4 S  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-6-(3-methylphenyl)-N-[2-(1-piperazinyl)phenyl]-  
 MF C22 H24 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[3-methyl-4-[[3-(methylsulfonyl)benzoyl]amino]phenyl]-  
 MF C20 H19 N5 O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C13 H14 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)-5-methylphenyl]-  
 MF C17 H22 N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Thieno[2,3-b]quinoline-2-carboxamide,  
 N-[(1S)-2-amino-1-[3-[[ (3-amino-2-pyrazinyl)carbonyl]amino]phenyl]ethyl]-6-(1,1-dimethylpropyl)-5,6,7,8-tetrahydro-, (6R)-  
 MF C30 H35 N7 O2 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[5-benzoyl-2-(1-piperazinyl)phenyl]-6-methyl-  
MF C23 H24 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(dimethylamino)sulfonyl]-4-methoxyphenyl]-  
MF C14 H17 N5 O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[4-(2-phenylethoxy)phenyl]-  
MF C19 H18 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[5-benzoyl-2-(1-piperazinyl)phenyl]-  
MF C22 H22 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-(2,3-difluorophenyl)-  
MF C11 H8 F2 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-(4-bromo-3-methylphenyl)-  
MF C12 H11 Br N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-(4-butylphenyl)-  
MF C15 H18 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1)  
 MF C23 H23 N7 O3 S . Cl H




● HCl

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)phenyl]-6-(2-fluorophenyl)-  
 MF C22 H23 F N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-[4-[(2,2-dimethyl-1-oxopropyl)aminol]phenyl]-  
MF C16 H19 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C22 H19 N7 O3




L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-6-bromo-N-[2-(1-piperazinyl)phenyl]-  
MF C15 H17 Br N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2-Pyrazinecarboxamide, 3-amino-N-(3-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-  
MF C22 H27 Br N7 O2

MF C22 H23 Br N6 O3 S  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(4-amino-1-piperidinyl)phenyl]-6-[3-(4-morpholinylcarbonyl)phenyl]-  
 MF C27 H31 N7 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[3-(acetylamino)-4-methoxyphenyl]-3-amino-  
 MF C14 H15 N5 O3





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 250 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Pyrazinecarboxamide, 3-amino-N-(2-methylphenyl)-  
 MF C12 H12 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> fil stnguide  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
187.32	187.54

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 18:07:57 ON 25 FEB 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Feb 20, 2009 (20090220/UP).

=> fil cap  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.56	188.10

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 18:12:37 ON 25 FEB 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Feb 2009 VOL 150 ISS 9  
FILE LAST UPDATED: 24 Feb 2009 (20090224/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 18:05:15 ON 25 FEB 2009)

FILE 'REGISTRY' ENTERED AT 18:05:21 ON 25 FEB 2009

L1 STRUCTURE UPLOADED  
L2 13 S L1 SSS SAM  
L3 250 S L1 SSS FULL

FILE 'STNGUIDE' ENTERED AT 18:07:57 ON 25 FEB 2009

FILE 'CAPLUS' ENTERED AT 18:12:37 ON 25 FEB 2009

=> s 13 and (pry<2005)  
39 L3



4600131 PRY<2005  
L4 17 L3 AND (PRY<2005)

=> d 1-17 ibib abs hitstr

L4 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2006:30413 CAPLUS  
DOCUMENT NUMBER: 144:129001  
TITLE: Preparation of azine-carboxamides as anti-cancer agents  
INVENTOR(S): Aquila, Brian; Ioannidis, Stephanos; Lyne, Paul; Pontz, Timothy  
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited  
SOURCE: PCT Int. Appl., 92 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2006003378	A1	20060112	WO 2005-GB2522	20050629 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,			


ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,  
 KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,  
 KZ, MD, RU, TJ, TM  
 AU 2005258996 A1 20060112 AU 2005-258996 20050629 <--  
 CA 2570169 A1 20060112 CA 2005-2570169 20050629 <--  
 EP 1765790 A1 20070328 EP 2005-755467 20050629 <--  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV  
 CN 101023063 A 20070822 CN 2005-80028484 20050629 <--  
 JP 2008505166 T 20080221 JP 2007-519860 20050629 <--  
 BR 2005012796 A 20080408 BR 2005-12796 20050629 <--  
 US 20070259849 A1 20071108 US 2006-570065 20061205 <--  
 MX 2006014745 A 20070321 MX 2006-14745 20061215 <--  
 NO 2007000566 A 20070130 NO 2007-566 20070130 <--  
 IN 2007DN00805 A 20070803 IN 2007-DN805 20070131 <--  
 KR 2007029837 A 20070314 KR 2007-702599 20070201 <--  
 PRIORITY APPLN. INFO.: US 2004-584129P P 20040701 <--  
 WO 2005-GB2522 W 20050629  
 OTHER SOURCE(S): CASREACT 144:129001; MARPAT 144:129001  
 GI



AB The title compds. I [ring A = (un)substituted carbocyclyl, heterocyclyl;  
 R1 = halo, NO<sub>2</sub>, CN, etc.; R2 = H, halo, NO<sub>2</sub>, etc.; X1 = N and X2-X5 =  
 CR<sub>12</sub>; or two of X1-X5 = N and the other X1-X5 = CR<sub>12</sub>; n = 0-4; R<sub>12</sub> = H,  
 halo, NO<sub>2</sub>, etc.] which possess B-Raf inhibitory activity and are  
 accordingly useful for their anti cancer activity and thus in methods of  
 treatment of the human or animal body, were prepared Thus, reacting  
 N-(3-amino-4-methylphenyl)-3-(1-cyano-1-methylethyl)benzamide with  
 6-methyl-2-(piperidin-1-yl)pyrimidine-4-carboxylic acid (prepns. given) in  
 the presence of HATU and DIEA in DMF afforded II which showed IC<sub>50</sub> of 5.7  
 μM when tested in B-Raf in vitro ELISA assay. The invention also  
 relates to processes for the manufacture of said compds. I, to pharmaceutical  
 compns. containing them and to their use in the manufacture of medicaments of  
 use

in the production of an anti-cancer effect in a warm blooded animal such as man.

IT 873449-35-5P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of azine-carboxamides as B-Raf inhibitors for treating cancer)  
RN 873449-35-5 CAPLUS  
CN 2-Pyrazinecarboxamide, 3-amino-N-[5-[[3-(1-cyano-1-methylethyl)benzoyl]amino]-2-methylphenyl]- (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:962046 CAPLUS  
DOCUMENT NUMBER: 143:266952  
TITLE: Preparation of bipyridyl amides as modulators of metabotropic glutamate receptor-5  
INVENTOR(S): Bonnefous, Celine; Kamenecka, Theodore M.; Vernier, Jean-Michel  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 79 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079802	A1	20050901	WO 2005-US3952	20050209 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005215379	A1	20050901	AU 2005-215379	20050209 <--
CA 2555402	A1	20050901	CA 2005-2555402	20050209 <--
EP 1715867	A1	20061102	EP 2005-713111	20050209 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1933838	A	20070321	CN 2005-80004732	20050209 <--
JP 2007524682	T	20070830	JP 2006-553189	20050209 <--
IN 2006DN04346	A	20070713	IN 2006-DN4346	20060727 <--
US 20070149547	A1	20070628	US 2006-589407	20060811 <--
PRIORITY APPLN. INFO.:			US 2004-544627P	P 20040212 <--

OTHER SOURCE(S):  
GI

CASREACT 143:266952; MARPAT 143:266952



AB The title compds. I [X = N, C; Y = N, C, C(halo); R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, aryl, etc.; R3 = aryl, halo, alkyl, etc.; R2 and R3 may be joined together with the atoms to which they are attached to form a (un)saturated 4-7 membered ring containing 0-2 heteroatoms selected from

O, S and N; R4 = aryl, heteroaryl, halo, etc.] which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases, were prepared. Thus, amidation of pyridin-2-amine with 3-amino-5,6-diphenylpyrazine-2-carboxylic acid afforded the amide II. The exemplified compds. I have mGluR5 inhibitory activity as shown by inhibition at 10  $\mu$ M or less in the calcium flux assay or 100  $\mu$ M or less or less in the PI assay. The invention is also directed to pharmaceutical compns. comprising compds. I.


IT 863908-38-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bipyridyl amides as modulators of metabotropic glutamate receptor-5)

RN 863908-38-7 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-chloro-N-phenyl- (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:470258 CAPLUS

DOCUMENT NUMBER: 143:1330  
 TITLE: Amide derivatives as kinase modulators, and their therapeutic use  
 INVENTOR(S): Mehta, Shamal A.; Grotzfeld, Robert M.; Milanov, Zdravko V.; Andiliy, Lai G.; Patel, Hitesh K.; Lockhart, David J.  
 PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA  
 SOURCE: PCT Int. Appl., 208 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048953	A2	20050602	WO 2004-US38433	20041115 <--
WO 2005048953	A3	20060223		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20050148605	A1	20050707	US 2004-989745	20041115 <--
US 20050165031	A1	20050728	US 2004-989814	20041115 <--
US 20050165024	A1	20050728	US 2004-989824	20041115 <--
US 20050165074	A1	20050728	US 2004-990007	20041115 <--
US 20050171171	A1	20050804	US 2004-989766	20041115 <--
US 20050171172	A1	20050804	US 2004-989823	20041115 <--
US 20050192314	A1	20050901	US 2004-990195	20041115 <--
US 20050197371	A1	20050908	US 2004-990194	20041115 <--
US 20050261315	A1	20051124	US 2004-989623	20041115 <--
US 20050267182	A1	20051201	US 2004-989717	20041115 <--
PRIORITY APPLN. INFO.:			US 2003-520273P	P 20031113 <--
			US 2003-527094P	P 20031203 <--
			US 2003-531082P	P 20031218 <--
			US 2003-531243P	P 20031218 <--

OTHER SOURCE(S): MARPAT 143:1330

AB The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of amide compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects. Preparation of N-(3-tert-butylisoxazol-5-yl)-2-[4-(benzyloxy)phenyl]acetamide is described.


IT 1044667-69-7

RL: PRPH (Prophetic)

(Amide derivatives as kinase modulators, and their therapeutic use)

RN 1044667-69-7 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-[4-[2-[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]-2-oxoethyl]phenyl]- (CA INDEX NAME)



L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:470256 CAPLUS  
 DOCUMENT NUMBER: 143:20052  
 TITLE: Urea derivatives as kinase modulators  
 INVENTOR(S): Milanov, Zdravko V.; Patel, Hitesh K.; Grotzfeld, Robert M.; Mehta, Shamal A.; Andiliy, Lai G.; Lockhart, David J.  
 PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA  
 SOURCE: PCT Int. Appl., 350 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048948	A2	20050602	WO 2004-US38288	20041115 <--
WO 2005048948	A3	20050728		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004291147	A1	20050602	AU 2004-291147	20041115 <--
CA 2545711	A1	20050602	CA 2004-2545711	20041115 <--
US 20050148605	A1	20050707	US 2004-989745	20041115 <--
US 20050165031	A1	20050728	US 2004-989814	20041115 <--
US 20050165024	A1	20050728	US 2004-989824	20041115 <--
US 20050165074	A1	20050728	US 2004-990007	20041115 <--
US 20050171171	A1	20050804	US 2004-989766	20041115 <--
US 20050171172	A1	20050804	US 2004-989823	20041115 <--
US 20050192314	A1	20050901	US 2004-990195	20041115 <--
US 20050197371	A1	20050908	US 2004-990194	20041115 <--
US 20050261315	A1	20051124	US 2004-989623	20041115 <--
US 20050267182	A1	20051201	US 2004-989717	20041115 <--
EP 1684762	A2	20060802	EP 2004-811122	20041115 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007512255	T	20070517	JP 2006-539991	20041115 <--
PRIORITY APPLN. INFO.:				
			US 2003-520273P	P 20031113 <--
			US 2003-527094P	P 20031203 <--
			US 2003-531082P	P 20031218 <--
			US 2003-531243P	P 20031218 <--

OTHER SOURCE(S): MARPAT 143:20052

AB The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of urea compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects such as cellular proliferative disorders.


IT 852668-84-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(urea derivs. as kinase modulators for treatment of cellular proliferative disorders)

RN 852668-84-9 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:182640 CAPLUS

DOCUMENT NUMBER: 142:280220

TITLE: Preparation of quinazoline-2,4(1H,3H)-dione derivatives as gonadotropin-releasing hormone antagonists

INVENTOR(S): Hamamura, Kazumasa; Oda, Tsuneo; Kusaka, Masami; Kanzaki, Naoyuki

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan

SOURCE: PCT Int. Appl., 541 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019188	A1	20050303	WO 2004-JP12322	20040820 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2536313	A1	20050303	CA 2004-2536313	20040820 <--
JP 2005097276	A	20050414	JP 2004-241721	20040820 <--




EP 1657238 A1 20060517 EP 2004-772278 20040820 <--  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
US 20070010537 A1 20070111 US 2006-569391 20060222 <--  
PRIORITY APPLN. INFO.: JP 2003-298637 A 20030822 <--  
WO 2004-JP12322 W 20040820 <--  
OTHER SOURCE(S): MARPAT 142:280220  
GI



AB The title quinazoline-2,4(1H,3H)-dione derivs. I [wherein R1 = H or (un)substituted hydrocarbly; ring A = (un)substituted aromatic 6-membered ring; ring B = (un)substituted (hetero)cyclyl; W = O or S; X1 and X2 = independently H, (un)substituted hydrocarbly, or heterocyclyl; or X1 and X2 together form =O, =S, or (un)substituted =NH; Y = a bond or (un)substituted alkylene], or salts or prodrugs thereof are prepared as gonadotropin-releasing hormone antagonists. For example, the compound II was prepared in a multi-step synthesis. I inhibited 75.4-99.9% of human gonadotropin releasing hormone at the concentration of 10 nM. I are useful for the treatment of prostatic hyperplasia, hysterymyoma, endometriosis, uterus fibroma, etc. (no data). Formulations containing I as an active ingredient were also described.

IT 847173-89-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of quinazoline-2,4(1H,3H)-dione derivs. as gonadotropin-releasing hormone antagonists)

RN 847173-89-1 CAPLUS  
CN 2-Pyrazinecarboxamide, 3-amino-N-[3-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]phenyl]- (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:759828 CAPLUS  
DOCUMENT NUMBER: 141:260774  
TITLE: Preparation of pyrazinecarboxamide compounds as inhibitors of transforming growth factor (TGF) signaling pathway  
INVENTOR(S): Munchhof, Michael J.  
PATENT ASSIGNEE(S): Pfizer Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 26 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040180905	A1	20040916	US 2004-798198	20040310 <--
US 7199123	B2	20070403		
CA 2517720	A1	20040923	CA 2004-2517720	20040223 <--
WO 2004080982	A1	20040923	WO 2004-IB581	20040223 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1606267	A1	20051221	EP 2004-713617	20040223 <--
EP 1606267	B1	20080730		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004008251	A	20060301	BR 2004-8251	20040223 <--
JP 2006519833	T	20060831	JP 2006-506288	20040223 <--
AT 402929	T	20080815	AT 2004-713617	20040223 <--
ES 2308151	T3	20081201	ES 2004-713617	20040223 <--
PRIORITY APPLN. INFO.:			US 2003-453784P	P 20030311 <--
			WO 2004-IB581	W 20040223 <--
OTHER SOURCE(S):		MARPAT 141:260774		
GI				




I




II

AB Pyrazine compds. of formula I [R = (substituted) Ph, heterocycllyl, heteroaryl, aryl; R1 = H, R2 = alkyl, cycloalkyl, aryl, heteroaryl, etc.; NR2R2 = (substituted) heterocycllyl, heteroaryl] are prepared The compds. are potent inhibitors of transforming growth factor (TGF)- $\beta$  signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases. Thus, II was prepared, and had IC50 of 1.19  $\mu$ M.

IT 625469-79-6P 756521-87-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of pyrazinecarboxamides as inhibitors of TGF- $\beta$  signaling  
 pathway)  
 RN 625469-79-6 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N,6-diphenyl- (CA INDEX NAME)



RN 756521-87-6 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-N-phenyl- (CA INDEX NAME)




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:534194 CAPLUS  
 DOCUMENT NUMBER: 141:89114  
 TITLE: Preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3  
 INVENTOR(S): Berg, Stefan; Hellberg, Sven  
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Soederman, Peter  
 SOURCE: PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055006	A1	20040701	WO 2003-SE1956	20031215 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2003287136 A1 20040709 AU 2003-287136 20031215 <--  
 EP 1575939 A1 20050921 EP 2003-781205 20031215 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2006516124 T 20060622 JP 2004-560224 20031215 <--  
 US 20060173014 A1 20060803 US 2005-539546 20050616 <--  
 PRIORITY APPLN. INFO.: SE 2002-3752 A 20021217 <--  
 WO 2003-SE1956 W 20031215 <--  
 OTHER SOURCE(S): MARPAT 141:89114  
 GI



AB The title compds. [I; Z = N; X = N; Y = CONR5; P = Ph; Q = Ph or 5-6  
 membered aromatic heteroarom. ring containing one or more heteroatoms selected  
 from N, O, S; R = alkyl(SO2)NR1R2, alkylCONR1R2, OalkylNR1R2 (wherein R1,  
 R2 = H, alkyl, 5-6 membered heterocyclyl, etc.; NR1R2 = 5-6 membered  
 heterocyclyl); R3, R4 = halo, NO2, CF3, etc.; m, n = 0-1; R5 = H; as a  
 free base or a pharmaceutically acceptable salt], were prepared and  
 formulated. Thus, treating 4-bromo-N-[(1R)-2-methoxy-1-  
 methylethyl]benzenesulfonamide with n-butyllithium and triisopropyl borate  
 in THF followed by reacting the intermediate with  
 3-amino-6-bromo-N-(pyridin-3-yl)pyrazine-2-carboxamide in the presence of  
 Pd(dppf)Cl2, and Na2CO3 in THF (preps. of reactants given) afforded 35%  
 3-amino-6-[4-({[(1R)-2-methoxy-1-methylethyl]amino}sulfonyl)phenyl]-N-  
 (pyridin-3-yl)pyrazine-2-carboxamide hydrochloride. Typical Ki values for  
 the compds. I are in the range of about 0.001 to about 10,000 nM in  
 GSK-3 $\beta$  assay.


IT 714237-14-6P 714237-16-8P 714237-17-9P  
 714237-18-0P 714237-19-1P 714237-20-4P  
 714237-21-5P 714237-22-6P 714237-32-8P  
 714237-33-9P 714237-34-0P 714237-35-1P  
 714237-36-2P 714237-43-1P 714237-47-5P  
 714237-48-6P 714237-49-7P 714237-50-0P  
 714237-51-1P 714237-52-2P 714237-57-7P  
 714237-58-8P 714237-68-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of novel 3-aminopyrazine-2-carboxamides having selective  
 inhibiting effect at GSK3)


RN 714237-14-6 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(3-nitrophenyl)-6-[4-(1-  
 pyrrolidinylsulfonyl)phenyl]- (CA INDEX NAME)



RN 714237-16-8 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-(2-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 714237-17-9 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 714237-18-0 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-[2-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 714237-19-1 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-[3-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 714237-20-4 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-21-5 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-(2-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-22-6 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-(3-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-32-8 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 714237-33-9 CAPLUS


CN 2-Pyrazinecarboxamide, N-(3-acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)






● HCl

RN 714237-34-0 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 714237-35-1 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-[3-(acetylamino)phenyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-36-2 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-[3-(aminosulfonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-43-1 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-47-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-48-6 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-[2-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (4-methoxyphenyl) (CA INDEX NAME)




RN 714237-49-7 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-[3-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (benzyl) (CA INDEX NAME)




RN 714237-50-0 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-51-1 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(2-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-52-2 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(3-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-57-7 CAPLUS


CN 2-Pyrazinecarboxamide, N-(3-acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 714237-58-8 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 714237-68-0 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-(2-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)



IT 714237-42-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3)  
 RN 714237-42-0 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-6-bromo-N-(3-methoxyphenyl)- (CA INDEX NAME)

NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:967968 CAPLUS

DOCUMENT NUMBER: 140:16655

TITLE: Preparation of quinolinamides as inhibitors of the GPIIb - vWF interaction for treatment of athero-thrombotic diseases

INVENTOR(S): Klingler, Otmar; Just, Melitta; Sakurai, Kuniya; Fukuchi, Naoyuki

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany; Ajinomoto Co., Inc.

SOURCE: Eur. Pat. Appl., 25 pp. CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1369420	A1	20031210	EP 2002-12590	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040067980	A1	20040408	US 2003-454939	20030604 <--
US 7235558	B2	20070626		
CA 2488193	A1	20031218	CA 2003-2488193	20030606 <--
WO 2003104221	A1	20031218	WO 2003-EP5955	20030606 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003274686	A1	20031222	AU 2003-274686	20030606 <--
EP 1509516	A1	20050302	EP 2003-740199	20030606 <--
EP 1509516	B1	20070131		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011826	A	20050329	BR 2003-11826	20030606 <--
JP 2005528459	T	20050922	JP 2004-511291	20030606 <--
AT 353082	T	20070215	AT 2003-740199	20030606 <--
MX 2004011408	A	20050930	MX 2004-11408	20041117 <--


US 20070173489  
PRIORITY APPLN. INFO.:

A1 20070726


US 2007-731978  
EP 2002-12590  
US 2002-416953P  
US 2003-454939  
WO 2003-EP5955

20070402 <--  
A 20020606 <--  
P 20021008 <--  
A3 20030604 <--  
W 20030606 <--

OTHER SOURCE(S): MARPAT 140:16655  
GI



I



II


AB Title compds. I [wherein m, n, and p = independently 0-4; R<sub>1</sub> = alkyl; R<sub>2</sub> = NR<sub>4</sub>R<sub>5</sub>; R<sub>4</sub> and R<sub>5</sub> = independently H or alkyl; A = NHCO or CONH; B = covalent bond, cycloalkyl, or (un)substituted monocyclic or bicyclic aryl or heterocyclyl; D = NHCO, CONH, or NH; E = (un)substituted monocyclic or bicyclic aryl or heterocyclyl; and their stereoisomeric forms, mixts., and physiol. tolerable salts thereof] were prepared I are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable for use as pharmaceutical preps. in the therapy and prophylaxis of athero-thrombotic diseases (no data). For example, reaction of 3-tert-butoxycarbonylaminopropionic acid and 2-methylquinoline-4,6-diamine in the presence of N-ethylmorpholine and TOTU in DMF gave 3-amino-N-(4-amino-2-methylquinolin-6-yl)propionamide (76%). Coupling with 2-amino-4-chloro-6-methylpyrimidine using diisopropylethylamine in DMA provided II. All disclosed compds. exhibited IC<sub>50</sub> < 100 μM in a von Willebrand factor - GPIb binding assay using human vWF and Eu-chelate-labeled chimeric GPIb-Fc protein.

IT 629629-95-4P, 4-Amino-N-[4-[(2-amino-3-pyrazinyl)carbonyl]amino]phenyl]-2-methyl-6-quinolinecarboxamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antithrombotic; preparation of quinolinamides as inhibitors of GPIb - vWF interaction for treatment of athero-thrombotic diseases)

RN 629629-95-4 CAPLUS

CN 6-Quinolinecarboxamide, 4-amino-N-[4-[(3-amino-2-pyrazinyl)carbonyl]amino]phenyl]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:892800 CAPLUS

DOCUMENT NUMBER: 139:395950

TITLE: Preparation of substituted pyrazines as protein kinase modulators

INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 468 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093297	A2	20031113	WO 2003-US13869	20030502 <--
WO 2003093297	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2484209	A1	20031113	CA 2003-2484209	20030502 <--
AU 2003234464	A1	20031117	AU 2003-234464	20030502 <--
EP 1501514	A2	20050202	EP 2003-728690	20030502 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005530760	T	20051013	JP 2004-501436	20030502 <--
US 20060211709	A1	20060921	US 2005-513081	20050727 <--
PRIORITY APPLN. INFO.:			US 2002-377933P	P 20020503 <--
			WO 2003-US13869	W 20030502 <--

OTHER SOURCE(S): MARPAT 139:395950

GI






AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C(:NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heteroalicyclyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-30, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.

IT 625469-79-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of protein kinase modulators)

RN 625469-79-6 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N,6-diphenyl- (CA INDEX NAME)



L4 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:633705 CAPLUS

DOCUMENT NUMBER: 139:180070


TITLE: Preparation of  
 2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazoles as  
 inhibitors of GSK-3

INVENTOR(S): Harbeson, Scott L.; Arnost, Michael J.; Green, Jeremy;  
 Savic, Vladimir


PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 93 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066629	A2	20030814	WO 2003-US3655	20030206 <--
WO 2003066629	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2475633	A1	20030814	CA 2003-2475633	20030206 <--
AU 2003215087	A1	20030902	AU 2003-215087	20030206 <--
US 20040034037	A1	20040219	US 2003-360535	20030206 <--
EP 1472245	A2	20041103	EP 2003-710903	20030206 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005526028	T	20050902	JP 2003-566002	20030206 <--
MX 2004007697	A	20041110	MX 2004-7697	20040806 <--
NO 2004003726	A	20041108	NO 2004-3726	20040906 <--
US 20070270420	A1	20071122	US 2007-776756	20070712 <--
PRIORITY APPLN. INFO.:			US 2002-354843P	P 20020206 <--
			US 2003-360535	A1 20030206 <--
			WO 2003-US3655	W 20030206 <--
OTHER SOURCE(S):		MARPAT 139:180070		
GI				




I



II

AB The title compds. [I; ring A = (un)substituted 5-7 membered (un)saturated ring having 0-3 heteroatoms, and wherein ring A is optionally fused to 5-8 membered ring having 0-3 heteroatoms; ring B = (un)substituted 5-6 membered ring having 0-4 heteroatoms; W = N, CR4; X = N, CH (wherein at least one of W and X = N); R3 = TCN, LR; T = a bond, alkylidene; L = a bond, alkylidene wherein up to two methylene units of L are replaced by O, S, CO, etc.; R4 = LR, halo, TNO2, TCN; R = H, alkyl, aryl, etc.], useful as inhibitors of GSK-3 and Lck protein kinases (biol. data given) for treating and preventing various disorders, such as diabetes, Alzheimer's disease, and transplant rejection, were prepared. Thus, reacting 1,2-phenylenediamine with Me 4-aminofurazan-3-carboximide in the presence of AcOH in MeOH afforded 76% II. A pharmaceutical composition comprising the title compound I, was claimed.

IT 581081-84-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazoles as inhibitors  
 of GSK-3)  
 RN 581081-84-7 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-(2-aminophenyl)- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:728847 CAPLUS  
 DOCUMENT NUMBER: 137:257628  
 TITLE: Antitumor agents containing novel chroman derivatives  
 INVENTOR(S): Fujita, Takashi; Wada, Kunio; Oguchi, Minoru;  
 Kurakata, Shinichi  
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 101 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002275064	A	20020925	JP 2002-5560	20020115 <--
PRIORITY APPLN. INFO.:			JP 2001-6574	A 20010115 <--
OTHER SOURCE(S):	MARPAT	137:257628		


GI




I

AB The invention provides chroman derivs. I (R1 = H, C1-6 alkyl, etc.; R2 = H, C1-6 alkyl, etc.; R3, R4, R5, R6 = H, C1-6 alkyl, etc.; X = single bond, CO, C:NOR7, etc.; R7, R8 = H, C1-6 alkyl, C2-6 alkenyl, etc.; A = CO, SO2; U = CH2, etc.; Y = O, S; Q = H, nitro, OH, etc.; k = 1-6; m, n = 0-8; Ar1 = benzene ring, etc.; Ar2 = benzene ring, etc.) as antitumor agents. The antitumor effect of N-[2-[4-(6-acetoxy-4-oxo-2,5,7,8-tetramethylchroman-2-ylmethoxy)phenyl]ethyl]-nicotinamide in SK-N-MC and D283-Med cells was examined Also, a capsule containing N-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)phenyl]-nicotinamide 100 mg was prepared

IT 321920-19-8P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (chroman derivs. as antitumor agents)  
 RN 321920-19-8 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-[4-[(6-amino-3,4-dihydro-2,5,7,8-tetramethyl-4-oxo-2H-1-benzopyran-2-yl)methoxy]phenyl]- (CA INDEX NAME)



IT 321920-21-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (chroman derivs. as antitumor agents)  
 RN 321920-21-2 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-[4-[[6-amino-3,4-dihydro-4-(methoxyimino)-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl]methoxy]phenyl]- (CA INDEX NAME)



L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:63989 CAPLUS  
 DOCUMENT NUMBER: 134:131426  
 TITLE: Preparation and effect of coumarone analogues as antitumor agents  
 INVENTOR(S): Fujita, Takashi; Wada, Kunio; Oguchi, Minoru; Kurakata, Shinichi  
 PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan  
 SOURCE: PCT Int. Appl., 238 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005780	A1	20010125	WO 2000-JP4732	20000714 <--
W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, TR,				


US, ZA  
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE  
 JP 2001089468 A 20010403 JP 2000-213985 20000714 <--  
 PRIORITY APPLN. INFO.: JP 1999-203159 A 19990716 <--  
 OTHER SOURCE(S): MARPAT 134:131426  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title coumarone analogs [I; wherein R1 is hydrogen, C1-C6 alkyl; R2 is hydrogen, C1-C6 alkyl; R3, R5 are each independently hydrogen, C1-C6 alkyl; R4, R6 are each independently hydroxy, C1-6 alkyl, NH2, acetoxy, methoxymethoxy; X is a single bond, C=O, C=NOR7; R7 and R8 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl; A is C=O, SO2; U is CH2, or the like; Y is O or S; Q is hydrogen, nitro, hydroxyl; p is an integer of 1 to 6; m and n are each independently an integer of 0 to 8; and Ar1 and Ar2 are each benzene ring or pyridine ring] exhibiting excellent antitumor activities are prepared and formulation are discussed. Thus, title compound II was prepared and tested.


IT 321920-19-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation and effect of coumarone analogs as antitumor agents)

RN 321920-19-8 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-[4-[(6-amino-3,4-dihydro-2,5,7,8-tetramethyl-4-oxo-2H-1-benzopyran-2-yl)methoxy]phenyl]- (CA INDEX NAME)



IT 321920-21-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and effect of coumarone analogs as antitumor agents)

RN 321920-21-2 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-[4-[[6-amino-3,4-dihydro-4-(methoxyimino)-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl]methoxy]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:175783 CAPLUS

DOCUMENT NUMBER: 130:209718

TITLE: Novel atropisomers of  
2,3-disubstituted-(5,6)-heteroaryl  
fused-pyrimidin-4-ones

INVENTOR(S): Chenard, Bertrand Leo; Welch, Willard McKowan, Jr.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 900799	A1	19990310	EP 1998-306744	19980824 <--
EP 900799	B1	20050608		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6323208	B1	20011127	US 1998-259413	19980723 <--
AT 297396	T	20050615	AT 1998-306744	19980824 <--
ES 2242261	T3	20051101	ES 1998-306744	19980824 <--
JP 11193283	A	19990721	JP 1998-294735	19980831 <--
JP 3351748	B2	20021203		
CA 2246595	A1	19990305	CA 1998-2246595	19980903 <--
CA 2246595	C	20050315		
BR 9803385	A	20000208	BR 1998-3385	19980904 <--
			US 1997-57990P	P 19970905 <--

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 130:209718


GI




AB Title compds. I [R = CH:CHR4, CH2CH2R4; R1 = (un)substituted Ph, pyridyl;

R2R3 = atoms required to complete a 5- or 6-membered heterocyclic ring; R4 = (un)substituted Ph, 5- or 6-membered azaheterocyclic] were prepared for use as glutamate receptor antagonists in treatment of neurodegenerative, psychotropic, and drug and alc. induced central and peripheral nervous system disorders (no data). I can be separated into their atropisomers. Thus, Me 3-amino-2-thiophenecarboxylate was N-acetylated, hydrolyzed to the acid, cyclized, and subjected to aminolysis with o-toluidine. The resulting 2-methyl-3-(2-methylphenyl)-3H-thieno[3,2-d]pyrimidin-4-one was treated with 2-FC6H4CHO to give the thienopyrimidinone II. The atropisomers of II were separable by chromatog. on Chiralcel OD.

IT 36204-81-6P 199599-60-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (atropisomers of disubstituted heteroaryl fused pyrimidinones as antagonists for excitatory amine receptors)  
 RN 36204-81-6 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-(2-methylphenyl)- (CA INDEX NAME)



RN 199599-60-5 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-(2-chlorophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:268489 CAPLUS

DOCUMENT NUMBER: 128:321568

ORIGINAL REFERENCE NO.: 128:63741a,63744a

TITLE: Anthranilic acid derivatives as multi drug resistance modulators

INVENTOR(S): Ryder, Hamish; Ashworth, Philip Anthony; Roe, Michael John; Brumwell, Julie Elizabeth; Hunjan, Sukhjit; Folkes, Adrian John; Sanderson, Jason Terry; Williams, Susannah; Maximen, Levi Michael; et al.

PATENT ASSIGNEE(S): Xenova Ltd., UK; Ryder, Hamish; Ashworth, Philip Anthony; Roe, Michael John; Brumwell, Julie Elizabeth; Hunjan, Sukhjit; Folkes, Adrian John; Sanderson, Jason Terry; Williams, Susannah; Maximen, Levi Michael

SOURCE: PCT Int. Appl., 203 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817648	A1	19980430	WO 1997-GB2885	19971017 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2268403	A1	19980430	CA 1997-2268403	19971017 <--
AU 9746339	A	19980515	AU 1997-46339	19971017 <--
AU 741922	B2	20011213		
ZA 9709329	A	19990419	ZA 1997-9329	19971017 <--
EP 934276	A1	19990811	EP 1997-945030	19971017 <--
EP 934276	B1	20031217		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9711935	A	19990824	BR 1997-11935	19971017 <--
GB 2334521	A	19990825	GB 1999-8193	19971017 <--
GB 2334521	B	20001004		
CN 1241181	A	20000112	CN 1997-180708	19971017 <--
CN 100354265	C	20071212		
HU 2000001531	A2	20000828	HU 2000-1531	19971017 <--
HU 2000001531	A3	20000928		
JP 2001502683	T	20010227	JP 1998-519108	19971017 <--
RU 2195454	C2	20021227	RU 1999-109990	19971017 <--
AT 256663	T	20040115	AT 1997-945030	19971017 <--
PT 934276	T	20040531	PT 1997-945030	19971017 <--
ES 2210586	T3	20040701	ES 1997-945030	19971017 <--
SK 284649	B6	20050804	SK 1999-509	19971017 <--
PL 191150	B1	20060331	PL 1997-332725	19971017 <--
CZ 298209	B6	20070725	CZ 1999-1353	19971017 <--
TW 498074	B	20020811	TW 1997-86115402	19971018 <--
BG 103327	A	20001130	BG 1999-103327	19990413 <--
NO 9901836	A	19990617	NO 1999-1836	19990416 <--
NO 313591	B1	20021028		
KR 2000049278	A	20000725	KR 1999-703389	19990417 <--
US 6218393	B1	20010417	US 1999-284642	19990609 <--
HK 1019330	A1	20010112	HK 1999-103773	19990901 <--
PRIORITY APPLN. INFO.:			WO 1996-GB2552	A 19961018 <--
			GB 1997-17576	A 19970819 <--
			WO 1997-GB2885	W 19971017 <--
OTHER SOURCE(S):	MARPAT 128:321568			
GI				


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Anthranilic acid derivs. I [R, R1, R2 = H, alkyl, OH, alkoxy, halo, NO2, amino; or R1R2 = OCH2O or OCH2CH2O; R3 = H, alkyl; R4 = alkyl, or CH2 or CH2CH2 bridged to either Ph ring; R5 = H, OH, alkyl; X = bond, O, S, S(CH2)p, O(CH2)p; p = 1-6; R6 = H, alkyl, alkoxy; q = 0 or 1; Ar = (un)saturated carbo- or heterocyclic; R7, R8 = H, (un)substituted alkyl, alkoxy, OH, halo, Ph, NHOH, NO2, amino, SH, alkylthio; or R7R8 = CH:CHCH:CH or OCH2O; n = 0, 1; m = 0-6] and their pharmaceutically acceptable salts are disclosed. The compds. are inhibitors of P-glycoprotein, and may thus be used, inter alia, as modulators of



multidrug resistance in the treatment of multidrug-resistant cancers, for example, to potentiate the cytotoxicity of a cancer drug. For instance, amidation of 3-quinolinecarboxylic acid with the corresponding aminothiophene derivative via the acid chloride gave title compound II in 44% yield. In a test for potentiation of doxorubicin toxicity to AR 1.0 cells, II had a potentiation index of 142 at 30 nM.

IT 206874-58-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of anthranilic acid derivs. as multi-drug resistance modulators)  
 RN 206874-58-0 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:761834 CAPLUS

DOCUMENT NUMBER: 128:34776

ORIGINAL REFERENCE NO.: 128:6857a

TITLE: Preparation of thienopyrimidinones and analogs as AMPA receptor antagonists

INVENTOR(S): Chenard, Bertrand Leo; Elliott, Mark Leonard; Welch, Willard McKowan, Jr.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: Eur. Pat. Appl., 39 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 807633	A2	19971119	EP 1997-303000	19970501 <--
EP 807633	A3	19980513		
EP 807633	B1	20021106		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
AT 227293	T	20021115	AT 1997-303000	19970501 <--
ES 2184960	T3	20030416	ES 1997-303000	19970501 <--
CA 2205274	A1	19971115	CA 1997-2205274	19970513 <--
CA 2205274	C	20030211		
US 5962457	A	19991005	US 1997-855630	19970514 <--
JP 10045757	A	19980217	JP 1997-125953	19970515 <--
JP 3270360	B2	20020402		
PRIORITY APPLN. INFO.:			US 1996-17737P	P 19960515 <--
OTHER SOURCE(S):	MARPAT	128:34776		


GI




AB Title compds. [I; R = CH<sub>2</sub>CH<sub>2</sub>R<sub>2</sub> or CH:CHR<sub>2</sub>; R<sub>1</sub> = (un)substituted Ph or -heteroaryl; R<sub>2</sub> = (un)substituted Ph or -heteroaryl; R<sub>3</sub>R<sub>4</sub> = atoms to complete an (un)substituted heteroarom. ring] were prepared as AMPA receptor antagonists (no data). Thus, Me 3-aminothiophene-2-carboxylate was N-acetylated and the saponified product cyclized to give 2-methylthieno[3,2-d][1,3]oxazin-4-one which was cyclocondensed with o-toluidine to give I (R<sub>1</sub> = C<sub>6</sub>H<sub>4</sub>Me-2, R<sub>3</sub>R<sub>4</sub> = CH:CHS) (II; R = Me). The latter was condensed with 3-FC<sub>6</sub>H<sub>4</sub>CHO to give II (R = CH:CHC<sub>6</sub>H<sub>4</sub>F-2).

IT 36204-81-6P 199599-60-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of thienopyrimidinones and analogs as AMPA receptor antagonists)

RN 36204-81-6 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-(2-methylphenyl)- (CA INDEX NAME)



RN 199599-60-5 CAPLUS  
 CN 2-Pyrazinecarboxamide, 3-amino-N-(2-chlorophenyl)- (CA INDEX NAME)



L4 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1972:434570 CAPLUS  
 DOCUMENT NUMBER: 77:34570  
 ORIGINAL REFERENCE NO.: 77:5763a,5766a  
 TITLE: Pyrazinamide derivatives as diuretics and natriuretics  
 INVENTOR(S): Cragoe, Edward J., Jr.; Shepard, Kenneth L.  
 PATENT ASSIGNEE(S): Merck and Co., Inc.  
 SOURCE: Fr. Demande, 54 pp.  
 CODEN: FRXXBL

DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2034542		19710108		<--
PRIORITY APPLN. INFO.:			US	19690212 <--


GI For diagram(s), see printed CA Issue.

AB Refluxing a mixture of I (R1 = Me, R2 = R3 = H, R4 = Cl), 5% aqueous NaOH, and iso-PrOH for 1 hr gave the carboxylic acid I (R1 = R2 = R3 = H, R4 = Cl) (II). A mixture of CH.tplbond.CCH2NH2, Me 3-amino-5,6-dichloropyrazinoate, and Me2SO when stirred for 1 hr gave I (R1 = Me, R2 = H, R3 = CH.tplbond.CCH2, R4 = Cl) which on hydrolysis gave the corresponding carboxylic acid, R1 = H. Using similar methods, 21 I were prepared in which R1 = H, R2 = H, Me, allyl, cyclopentyl, Me2NCH2CH2, 2-furylmethyl, MeO, NH2, etc., R3 = H or Me, R4 = Cl, Br, or iodo. To a solution of II, Et3N, and Me2NCHO was added N-tert-butyl-5-methylisoxazolium perchlorate (III) and the mixture stirred 2 hr to give IV (R2 = R3 = H, R4 = Cl, R5 = Me, R6 = Me3C) (V). Nineteen IV were similarly prepared in which R2 = H, allyl, propargyl, cyclopentyl, hydroxyalkyl, benzyl, furylmethyl, phenyl, substituted phenyl, MeO, NH2, Me, or Et; R3 = H or Me; R4 = Cl, Br, or iodo; R5 = Me or Ph; R6 = Et, CMe3, or Me. Refluxing a mixture of 1-aminopyrrolidino and V for 2 hr gave VI (R2 = R3 = H, R4 = Cl, R1 = pyrrolidino) as a high m.p. solid. Twenty-two VI were similarly prepared in which R2, R3, and R4 were as in V and R1 was a group such as MePrN(CH2)2, MeOCH2CH2, benzyl, Me2NCH2CH2, pyrrolidinoethyl, and 1-methyl-4-piperazinoethyl. VI (R2 = R3 = H, R4 = Cl, R1 = 2-pyridylamino) was prepared by refluxing a mixture of 2-hydrazinopyridine (VII) and MeCN. Reacting III, 3,5-diamino-6-chloropyrazinoic acid (VIII) with Et3N in Me2NCHO, then addition of 2-hydrazinopyrimidine in DMF and further heating gave VI (R2 = R3 = H, R4 = Cl, R1 = 2-pyrimidinylamino). In THF, under similar conditions were prepared a further 14 amides and hydrazines VI including VI (R2 = R3 = H, R4 = Cl, R1 = 4H-1,2,4-triazolyl). Stirring a mixture of benzamidine and VII in H2O for 2 hr gave IX. Five analogs were prepared using other amidines. In a similar manner using guanidine in place of benzamidine was prepared X (R = H) (XI) giving a crystalline hydrochloride. XI could also be prepared directly from

VIII without isolation of intermediates. By similar methods were prepared X (R = OH, CH2Ph) and 39 analogs of X in which the NH2 adjacent to the Cl could also be substituted. With aminoguanidine and 2-hydrazino-2-imidazoline were prepared X (R = NH2 and 2-aminoimidazoline). A mixture of CNNH2 and Na in iso-PrOH was refluxed for 0.5 hr and then heated with N-tert-butyl-3-(3,5-diamino-6-chloropyrazinylcarbonyloxy)crotonamide to give N-cyano-3,5-diamino-6-chloropyrazinecarboxamide. Refluxing N-tert-butyl-3-methyl-3-(3,5-diamino-6-chloropyrazinylcarbonyloxy)acrylamide (XII) and benzyloxydiguanide in THF gave XIII (R = H, R1 = CH2Ph). Twelve XI in which R was H and R1 1-6C alkyl, or R was a substituent such as cyclopentyl, PhCH2, and furylmethyl, and R1 was substituted benzyl were prepared Refluxing a mixture of 2-amino-2-thiazoline, XII, and THF gave N-(2-thiazolin-2-yl)-3,5-diamino-6-chloropyrazinecarboxamide (XIV, R = R1 = R2 = R3 = H). Three analogs were prepared in which R was cyclopentyl, benzyl and HO(CH2)2, the other substituents being H, Me, or C6H13. XIV where RNH was pyrrolidino was also prepared The 4- and 2-pyridyl groups and 2-pyrimidinyl could be substituted for the thiazoline. Reaction of V with sulfamide and Et3N in MeCN at room-temperature gave XV (R = R1 = R2 = H, X = Cl). Eighteen XV were similarly prepared Properties are also given for a further 19 amides XVI. containing a wide variety of substituents. The products are useful in treatment of hypertension and related conditions by causing diuresis without elimination of potassium. Daily doses are 5 mg-1 g.

IT 32209-55-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 32209-55-5 CAPLUS  
CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-phenyl- (CA INDEX NAME)




L4 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1971:420438 CAPLUS  
DOCUMENT NUMBER: 75:20438  
ORIGINAL REFERENCE NO.: 75:3278h,3279a  
TITLE: N-substituted 3,5-diamino-6-halopyrazinamides  
INVENTOR(S): Shepard, Kenneth L.; Cragoe, Edward J., Jr.  
PATENT ASSIGNEE(S): Merck and Co., Inc.  
SOURCE: U.S., 10 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 3573306	A	19710330	US 1969-804663	19690305
NL 7001141	A	19700908	NL 1970-1141	19700127 <--
BE 746816	A	19700904	BE 1970-746816	19700304 <--
PRIORITY APPLN. INFO.:			US 1969-804663	A 19690305 <--

AB Addition of diphenylcarbonyl chloride to 3,5-diamino-6-chloropyrazinoic acid and Et3N in HCONMe2 gave 3,5-diamino-6-chloropyrazinecarboxylic diphenylcarbamic anhydride (I). Refluxing Na in iso-PrOH with guanidine-HCl and addition of I gave 1-(3,5-diamino-6-chloropyrazinoyl)guanidine. Similarly prepared were 1,1,3,3-tetramethyl-2-(3,5-diamino-6-chloropyrazinoyl)guanidine, 1-(3,5-diamino-6-chloropyrazinoyl)-3-cyanoguanidine, N-methyl-N-(cyanomethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(2,2-diethoxyethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(2-morpholinoethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(4-pyridylmethyl)-3,5-diamino-6-chloropyrazinecarboxamide, N-(2-pyridyl)-3,5-diamino-6-chloropyrazinecarboxamide, 3,5-diamino-6-chloropyrazinecarboxylic acid 1,2-dimethylhydrazide, 3,5-diamino-6-chloropyrazinecarboxylic acid 1-methyl-2-benzylidenehydrazide, and N-(3,5-diamino-6-chloropyrazinoyl)morpholine. These compds. had diuretic activity at 10-100 mg.

IT 32209-55-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 32209-55-5 CAPLUS  
CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-phenyl- (CA INDEX NAME)



=> filstnguide

FILSTNGUIDE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> fil stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	98.62	286.72
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-13.94	-13.94

FILE 'STNGUIDE' ENTERED AT 18:13:27 ON 25 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 20, 2009 (20090220/UP).

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.54	288.26
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-13.94

STN INTERNATIONAL LOGOFF AT 18:26:24 ON 25 FEB 2009